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Abstract   
  
Personalised medicine is a medical approach that emphasises the customisation of healthcare, with 
all decisions and practices being tailored to individual patients.   
  
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing condition of the lungs with a median 
survival of 2-3 years from diagnosis. There is however vast heterogeneity in terms of presenting 
features, severity and disease course. Individual survival varies greatly as a result, leading to difficulties 
for patients and clinicians in terms of end-of-life discussions, treatment choices and conduct of clinical 
trials.   
Clinicians would benefit from tools that would help to better predict clinical progression or track 
response to therapy. Several prognostic tools have been used in IPF with variable success. 
CardioPulmonary Exercise Testing (CPET) has been proposed as a potentially effective tool for the early 
detection of gas exchange abnormalities in lung diseases but its prognostic value remains uncertain. 
There are limited data available on the use of CPET as a predictive tool for disease progression in the 
setting of IPF, with a weak correlation between CPET and mortality reported in small cohorts. The 
predictive value of CPET in determining future disease progression and its relationship with Quality of 
Life (QoL) measurements and lung physiology is not known.   
This thesis aims to test the hypothesis that CPET would be feasible in a population of mild to moderate 
IPF patients and more sensitive to change in patient’s health status than 6 Minute Walk Test (6MWT), 
Forced Vital Capacity (FVC) or Transfer factor for carbon monoxide (TLCO), the routine clinical tests 
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Chapter 1. Introduction  
  
The Interstitial Lung Diseases (ILDs) also known as the Diffuse Parenchymal Lung Diseases (DPLD) are 
a group of over 200 heterogeneous acute and chronic lung disorders. Whilst some of these lung 
disorders may be triggered by an underlying autoimmune condition, or occur secondary to a 
hazardous chemical such as asbestos, among these disorders are the Idiopathic Interstitial 
Pneumonias (IIPs), all with an unknown aetiology and include Idiopathic Pulmonary Fibrosis (IPF) 
(Figure 1.1) (Demedts and Costabel 2002).  
 
Figure 1.1. Classification of ILD. Adapted from ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial 
pneumonias. (Demedts and Costabel 2002)  
1.1. Idiopathic Pulmonary Fibrosis  
IPF is a progressive and in most cases fatal pulmonary disease of unknown cause, affecting gaseous 
exchange at the lung parenchyma. Although the causal pathology for disease onset is uncertain and 
discussed later in this chapter, it is apparent the body’s repair cascade malfunctions leading to 
aberrant wound healing, irreversible epithelial remodelling and the formation of scar tissue (Figure 
1.2) (Chambers 2008).   
  
Figure 1.2. Graphical description of the thickening of alveoli walls in pathogenesis of IPF. Copied with permission from PulmonaryFibrosis.org 





1.1.2. Epidemiology  
Whilst classified as a rare disease (this is defined by the European Medicines Agency (EMA) as a disease 
affecting fewer than 5 in 10,000 across the European Union) there are an estimated 32,500 patients 
living in the UK with IPF, with approximately 6000 new cases per year. IPF largely affects patients over 
the age of 60 and is significantly more prevalent in males than females (Snell, Strachan and Hubbard 
2016), although there is no evidence to suggest a difference of IPF incidence based on race, ethnic 
group or social environment (Meltzer and Noble 2008). In the US, due to a rising number & aging 
population, it is thought there will be a doubling of IPF cases between 2005 and 2030 (Fernández Pérez 
et al. 2010).   
1.1.3. Proposed Risk Factors for disease development  
The origin of the initial epithelial injury, thought to be the triggering factor of this disease is largely 
unknown (idiopathic), however a number of exposures have been suggested as risk factors for 
development of IPF. The most common of these being a history of smoking and older age (Bellou et 
al. 2017) although no direct causal association has been established for either of these and estimates 
of effect vary between studies depending on study design and case definition (Ryu et al. 2001).  
Occupational exposures, such as farm workers, vets, gardeners and metal or steel industry workers 
have an independent association with the development of the high-resolution computed tomography 
(HRCT) pattern associated with but not definitive for IPF, usual interstitial pneumonia (UIP). Further 
work from Baumgartner and colleagues suggested raising birds, hairdressing and exposure to 
vegetable or animal dust were significantly associated with a diagnosis of IPF when compared to 
agematched controls (odds ratio for all, in excess of 4.0) (Baumgartner et al. 2000).   
Furthermore, one study suggested up to 87% of IPF patients report the symptom of gastrooesophageal 
reflux disease (GORD), leading to the hypothesis that micro-aspiration of acid into the lungs is a 
significant initiating factor for this disease (Raghu et al. 2006a). Support for this hypothesis has grown 
by evidence linking GORD and the presence of hiatus hernia (Fein et al. 1999), suggesting that hiatus 
hernia may be a co-factor in not only the pathogenesis of IPF, but also the subsequent disease 
progression (Mackintosh et al. 2019).  
Other potential risk factors for development of IPF include diabetes (Gribbin, Hubbard and Smith 2009)  
and viral infection. Whilst some evidence exists pointing towards a role of viruses in acute 
exacerbations of IPF (AE-IPF), including Epstein Barr virus (EBV) & Hepatitis C (HCV) (ATS/ERS Statement 
2000) their exact role remains uncertain. The propensity of both virus’ and bacterial infection to cause 




disease is little understood (Yin et al. 2020).  A recent paper from the UK has also examined a causal 
effect of telomere shortening as a mechanism for pathogenesis that is unique to IPF and is not seen in 
other chronic lung diseases, such as COPD (Duckworth et al. 2020). Finally, the role of genetics has 
been long explored as a cause of IPF, with one estimation that up to 20% of IPF cases could have a 
genetic foundation (García-Sancho et al. 2011). Whilst numerous studies have investigated the role of 
individual genes in IPF pathogenesis, a gain of function MUC5B gene polymorphism appears to be the 
strongest genetic risk factor and effect size for IPF (Evans et al. 2016) (Figure 1.3) and has been 
implicated in familial forms (Yang et al. 2015). Animal models observing the overexpression of this gene 
have suggested impaired mucus clearance, leading to the initiation of fibrosis as a plausible scientific 
pathway, although further research on this continues (Hancock et al.  
2018).   
  
  
 Fig 1.3. Relationship between allele frequency and penetrance of the risk allele. Adapted from Figure 1 (Antonarakis et al. 2010)  
  
Genetic profiling as a potential prognostic tool has to date been little explored. An earlier age of onset 
of familial IPF (f-IPF) is associated with a more aggressive disease course (Krauss et al. 2019) and an 
ERS taskforce is due to publish a consensus paper on genetic involvement in progressive fibrosis within 
the coming twelve months (Borie and Van Moorsel 2021).  
1.2. Pathogenesis of IPF  
There remains no clear consensus on the pathogenesis of IPF. Generalised inflammation progressing 
to widespread parenchymal fibrosis was an historical paradigm (Kim, Collard and King 2006) that has 
become less popular over the last decade and increasingly it is considered, that repetitive epithelial 
injury and activation of fibroblasts are critical early events. This in turn triggers a cascade eventually 
leading to reorganisation of pulmonary tissue where fibrosis is believed to predominate over 




lungs and the bloodstream, is made largely of two types of Alveolar Epithelial cells (AECs), type I and 
type II, with the former covering up to 95% of the alveolar epithelial surface (McElroy and Kasper 
2004). Type I cells increase the surface area of the alveolar wall and facilitate gaseous exchange. Type 
II AEC’s secrete surfactant in order to lower surface tension and prevent alveolar atelectasis. Upon 
injury, type II AECs are stimulated to proliferate and then differentiate, to facilitate replacement of 
type I AECs. This process is known as re-epithelialisation and such a wound healing process is essential 
to restore the barrier integrity. An aberrant response to repeated injury of this surface is now thought 
to be the primary mechanism of IPF (Herzog et al. 2008).  
Damage to the alveolar capillary membrane is a triggering event that mediates a down-stream 
cascade resulting in epithelial-mesenchymal transition (EMT) whereby epithelial cells undertake 
molecular changes gaining a mesenchymal phenotype.  A subsequent increase in fibroblast 
differentiation, activation of the coagulation cascade, fibroblast/myofibroblast differentiation and 
recruitment to sites of injury with deposition of extracellular matrix, and disruption of normal lung 
architecture results in scar tissue formation.  This can be seen as the characteristic usual interstitial 
pneumonia (UIP) scarring pattern observed on high-resolution computed tomography (HRCT) in IPF 
patients. Such a radiological finding may not be conclusive of an IPF diagnosis but is highly suggestive 
given an absence of other clinical or serological history (Figure 1.4) (Paolocci et al. 2018).  
  
   
Figure 1.4. Patient with diagnosed IPF with HRCT pattern consistent with UIP. Reticulation with honeycombing     .  Picture shown with 




1.3. Clinical Course of IPF  
The most frequent symptom patients will report to their healthcare professional is breathlessness, 
with which many patients will have experienced a progressive worsening over >6-month period 
(ATS/ERS Statement 2000) .A non-productive cough is another common symptom at presentation, 
whilst on examination, lower lobe, bibasilar ‘velcro-like’ crackles are present in approximately 80% of 
IPF patients. Although less common, finger clubbing is reported in 30-50% of patients at initial 
presentation (Nakamura and Suda 2015).  
The clinical course varies greatly between patients and is very difficult to predict (Ley, Collard and King 
2011, Raghu et al. 2011), (Kim et al. 2006) as seen graphically in figure 1.5 (Kim, Perlman and Tomic 
2015). Whilst some patients rapidly deteriorate within months, others may have a much slower 
disease progression. At any point in the disease trajectory, acute deteriorations may be experienced. 
Traditionally, this acute worsening (including new radiographic abnormalities on HRCT), accompanied 
by the absence of specific cause for this disease change, is known as an Acute Exacerbation of IPF 
(AEIPF). More recent thinking from an international expert panel following a literature review in to 
these often catastrophic events, has suggested AE-IPF share many clinical features with patients 
experiencing Acute Lung Injury (ALI) from a known cause (e.g. Infection) and such events should be 
labelled as ‘triggered’ or ‘idiopathic’, with an awareness that outcome can often be similar (Collard et 
al. 2016).  After an AE-IPF, in hospital mortality rates are extremely high with a mortality rate up to 
85% and mean survival rate of 3-13 days (Collard et al. 2016). This disease heterogeneity makes it 
difficult for clinicians to give an accurate prognosis at presentation and poses challenges with regards 
to timing of lung transplantation and palliative care. Understanding an individual’s risk of rapid 
progression or susceptibility to AE-IPF, may allow clinicians to increase observation and provide an 
improved personal care plan.  
 
  

















1.4. Diagnosis  
Within the UK, specialist tertiary referral centres have been introduced alongside a National Institute 
for Health and Care Excellence (NICE) clinical guideline to support the diagnosis and management of 
IPF (2017). As outlined in the recently updated International consensus diagnosis guidelines agreed 
by the American Thoracic Society (ATS), European Thoracic Society (ERS), Japanese Respiratory 
Society (JRS) and the Latin American Thoracic Society (ALAT), the gold standard of IPF diagnosis is 
through multi-disciplinary team (MDT) discussion, with the clinical team, radiologist and when 
applicable, pathologist (Raghu et al. 2018). In the context of a classical radiological pattern 
associated with IPF and no clear alternative cause, a diagnosis of IPF can be made by MDT consensus 
without the need for lung biopsy.   
These International diagnostic guidelines suggest biopsies should be performed where diagnosis 
remains uncertain from HRCT. However, this is a cause of debate internationally given the high 30-day 
post-operative complication rate and 3-4% mortality (Kaarteenaho 2013) following video-assisted 
thoracoscopic (VATS) biopsy. There is an increasing use of transbronchial lung cryobiopsy (TBLC), with 
a reduced complication and mortality rate. Producing smaller sample yields, its diagnostic use across 
all ILDs remains uncertain, however in UIP specifically, results are suggestive of being similar to those 
gained via VATS (Zaizen et al. 2019). The first set of guidelines for the use of cryobiopsy in ILD have 
recently been published by expert panel agreement (Maldonado et al. 2020).  
Average life expectancy for an IPF patient is 2-3 years (Ley et al. 2011) and whilst respiratory failure, 
often due to an acute worsening of the disease with an exacerbation of the disease (AE-IPF) is the 
leading course of death, up to 35% of deaths may be unrelated to respiratory failure (cardiac or 
noncardiopulmonary) (Daniels, Yi and Ryu 2008). This prognosis for IPF patients is significantly worse 
than many cancer outcomes with a review in America suggesting a 5-year life expectancy around 20%  





    
Fig 1.6. Life expectancy of patients with IPF vs different cancers. Adapted from (Kim et al. 2015).  
  
To date, there remains no cure for this condition; two anti-fibrotic medications have been approved 
for the treatment of IPF (nintedanib and pirfenidone) and have both been shown to slow down lung 
function decline in large scale clinical trials and real-world data (Richeldi et al. 2014), (King et al. 2014, 
Rodríguez-Portal 2018). Care should focus on holistic supportive management with involvement of 
Pulmonary Rehabilitation (PR), Oxygen services, symptom control, early referral to lung transplant 
where appropriate and palliative care (Shaw et al. 2017).   
As well as the extensive mortality and morbidity an IPF diagnosis presents, the healthcare costs are 
disparate to the disease prevalence. A Medicare analysis of an over 65-year-old population in the USA 
showed the healthcare costs both pre and post IPF diagnosis to be almost double that of an age 
matched non IPF cohort, with increased outpatient and emergency department visits (Morrow 2019).    
  
1.5. CURRENT PROGNOSTIC TOOLS IN IPF  
1.5.1 Health related quality of life (HRQoL) assessments in IPF  
Until recently, few quality of life measurement questionnaires or disease specific instruments have 
been available to a treating physician to gain an accurate understanding of an individual’s perception 
of their disease severity, how this can impact a patient’s psychological wellbeing and also their ability 
to exercise or perform usual activities of daily living. The relationship between such measures and the 
standard functional testing used for disease severity (FVC, DLCO) is also largely unexplored. In 2004, a 
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subjects was not fully explained by the patient’s breathlessness or lung function results and an 
individual’s QoL scores may provide unique information aside from clinical measurements.   
The most widely used assessment of QoL in IPF patients to date is the St. Georges Respiratory 
Questionnaire (SGRQ). Developed in 1991 and containing a total of 50 items, the questions are specific 
to the measurement of impact of obstructive airways disease, especially Chronic Obstructive 
Pulmonary Disease (COPD). The utility of SGRQ with IPF patients remains questionable and a review 
of its use in this population concluded further research was needed with regards its validity in IPF, 
(Swigris et al. 2014) although a small retrospective study undertaken in Japan has suggested a score 
>30 has an independent mortality prognosis in patients with IPF (Furukawa et al. 2017).   
To overcome the inherent problems of the lack of disease specificity of SGRQ, 20 years after its first 
iteration, the original authors created an IPF specific SGRQ-I. The item number was reduced to 34 with 
different scales and weightings to the original and the removal of airways particular effects (such as 
wheeze). However, the prospective validation of this questionnaire remains unclear and its use 
globally within clinical trials or in daily clinic use is limited (Yorke, Jones and Swigris 2010).  
More recently, Patel et al. developed an ILD specific questionnaire named King’s Brief Interstitial Lung 
Disease Health Status Questionnaire (K-BILD) (Patel et al. 2012). With a much-reduced item burden, 
comprising 15 questions across 3 domains (breathlessness and activity, chest symptoms and 
psychological), this questionnaire has been validated across several ILD cohorts (Wapenaar et al. 
2017), including large numbers of IPF patients. The condensed question load and time consumption 
allows its use across multiple clinical settings for quick assessment of a patients’ own perspective on 
their disease. In 2019, K-BILD was used for the first time in a large phase III clinical study for a wider 
ILD cohort (Flaherty et al. 2019) and appears to now be the gold standard across fibrosing lung 
conditions with validated minimal clinically important differences (MCIDs) now established across 
different ILD cohorts (Sinha et al. 2019) for total and individual domain scores.  
Finally, and as yet un-validated questionnaire across larger cohorts, is the Idiopathic Pulmonary 
Fibrosis - Patient Reported Outcome Measure (IPF-PROM). This set of questions has been further 
refined to just 13 questions across 4 domains (physical experience of breathlessness, psychological 
experience of breathlessness, emotional well-being and energy) (Russell 2017). This questionnaire 
remains the only IPF specific tool available for patient reported outcomes and assessment of health 
status and may add to our clinical knowledge of an individual’s disease perception and potential 





1.5.2 Static measurements  
As has been highlighted, predicting the prognosis to individual patients is extremely challenging. As 
such, a number of prediction tools have been designed and are proposed. Forced Vital Capacity (FVC), 
the amount of air a patient can exhale in a single breath (measured in ml) and specifically a decline in 
a patient’s expected percent predicted FVC is now widely accepted in larger phase II and phase III 
clinical trials as a surrogate marker for mortality (Karimi-Shah and Chowdhury 2015). The magnitude 
of change measured in FVC over a period of time, to be suggestive of a poorer outcome, however, still 
causes debate today. Richeldi and colleagues have concluded a ≥10% decline in FVC over 12 months, 
not only signals a clinically meaningful change to an individual’s lung capacity but also maintains 
prognostic accuracy (Richeldi et al. 2012). A further physiological test measuring the ability of the lungs 
to transfer gases across the alveolar:blood stream barrier, routinely performed by IPF patients is that 
of diffusion capacity (or Transfer factor) of the lungs for carbon monoxide (TLCO). A number of studies 
have alluded to the idea that this measurement is more accurate than FVC at a given point in the 
patient’s disease, and can predict with greater accuracy, the severity of IPF. Sharpe et al suggested 
TLCO outperformed FVC % predicted when considering 12- and 24-month survival (Sharp, Adamali and 
Millar 2017) however, data from a patient registry in the US (Snyder et al. 2019) has proposed that a 
low FVC % predicted has similar prognostic predictive accuracy as a low TLCO % predicted. Furthermore, 
the difficulty in the reproducibility of this test and the inability of some patients to perform the breath 
hold needed to undertake the measurement has meant TLCO alone, is rarely used to predict survival.  
A number of composite mortality prediction tools have been designed with the most widely used being 
the gender, age, physiology model (GAP). With a simple scoring system, this combines a patient’s 
gender, age and certain physiological scores and places them in to three stages (I – III) to predict a 
survival probability (in months) (Ley et al. 2012) (Figure 1.7). Accurate on a population level, its 







Figure 1.7. Longitudinal GAP staging score and probability of survival by stage. Adapted from (Ley et al. 2012).  
One recent addition to the traditional GAP scoring, was suggested by Mikolasch et al (Mikolasch, 
Sahota and Garthwaite 2018). The tallying of the standard GAP score, in addition to the Neutrophil: 
Lymphocyte ratio (NLR), previously shown to be prognostic in certain cancers (Ren et al. 2019), may 
provide improved projective accuracy across a broad IPF patient spectrum with a high NLR predictive 
of earlier mortality (Figure 1.8).  
  




In this small study (n=75), the authors concluded a high NLR in IPF patients doubled the possibility of 
death in the follow up period. This was independent of GAP score, but it is suggested this biomarker 
ratio, in conjunction with the GAP scoring can refine and add accuracy to prediction of an individual’s 
prognosis.  
Largely now superseded by the arrival of CPI (described below), the clinical–radiographic–physiologic 
(CRP) scoring system uses seven variables (dyspnoea, chest HRCT, spirometry, lung volume, TLCO, 
resting alveolar-arterial PO2, and exercise O2 saturation). This score was initially devised to assess the 
severity of disease and suitability for transplant whereby each variable was graded in to between 2 – 
9 levels of severity (dependant on the range of data available). The variables were subsequently 
weighted to ensure equivalence across each (Watters et al. 1986). The CRP has more recently been 
adapted and evaluated to predict patient survival (King et al. 2001) although remains little used in 
clinical or research practice.  
The Composite Physiological Index (CPI) (Wells et al. 2003) is a second relatively simple prognostic 
scoring system, which may have greater accuracy than GAP staging when comparing mortality data to 
three years (Lee et al. 2018). The CPI not only includes physiology results but also those from HRCT, 
importantly taking in to account the co-existence of emphysema and fits disease extent against 
pulmonary function testing, providing a more accurate prognostic assessment that pulmonary 
function tests alone (Figure 1.9).   
  
The formula for the CPI was as follows: 
extent of disease on CT = 91.0 - (0.65 x 
percent predicted diffusing capacity for 
carbon monoxide [DLCO]) - (0.53 x percent 
predicted FVC) + (0.34 x percent predicted 
FEV1).  
  
Figure 1.9. Composite Physiologic Index relationship to Disease Extent Observed by Computed Tomography. Shown with permission (Wells 
et al. 2003).  
  
  
The final and most recently published tool for IPF prognosis is a staging instrument developed by 
Torrisi et al.; the Torvan Index (Torrisi et al. 2019). The calculation of a scoring system assigned to pre-




provided significantly improved accuracy of performance across two independent cohorts although 
its validation & use in large scale clinical trials remains uncertain.   
  
  
Figure 1.10. Torvan scoring system and staging. With permission (Torrisi et al. 2019).  
  
Although relatively quick and easy to perform, the true prognostic value given to these static 
measurements remains unclear and it is likely an individual’s dynamic longitudinal changes, for 
example dyspnoea, HRCT changes and physiological changes over a given time period, will allow a 
much greater accuracy of a likely survival estimate (Kolb and Collard 2014). Furthermore, whilst there 
remains no consensus globally as to the preferred predictive tool of choice, clinicians will be making 
their individual choice for preference and communication of such information to patients will remain 
variable.  
  
1.5.3 Dynamic measurements  
A small number of dynamic exercise tests have been utilised to assess IPF outcomes including 
Cardiopulmonary Exercise testing (CPET) (Fell et al. 2009), 4 metre gait speed (4MGS) (Nolan et al. 
2019) and the Six Minute Walk Test (6MWT) (du Bois et al. 2011). Routinely used around the world, 
patients undertaking the 6MWT are asked to shuttle walk as far as they can within a six-minute period. 
Total distance covered (in metres) and also change in distance over time are two outcomes shown to 
have good prediction of mortality. Du Bois et al showed a reduction of 50m over a 24-week period to 




colleagues showed patients walking less than 212m in 6 minutes had a poorer outcome (Caminati et 
al. 2009). Whilst this test has a number of potential benefits in that it has widespread availability, is 
easily reproducible and inexpensive with limited experience needed from the physiologist perspective, 
there are a number of potential pit falls. Patient variability in terms of test effort will have a significant 
effect on the outcome results; fragility, age, gender and a patient’s cognitive function can all provide 
limitations to its usefulness (Heresi and Dweik 2011).   
A more recently explained dynamic test is the 4 MGS. Awaiting further validation, early data whereby 
the time of an individual to walk a 4-meter distance is recorded has suggested 4MGS correlated 
significantly with 6MWT and total KBILD although its prognostic use is unexplored.  
Cardiopulmonary exercise testing has been extensively utilised within secondary care settings but to 
date, there is limited knowledge of its use in the IPF setting. The test itself allows assessment and 
causes of limitations to exercise to be identified via numerous gaseous exchange measurements 
during exercise stress to the ventilatory, circulatory and muscular systems. In addition to conventional 
exercise testing, CPET allows for the measurements of breathing (ventilation) and gas volumes, both 
inhaled (oxygen) and exhaled (carbon dioxide) to be measured. This provides the clinician with a multi 
organ view of the transport and delivery of oxygen to the muscles (mitochondria) and its use during 
activity (Figure 1.12).   
  
   
Figure 1.11. Gas exchange and O2 utilisation during CPET testing (Wasserman 2012).   
  
CPET has been performed for over 50 years (Schraufnagel and Agostoni 2017) although for much of 
this time, only in adults with single disease to aid the evaluation of dyspnoea. Today it is routinely 
used to assess a much more heterogeneous population, from young to old and fit to frail across 
numerous disease states and those with multiple comorbidities. Its use within the field of cardiology 




patient known to have cardiac disease (Albouaini et al. 2007, Akinpelu 2018). However, its reach 
extends well beyond assessment of the heart and it is now widely used in the pre-operative 
assessment to aid peri-operative planning and assess a patient’s suitability and potential survival of 
surgery for organ transplant, especially of the heart (Ong et al. 2000) and lung (Dudley and El-Chemaly 
2012). The standardisation of procedures, including COPD, cystic fibrosis, Exercise Induced 
Bronchospasm (EIB) and Lung Volume Reduction Surgery (LVRS) among others were outlined in 
International guidelines published jointly by the American Thoracic Society (ATS) and American 
College of Chest Physicians as far back as 2002 (Society and Society 2002). More recently in 2019, the 
European Respiratory Society published an updated standardisation of CPET with a greater focus on 
the procedural aspect across all chronic lung diseases (Radtke et al. 2019).  
Over the course of a CPET, usually lasting between 8-12 minutes, thousands of measurements will be 
taken from each breath and heartbeat which will be averaged out over a short period of time (often 
30 seconds) and plotted and presented on a 9-panel plot (Figure 1.13) which can essentially be split in 
to four categories:   
1) Work rate (Watts)  
2) Gas exchange (including O2 consumption VO2, CO2 production VCO2 and the output of VCO2 / VO2 
known as the Respiratory Exchange Ratio or RER)  
3) Ventilatory Assessment (including ventilation rate VE, ventilatory equivalents for O2 and CO2 - VE/VO2 
and VE/VCO2 and oxygen saturation)  





Figure 1.12. Example of 9-panel plot in a healthy individual. This presentation of outputs was described by Wasserman and colleagues in 
2012 (Wasserman 2012) with 30-second averaging of data. Panels 2 and 3 present circulatory parameters, panels 5 and 9 represent 
ventilatory parameters whilst 4, 6 And 7 represent ventilatory efficiency. Panel 8 (RER) shows metabolic changes. AT is most easily 
calculated in panel 3 with the divergence of VCO2 against VO2.  
  
Experience of using such data presentation will lead a physiologist or clinician to have focus on these 
different plots dependent upon the measurement they have an emphasis on. Generally, panels 2,3 
and 5 represent the cardiac outputs, the ventilatory system is shown in plots 1, 4 and 7 whilst the 
remaining graphs (6, 8 and 9), represent the ventilation-perfusion relationship.  
As the work requirements increase with load, so do the muscles energy needs, initiating the use of 
anaerobic metabolism as the oxygen supply cannot meet the muscles metabolic demands. This causes 
a rise in blood lactate concentrations alongside metabolic acidosis. The resulting hydrogen ion 
generation in the cells (from lactic acid dissociation) are buffered by bicarbonate resulting in a sharp 
rise in VCO2 when compared to VO2 (which until this point will rise at a similar rate). This point, which 
is most clearly seen in panel 3 in figure 1.12 utilising the VCO2 versus VO2 is known as the Anaerobic 
Threshold (AT) and is often observed at 50-60% of VO2 peak. This method of calculation is the V Slope 




cardiovascular fitness and its observation (or lack of) can often distinguish between the cause of 
exercise limitation being cardiac or ventilatory associated (Albouaini et al. 2007).  
Essential to the interpretation of CPET results is the patient’s attainment of a maximal effort test and 
the parameters to assess this are outlined later in the thesis. The test itself can take place on a 
treadmill with the patient walking/running or on a cycle ergometer. Often the use of a treadmill can 
provide greater VO2 peak values, simply by the greater muscle volume being worked, but it may not 
be suitable for all. The choice of each is often made by the physiologist and may be dependent on 
patient preference or indeed ability/fragility.   
Despite the abundance of data derived from CPET it does come with potential issues when compared 
to more widely used functional tests. Costs in an ever increasing financially restricted health service, 
including both equipment and staffing per test are well in excess of 6MWT and standard LFTs.  
Although serious adverse events during CPETs are rare, this must still be considered on an individual 
basis. In a large Korean retrospective cohort of nearly 1500 elderly patients, serious cardiovascular 
complications occurred in 0.2% (Kim et al. 2019). Finally, and more pertinent to the current day, 
infection control and associated time and costs is a consideration.   
Previous studies with the use of CPET across all ILD subtypes have identified declining functional 
capacity and muscle weakness as strongly predictive of disease progression and increased mortality 
(Panagiotou, Polychronopoulos and Strange 2016), whilst measures of gas exchange may be more 
valuable predictors of outcome than measures of lung mechanics (Lederer et al. 2006, Flaherty et al. 
2006, Ley et al. 2011). Nevertheless, further efforts to develop definitive prediction models are 
required for clinical practice (Kolb and Collard 2014, Ley et al. 2011). Our current knowledge on the 






     
  
  





2.1 Introduction  
As discussed in section 1.5.3, cardio-pulmonary exercise testing (CPET) provides a comprehensive 
assessment of the physiological changes in the respiratory, cardiovascular, and musculoskeletal 
systems in a controlled laboratory environment (Layton et al. 2017), that has shown promise in terms 
of prognostic value in a number of chronic respiratory conditions (Ferrazza et al. 2009, Arena and 
Sietsema 2011). My hypothesis that CPET variables could be more sensitive to change in patient’s 
health status than the more traditional lung function parameters (FVC, TLCO or 6MWT) arose from the 
volume of data suggesting other potentially useful markers for example, progression of fibrosis on CT 
bare no correlation with these traditional (and globally accepted) lung function measurements 
(Clukers et al. 2018), (Hayton et al. 2019). Furthermore, patient reported outcomes within larger IPF 
cohort studies has shown no correlation to lung physiology measurements (Richeldi et al. 2014, King 
et al. 2014, Noble et al. 2011). Whilst CPET has been widely used across other disease states to predict 
clinical outcomes and prognosis, especially among cardiology, oncology and suitability for 
transplantation (Patel et al. 2019, Kleber and Köln 2018, Ney et al. 2016), relatively little is known 
about its role in IPF. I was keen to confirm a belief that not only such a test was safely achievable in 
an IPF patient population but also, that relationships between CPET outcomes, patient’s prognosis and 
self-perceived QoL existed.  
To provide a detailed understanding of the currently available data on the longitudinal use of CPET as 
a prognostic tool in IPF patients and in order to gain insight in to difficulties previously encountered 
by research teams around the world in such study cohorts, a formal systematic review was undertaken 
to better inform the study protocols. The primary objective of this search was two-fold. Firstly, to 
better comprehend the safety of this test in our likely cohort, enabling the formulation of the inclusion 
and exclusion criteria and understand the feasibility of recruitment in a mild to moderate population. 
Secondly, to gain an insight in the current knowledge gaps in the prognostic use of CPET in both IPF 
and the wider ILD umbrella diseases and evaluate the current understanding of CPET in predicting 
disease-specific outcomes in long term follow up of ILD populations. The outcomes of this review were 
utilised to formulate a clear understanding of published data, inform our hypothesis and ultimately 
finalise the study design. Should the hypothesis be correct and a prognostic role for CPET be 
confirmed, it could be used to guide earlier intervention for at-risk patients, support cohort 
enrichment for ILD clinical trials and allay anxiety and unnecessary monitoring amongst patients with 
stable ILD.   
 A brief online non-systematic search of the literature suggested small numbers of studies in IPF and 
thus the decision was made to include all ILDs and not just IPF to broaden the potential reader interest 




To explore the data available, we undertook a full literature review of all studies where CPET variables 
had been used to estimate prognosis across all ILDs. The study selection (according to PRISMA 
statement) can be seen in appendix C, however, of the 946 articles identified by the search criteria 
and subsequent reduction to 658 after duplication extraction, only 18 papers went through to full 
review. By far the dominant reason for rejection was the inclusion criteria not being met, but other 
reasons included the lack of longitudinal data, congress abstracts, and the primary disease state being 
studied was not ILD, see figure 2.1.  
  
Figure 2.1. Study selection flow diagram presented according to PRISMA statement.   
  
  
After full review of 18 papers and exclusion of a further 5 studies due again, to the lack of a longitudinal 
component to the research, only 13 studies remained. Of the studies included, 8 were specifically 
focussed on IPF patients although only 2 provided prospective analysis. The full published article of 




2.2. Materials and methods  
The protocol for this review was prepared in accordance with Preferred Reporting Items for Systematic 




International Prospective Register of Systematic Reviews (PROSPERO 110198/2018). The benefits of 
utilising PRISMA provides a standardised structure to the writing, allowing critical review of the 
strengths and weakness’, allowing direct replication of the methods undertaken at a future point in 
time. Furthermore, is indicative of the quality of the work undertaken (Moher et al. 2009). Prospective 
registration of the review on PROSPERO gives a published record of the planned work to be 
undertaken, potentially reducing the risk of bias and importantly, avoiding duplication of work 
(Stewart, Moher and Shekelle 2012). In line with PROSPERO registration and the need with our initial 
findings on the limited data available for IPF populations alone, the review team made an amendment 
to the protocol to include the term ‘ILD’ rather than ‘IPF’, furthermore, the allowance of non-English 
language publications was accepted to incorporate all available data.  
2.2.1 Eligibility criteria   
Studies that reported the relationship between CPET assessment and disease progression, prognosis 
or the presence/emergence of specific clinical outcomes of ILD were included.   
Using the PICO framework outlined below, we evaluated publications that fulfilled the following 
criteria:   
Population   
Adults (18 years or older) with a diagnosis of ILD (including but not limited to idiopathic pulmonary 
fibrosis, CTD-related ILD and sarcoid-related ILD).  
Intervention  
Studies reporting the outcome of CPET assessment as a prognostic factor. All available methods of 1) 
performing formal CPET and 2) reporting CPET results were included.   
Comparison  
Patients with/who developed relevant outcomes (see below) were compared with those who did not, 
using CPET testing at baseline in both groups.    
  
  
Outcome measures  
The primary objective was to evaluate the prognostic value of CPET in predicting disease course and 
outcomes in longitudinal (retrospective or prospective) studies of ILD. The relationship between CPET 




phenotype and disease demographics (e.g. disease duration, gender, age, lung physiology), disease 
outcomes (e.g. death, hospitalisation), surrogates of disease severity (including, but not limited to lung 
physiology, circulating biomarkers etc.), health-related quality of life (HRQoL) and functional status, 
were examined.    
2.2.2. Study design  
Eligible studies included cohort (retrospective or prospective) and observational longitudinal studies, 
that reported outcomes at a time point distinct from the baseline CPET (i.e. were of an appropriate 
design to evaluate prognostic value). The following types of studies were excluded: 1) animal studies 
2) studies including patients with lung disease where an ILD cohort was not described and reported 
separately 3) studies designed to develop or validate health measurement scales 4) randomized 
controlled trials 5) case reports 6) qualitative research 7) non-original research publications (i.e., 
editorials, reviews) 8) abbreviated reports (e.g. letters to editors) and conference proceedings.  
2.2.3. Search strategy   
The search criteria were developed in accordance with search recommendations for systematic 
reviews of evaluations of prognostic variables (Altman et al. 2000). Electronic searches were 
performed in Medline and EMBASE, with no publication date or language restrictions.  Full details of 
the specific search criteria can be seen in figure 2.2.  
((Cardiopulmonary exercise test*) OR (cardiopulmonary exercise) OR (exercise test*)) AND 
((idiopathic pulmonary fibrosis) OR (pulmonary fibrosis) OR (interstitial lung disease) OR 
(idiopathic interstitial pneumonia) OR (Cryptogenic fibrosing alveolitis) OR (fibrosing 
alveolitis) OR (Connective tissue disease-related interstitial lung disease) OR (Connective 
tissue disease-associated interstitial lung disease) OR (rheumatoid lung) OR (systemic 
sclerosis) OR (scleroderma) OR (polymyositis) OR (myositis)) AND ((cohort studies) OR 
(longitudinal studies) OR (case-control studies) OR (follow-up studies) OR (retrospective 
studies) OR (prospective studies) OR (incidence) OR (mortality) OR (follow-up studies) OR 
(prognos*) OR (predict*) OR (course) OR (prognostic) OR (prognosis) OR (progression) OR 
(future) OR (development) OR (outcome) OR (treatment outcome) OR (disease-free 
survival) OR (treatment failure) OR (morbidity) OR (mortality) OR (survival rate) OR (survival) 
OR (cause of death) OR (survival analysis)).  
  
Figure 2.2. Specific search criteria performed in Medline and EMBASE.  
  
All titles and abstracts generated by the search criteria were screened independently by myself and a 
second independent reviewer, identifying those studies relevant and eligible for full text review. 




statistics (Cohen 1968). This methodology used to assess reliability between those rating variables 
within data is now more widely used than assigning an arbitrary percentage score previously utilised, 
as it accounts for the possibility of chance agreement. The kappa score has a range from -1 to +1 
although there is some disagreement on its agreement values in health studies, given a value of 0.41 
is suggestive of assessor agreement (McHugh 2012).  
Any discrepancies/disagreements within our review were resolved by discussion between reviewers 
and included a third party where necessary. Discussions between reviewers resolved any 
discrepancies at each stage of the study selection process. Review articles or editorials focussing on 
the “prognostic aspects of cardiopulmonary exercise testing in Interstitial Lung Disease” were also 
reviewed, to facilitate a grey search of cited manuscripts within these reviews.   
2.2.4. Data extraction   
A standardised form was used to independently extract relevant study details from each of the 
selected studies that included: date of publication, journal or publication source, study design, initial 
population of the study, study inclusion criteria, study exclusion criteria, CPET method, CPET analysis 
endpoints, disease outcomes assessed and a summary of key findings. Study corresponding authors 
were contacted when clarification was required. See Appendix C.  
2.2.5. Risk of bias assessment  
The QUIPS (Quality in Prognosis Study) risk of bias tool was used to assess the risk of bias within every 
included study (Huguet et al. 2013), see figure 2.3. Assessment in this way, scored across 6 domains 
places a high (red), medium (amber) or low (green) risk against the various categories to interpret the 





Figure 2.3. QUIPS tool assessment of bias.  
  
2.3. Results   
Study selection  
Initial simultaneous searches in EMBASE (n=573) and Medline (n=373), performed in early 2019, 
identified a total of 946 articles. After removal of duplicates (n=288), 658 articles generated by the 
search were screened for eligibility and exclusion criteria based on titles and abstract review. There 
was moderate initial agreement between the two reviewers (Cohen’s kappa 0.462 – see appendix E), 
with discordance in 20 abstracts, that was easily resolved through discussion. Eighteen articles 
proceeded to full text review and this led exclusion of a further 5 studies. A total of 13 studies were 
deemed eligible for inclusion. The full study selection process is detailed in figure 2.1.   
2.3.1. Geographical participation and date of publication  
Five studies were undertaken in Europe (5/13, 38%)(Triantafillidou et al. 2013, van der Plas et al. 2014, 
Gläser et al. 2013, Wallaert et al. 2011, Kollert et al. 2011), five in USA (5/13, 38%)(Fell et al. 2009, 
Kawut et al. 2005, Layton et al. 2017, Swigris et al. 2009, King et al. 2001) and the remainder in Israel 
(Vainshelboim et al. 2016), Japan (Miki et al. 2003) and Brazil (Lopes et al. 2012). The majority of 
studies were published in the last 10 years (10/13, 77%)(Layton et al. 2017, Triantafillidou et al. 2013, 
van der Plas et al. 2014, Gläser et al. 2013, Vainshelboim et al. 2016, Lopes et al. 2012, Wallaert et al. 
2011, Swigris et al. 2009, King et al. 2001, Kollert et al. 2011) and only three studies published in the 
years preceding 2009 (Miki et al. 2003, Fell et al. 2009, Kawut et al. 2005).  
2.3.2. Study characteristics  
Most studies were retrospective cohort analyses (11/13, 85%), with variable follow-up periods (range 
23 days (Kawut et al. 2005) - 20 years (Swigris et al. 2009)). The majority of retrospective studies 
evaluated independent risk factors for survival or mortality outcomes in ILD (9/11, 82%) and had an 
average follow up time of between 1-4 years (Gläser et al. 2013, Kawut et al. 2005, Layton et al. 2017, 
van der Plas et al. 2014, Miki et al. 2003, Vainshelboim et al. 2016, Triantafillidou et al. 2013, Wallaert 
et al. 2011, King et al. 2001). The longest planned follow up was in a study examining a non- IPF cohort 
(of systemic sclerosis ILD patients) which was truncated at 20 years (Swigris et al. 2009).   
There were two prospective studies (Triantafillidou et al. 2013, Vainshelboim et al. 2016). One 
investigating the relationship between CPET and survival characteristics in IPF had a variable duration 




as part of a wider investigation into the role of exercise testing in the prognostication of ILD and 
followed patients up for a fixed period of 40 months (Vainshelboim et al. 2016).   
2.3.3. Study populations  
Of the studies identified, 8/13 (62%) exclusively recruited patients with IPF, two recruited only 
sarcoidosis patients (Lopes et al. 2012, Kollert et al. 2011), and one study systemic-sclerosis associated 
ILD (Swigris et al. 2009). The remaining studies (2/13, 15%) evaluated more heterogeneous cohorts of 
ILD patients referred for lung transplantation assessment (Kawut et al. 2005, Layton et al. 2017).   
The prognostic value of CPET has been retrospectively reported in a total of 703 patients with IPF, and 
prospectively in a further 59 patients in 2 small, single centre studies (n=25 (Triantafillidou et al. 2013) 
and n=34 (Vainshelboim et al. 2016)).  Patients were recruited to studies according to consensus 
statements on the diagnosis of IPF available at the time of enrolment; the 2000 American Thoracic  
Society (ATS) international consensus statement for the diagnosis of IPF (Miki et al. 2003, 
Triantafillidou et al. 2013, van der Plas et al. 2014, Fell et al. 2009, King et al. 2001, ATS/ERS Statement 
2000) and the later 2002 ATS/ERS International consensus classification of the idiopathic interstitial 
pneumonias (including IPF) (Wallaert et al. 2011, Kawut et al. 2005, Society and Society 2002). The 
updated 2011 ATS/ERS/JRS/ALAT evidence based guidelines for the diagnosis of IPF (Raghu et al. 2011) 
were applied in all (Triantafillidou et al. 2013, Gläser et al. 2013, Layton et al. 2017, Vainshelboim et 
al. 2016) but one of the studies (van der Plas et al. 2014) published after 2011 (the latter was a 
retrospective study that may have recruited patients prior to the publication of the 2011 guidelines).   
We identified two retrospective studies that examined the role of CPET in predicting outcomes in 
mixed populations of ILD patients (Layton et al. 2017, Kawut et al. 2005). Cumulative patient numbers 
were small (a heterogeneous group of connective tissue disorders n=28, HP n=8, unclassifiable ILD 
n=7, sarcoid n=15, IIP n=21 (NSIP n=18, COP, DIP, COP). Whilst the cohorts could be considered to be 
representative of mixed ILD cohorts, patient numbers for each subtype were too small to consider 
each subgroup separately.  
With regards to the study participant populations, the QUIPS risk of bias was considered to be low for 
only 3/13 (23%) studies (Triantafillidou et al. 2013, Wallaert et al. 2011, Vainshelboim et al. 2016), 
with the majority regarded as having a moderate (6/13, 46%) or high (4/13, 31%) (Miki et al. 2003, 
Layton et al. 2017, Kawut et al. 2005, Kollert et al. 2011) risk of bias. The generalisability of one study 
was potentially limited by the reported high diagnostic lung biopsy rate for IPF patients (64% (75/117) 
(Fell et al. 2009), as previously alluded to, a condition that can often be confidently diagnosed without 
biopsy in the presence of typical radiological findings and by consensus agreement in the 




was representative of IPF populations in the ‘real world’. Two studies examined disease outcomes that 
necessitated a particular baseline clinical phenotype e.g. recruitment from source populations 
referred for lung transplant evaluation and thus by definition only analysed selected cohorts of 
advanced ILD patients (Layton et al. 2017, Kawut et al. 2005). Others incorporated a priori patient 
grouping, for example the presence of pulmonary hypertension (Gläser et al. 2013), to enrich 
populations with patients at high risk of developing outcomes of interest, or required the active 
exclusion of patients with a relevant phenotype e.g. those that died from a cause other than 
respiratory failure (Miki et al. 2003).   
Study attrition was generally reported to be low, which may reflect the retrospective nature of the 
majority of the studies identified. The QUIPS risk of bias for study attrition was reported to be high in 
two studies, increasing the potential for selection bias;  >25% patients identified were excluded from 
the analysis by Lopes et al.(Lopes et al. 2012), whilst in the study by King et al. (King et al. 2001), 34% 
(80/238) of the originally identified population were excluded from inclusion in the final analysis 
because of  incomplete data sets.   
2.3.4. Prognostic factor measurement  
CPET was the sole prognostic factor for the majority of studies 8/13 (62%), with a minority using CPET 
as part of a broader repertoire of exploratory physiological tests including 6MWT (Kawut et al. 2005, 
Triantafillidou et al. 2013, Layton et al. 2017) or lung function parameters (Gläser et al. 2013). One 
study used CPET in conjunction with clinical, radiological and resting physiological tests to devise a 
scoring system to predict survival in newly diagnosed cases of IPF (the CRP score: Clinical Radiological 
Physiological score) (King et al. 2001).  
In two studies, CPET was used as the principal method to achieve a standardised form of maximal 
exercise (Kollert et al. 2011, Swigris et al. 2009) where upon arterial blood gas sampling or peripheral 
oxygenation measurements were taken to determine the effect of exercise on gas exchange. In both 
of these studies, typical CPET measures, such as maximal oxygen consumption (VO2max) were not 
recorded.   
Across all studies, the bias rating for prognostic factor measurement using the QUIPS tool was 
considered low-to-moderate (figure 2.3), with the majority of studies reporting a standardised 
approach to CPET and analysis that would be easily reproducible and less amenable to bias. Most 
studies provided a sufficient description of the CPET protocol used, adhering to the 2003 American  
Thoracic Society statement on cardiopulmonary exercise testing (Society and Physicians 2003) (6/10, 
60%)(Kawut et al. 2005, Wallaert et al. 2011, van der Plas et al. 2014, Layton et al. 2017, Triantafillidou 




and updated 2007 (Vainshelboim et al. 2016, Palange et al. 2007) recommendations. In others 
important details were missing e.g. if oxygenation was measured during CPET (van der Plas et al. 2014). 
Variation in the methodological approach to CPET was also observed. For example, in one study, 
oxygen usage during CPET was an inclusion criteria (Layton et al. 2017), whilst in another, 
supplemental oxygen during exercise was supplied variably to participants depending on a pre-study 
requirement for home oxygen or saturation on room air <90% (Kawut et al. 2005). In 7/13 (54%)  
studies, blood gas analysis was used to assess the adequacy of gas exchange during exercise (Fell et 
al. 2009, Miki et al. 2003, Lopes et al. 2012, Wallaert et al. 2011, Kollert et al. 2011, Swigris et al. 2009, 
King et al. 2001), whilst the remainder used pulse oximetry, considered by some experts to be a 
suboptimal substitute (Society and Physicians 2003). A broad range of quantitative CPET parameters 
were presented/analysed raising the possibility of reporting bias (see later).  
All but one study used cycle ergometry. Treadmill exercise testing was used as the method of CPET in 
the remaining study; in which exercise increments were chosen for participants based on patient’s 
daily activities and parameters of resting pulmonary function, raising concerns whether a standardised 
approach had been adopted (Miki et al. 2003). Additionally, non-uniform speed increases, often 
inherent to treadmill testing, results in nonlinear metabolic rate increases and fundamental difficulties 
in calculating an accurate external work rate and an estimation of peak VO2. Thus, direct comparisons 
of peak VO2 obtained during treadmill testing studies cannot be compared with those obtained from 
cycle ergometry studies.   
  
  
2.3.5. Outcome measurement  
The most commonly reported outcome was mortality/survival 11/13 (85%). The majority of these 
studies that used survival/mortality as an outcome measurement (10/11, 91%) examined all-cause 
mortality, considering death or lung transplantation as composite endpoint. One study used an 
outcome measurement that was restricted to respiratory deaths only (Miki et al. 2003) and another 
study assessed the discriminatory ability of CPET to identify patients who would die on the lung 
transplant list before receiving transplantation (Kawut et al. 2005). Other outcomes included 
interceding pulmonary hypertension (PH) (Gläser et al. 2013) and decline in pulmonary function (FVC 
and DLCO) or duration of immunosuppressive therapy in two non-IPF cohorts with sarcoidosis (Lopes 
et al. 2012, Kollert et al. 2011).  
Using the QUIPS tool, the risk of bias in the approach to outcome measure assessment was considered 





2.4 Reported prognostic associations of CPET in the IPF cohorts  
All studies reported at least 1 positive association between CPET and clinical outcomes, raising the 
possibility of positive reporting bias. Significant heterogeneity in study design, study populations (and 
classification criteria adopted), CPET protocols, CPET endpoints and defined endpoints precluded any 
useful attempt at meta-analysis.  
The prognostic role of peak VO2 has been examined across several studies of IPF. Fell et al. (Fell et al. 
2009) retrospectively suggested a baseline threshold of peak VO2 8.3ml/kg/min predicted survival in 
117 patients with IPF (peak VO2 <8.3ml/kg/min HR 3.24, CI 1.10-9.56, p=0.03). Patient numbers in the 
subgroup with peak VO2 < 8.3ml/kg/min were small however (n=8, 7%), compared to the 46% patients 
that actually died, suggesting that the threshold sensitivity was not high. In another study, 
Triantafillidou et al. (Triantafillidou et al. 2013) prospectively identified a threshold of 14.2ml/kg/min 
for survival in 25 patients with moderate IPF (mean FVC 77.5 ±21.8), whilst Vainshelboim et al. 
(Vainshelboim et al. 2016) suggested VO2 <13.8 ml/kg/min as one of 5 CPET parameter thresholds 
(peak work rate, tidal volume reserve, VE/VO2 nadir and VE/VCO2 at AT) predicting survival in a 
prospective cohort study of 34 patients with IPF. Finally, Gläser et al. (Gläser et al. 2013) identified 
that the presence of PH (invasively assessed by right heart catheter) and peak VO2 % predicted were 
the only variables independently predictive of survival in a retrospective cohort of 133 patients, and 
application of % predicted values showed statically significant superiority to absolute data values. 
These results contrast with the findings of other studies where no independent association between 
survival in IPF and peak VO2 has been demonstrated (Wallaert et al. 2011, Miki et al. 2003). 
Heterogeneity in terms of disease severity, follow-up periods and accompanying disease co-morbidity 
may have impacted on results of these studies and larger prospective studies are required to ascertain 
the prognostic role of peak VO2 in predicting IPF survival.   
Gläser et al. found that the development of interceding PH in IPF was best predicted by reductions in 
ventilatory efficiency, the VE/VCO2 slopepred (cut off of ≥152.4, AUC 0.938; CI 0.892-0.984), with a 
sensitivity of 87.2% and specificity of 88.4%, but analysis of PH subgroup alone did not identify any 
CPET parameters that provided independent prognostic information.  VE/VCO2 at AT has also been 
shown to be a discriminating factor to determine the presence of PH across a cohort of IPF patients 
(adjusted OR 1.182; CI 1.029-1.384, p=0.021, n=81), but once again the prognostic value of this 
parameter has not been determined (Boutou et al. 2011).   
The prognostic value of an alternative measure of ventilatory efficiency, the ventilatory equivalent for 




et al. 2014). In a retrospective study of 38 IPF patients, those with VE/VCO2 at AT >45 had a significantly 
worse survival compared to patients with VE/VCO2 at AT ≤ 45 (HR 4.58, p=0.001), and this parameter 
remained a strong predictor even after correcting for functional severity of ILD, highlighting its 
possible use in the early detection of vascular impairment. Furthermore, the ventilator equivalent for 
oxygen at AT (VE/VO2 at AT) >45 was reported to be an independent poor predictor of 3 year-survival 
in a cohort of 63 IPF patients (Wallaert et al. 2011), findings consistent with the univariate analysis of 
Miki et al. (Miki et al. 2003). Results suggest that the magnitude of hyperventilation at ventilatory 
threshold may be determining prognostic value, but further prospective studies are required to 
confirm the value of these parameters of ventilatory efficiency in the prognostication of IPF.   
Exercise induce hypoxaemia was also considered as a potential prognostic factor in IPF. Miki et al (Miki 
et al. 2003) found that only two factors, age and PaO2 slope (defined as change in arterial oxygen 
pressure in mmHg / change in VO2 uptake during exercise (∆PaO2/∆VO2)), provided independent 
prognostic information in a cohort of 41 IPF patients (HR 1.096, CI 1.012-1.187, p=0.025 and HR 0.841, 
CI 0.731-0.967, p=0.015 respectively) and stratification of patients according to this slope 
(≤60mmHg/l/min or >-60mmHg/l/min) identified significant differences in median survival (1.6 years 
vs 4.5 years respectively). Measurement of this parameter does however, require invasive arterial 
blood gas analysis during exercise testing, that is unavailable in the many clinical exercise laboratories. 
In the study by King et al. (King et al. 2001), PaO2 at the end of maximal exercise was the only CPET 
derived parameter included in their comprehensive clinical-radiologic-physiologic scoring model to 
predict survival in IPF, and when weighted, accounted for as much as 10.5% of the maximum score in 
the complete model. Nevertheless, there were methodological limitations in this latter study; only 
158/238 patients performed exercise testing and patients received supplemental oxygen when 
significant hypoxaemia ensued.   
As a consequence of the utilisation of numerous different CPET parameters, CPET cut-off values, and 
timing of mortality evaluation, it was not possible to determine definitive thresholds for mortality or 
the development of pulmonary hypertension based on the analysed data.   
  
2.5. Study confounders, statistical analysis and reporting across all studies  
The majority of studies were considered to be at ‘high’ risk of bias due to inadequate account of 
potential confounding factors or methods of statistical analysis/reporting (figure 2.3).    
The data used in the majority of studies was obtained from existing databases and/or case note review 
(n=11, 85%). As the data was not collected as part of a designed study, several potential confounders 




et al. 2009, Miki et al. 2003, Gläser et al. 2013, Lopes et al. 2012, Swigris et al. 2009), body mass index 
(Triantafillidou et al. 2013, Fell et al. 2009, Miki et al. 2003, Kawut et al. 2005, van der Plas et al. 2014, 
Lopes et al. 2012) and smoking status (Wallaert et al. 2011, Kawut et al. 2005, Gläser et al. 2013, Lopes 
et al. 2012).   
The most important potential confounder was baseline ‘disease severity’ which was only specifically 
addressed as a confounder in one study; through the inclusion of lung function parameters and a 
composite physiological index (as markers of disease severity) into the Cox regression model used for 
analysis (van der Plas et al. 2014). This same study also stratified patients in an attempt to control for 
other potential confounders. Patients were sub-grouped into those with a systolic pulmonary artery 
pressure greater than or less than 40mmHg, in an attempt to control for interceding pulmonary 
hypertension, but this reduced subgroup sample sizes and thus may have reduced the statistical power 
to detect an effect.   
 Eligibility criteria were used to increase uniformity of study participants and reduce potential 
confounders. For example, two studies used participants referred for transplantation and thus by 
definition analysed distinct cohorts of more advanced patients but this selection bias reduced the 
generalisability of results (van der Plas et al. 2014, Layton et al. 2017). Other studies focused on 
healthier populations of ILD patients who did not need supplemental oxygen during CPET testing, but 
this, unsurprisingly, resulted in low mortality rates (n<10) leading to reporting bias (Vainshelboim et 
al. 2016, Fell et al. 2009, Triantafillidou et al. 2013).   
Multiple regression analysis was the dominant statistical methodology used to determine the 
relationship between CPET parameters and clinical outcomes in ILD. Whilst this approach is generally 
considered to be one of the better statistical approaches to minimise unknown confounders, many of 
the studies reported on sample sizes much smaller than the minimum requirement for multiple logistic 
regression analysis as determined by Bujang et al. (Bujang, Sa’at and Sidik 2017). Furthermore, of all 
of the studies examined, only one detailed an a priori power calculation (Vainshelboim et al. 2016) 
and important consideration taken forward to the design of this study to better prove my hypothesis. 
Many studies were likely to be underpowered to detect the outcomes proposed. This research 
remains a feasibility study but may go some way to predict expected outcomes in future trials and aid 
such power calculations.  
Stepwise multiple regression was used by some studies to determine the optimal model parameters 
to predict increased mortality (Triantafillidou et al. 2013, King et al. 2001). One criticism of this 
statistical approach is that model selection is conducted through parameter inference, which may lead 




(Whittingham et al. 2006). Furthermore, the order of parameter entry (or deletion) and the number 
of parameters, can also affect the selected model (Derksen and Keselman 1992), whilst the multiple 
hypotheses tests, performed as part of this analysis, increases the probability of Type I error 
(Whittingham et al. 2006). The authors of one study did however attempt to overcome some of these 
limitations by checking for consistency between forward selection and backward elimination 
algorithms (Triantafillidou et al. 2013).   
  
2.6. Discussion  
Maximum oxygen consumption (VO2max) is a measurement of the capacity for aerobic exercise and is 
determined by variables that define oxygen delivery by the Fick equation (Society and Physicians 
2003); thus gas exchange across the lung, oxygen content of blood, oxygen delivery to tissues and 
oxygen uptake in the tissues can all affect the VO2max. In healthy individuals, constraints of the 
cardiovascular system are most responsible for limiting VO2max (Wagner 1996, Stickland et al. 2012). 
In patients with ILD, limitation to exercise may generally occur as a consequence of one of more of: 1) 
ventilatory mechanical limitation (unable to increase tidal volume (VT) sufficiently and may reach their 
maximal predicted minute ventilation (% pred VEmax)), 2) abnormal gas exchange (or reduction in 
ventilatory efficiency, indicated by variables such as the increment in minute ventilation (VE) relative 
to carbon dioxide production (CO2; VE/VCO2) 3) and/or diffusion limitation (indicated by variables such 
as reduction in oxygenation ≥ 4% or hypoxia at anaerobic threshold (AT)/peak exercise).    
To my knowledge, this is the first study to systematically review and critically appraise studies that 
have reported the prognostic value of CPET in ILD. This field has gained recent attention with the 
majority of studies published within the last 8 years. Thirteen studies were identified that examined 
the prognostic value of CPET in ILD, all of which reported a prognostic role for CPET parameters in 
predicting clinical outcomes in ILD, with survival being the principle clinical outcome measured. Issues 
with study quality (relating primarily to the inherent problems of retrospective studies, patient 
selection and presentation of numerous CPET parameters), limits the strength of conclusions that can 
be drawn from the studies reviewed and thus whilst the associations presented shed important light 
to the potential role of CPET in disease prognostication in ILD, there is insufficient evidence at the 
moment to support its use in facilitating ‘real-world’ clinical decisions.   
The exclusion of unpublished studies (e.g. conference abstracts) and abbreviated reports from this 




ensure sufficient information was available to enable detailed data extraction from each study and aid 
this study design.    
One published article was identified that described the prognostic value of CPET in IPF that was not 
originally eligible for inclusion in our study analysis due to the full text being published in French 
(Wallaert et al. 2011). As touched on, the decision was taken to amend our published protocol to 
include this study as the subject of the study was deemed to be important by independent reviewers.    
This work has identified several considerations for future prognostic studies of CPET in ILD, including 
my research. Common to many human diseases, the disease progression in ILD is likely influenced by 
a complex interplay of patient, genetic, environmental and treatment factors. As such, a multivariable 
approach to the design and analysis of any future prognostic studies of ILD is essential if we are to 
confirm a specific role for CPET in routine monitoring. In contrast to randomised controlled trials, there 
are no robust standards defining the need to register or publish protocols for prognostic research and 
as such it is not always transparent whether statistical analysis were part of a priori plan (Hemingway, 
Riley and Altman 2009). Almost all studies in this review examined multiple prognostic CPET variables 
and as such there is potential for selective reporting bias that I intend to overcome by more stringent 
protocol registration with pre-specified outcomes of interest. A confounder overcome within my study 
by pre-identified CPET variables for evaluation.  
  
2.7. Conclusion  
The quality of existing studies on the role of CPET in the prognostication of ILD limits the conclusions 
that can be drawn from such work. Larger prospective studies are needed to establish the role of CPET 
in the longitudinal assessment of ILD in the future.   
The review has however guided my study development and provided additional knowledge to the 
protocol. From the data available, CPET has been performed in a similar IPF cohort to the planned 
patient group from the Bristol ILD service. The team gained confidence in its safety in a moderate 
patient group (as defined by an FVC % predicted between 50-80%) and as a result, extended the 
inclusion criteria to include such patients. Unsure of the likely decline in exercise capacity of the more 
moderate group, the decision was made to only repeat CPET in the mild cohort and to enrich for this 
patient group (30 mild: 20 moderate) to reduce potential loss to follow up.   
Whilst the majority of the studies are retrospective, and therefore open to suggestion of bias, the 
enrolment will be prospective in order to reduce this chance. Furthermore, this study will have 
predefined CPET parameters to avoid the previously mentioned selection bias of CPET outcomes. The 




study more focused on patient outcomes, the decision was made to include two different IPF specific 
questionnaires and assess the relationships of how the patient perceives their disease against clinical 
outcomes, making this study unique to those previously reported. Whilst many of the studies primary 
endpoints include mortality or time to transplantation, my initial discussions focused on correlations 
with the commonly used lung function outcomes of FVC and DLCO % predicted. The former being widely 
accepted by international licensing authorities as an acceptable marker for mortality. As outlined in 
chapter 1, a great volume of data exists on the prognostic use of declines in these PFT measurements 
and initial thoughts were that a 12 month follow up may provide sufficient evidence for a confident 
prediction on the prognostic markers of CPET. However, the follow up times throughout this evidence 
base suggested this may not be long enough due to the heterogeneity of IPF. As a result of this, the 
decision was to increase to the total follow up to a maximum of five years to gain a better 





Chapter 3: Feasibility of CPET in a mild to moderate IPF population  
  
3.1. Introduction:   
Hypothesis: CPET is feasible in a population of mild to moderate IPF patients and more sensitive to 
change in patient’s health status than 6 Minute Walk Test (6MWT), Forced Vital Capacity (FVC) or 
Transfer factor for carbon monoxide (TLCO), the routine clinical tests used globally today.  
Hypothesis Generation: Whilst the use of exercise for the purposes of prognostication has been well 
explored in various IPF cohorts, this has very much focused on the use of a 6MWT, utilising either the 
patient’s total distance or distance as a % predicted, as discussed in chapter 1. After initial discussion 
with the NBT physiology team, it was clear that, at the time, CPET was rarely used in the wider 
respiratory department and few, if any IPF patients were assessed in this way. At this point I initiated 
a literature review of all the evidence for the use of CPET as a prognostic tool in IPF and as seen in the 
previous chapter, ‘The quality of existing studies on the role of CPET in the prognostication of ILD limits 
the conclusions that can be drawn from such work’. Having been guided by the review and with 
questions outstanding from the initial hypothesis, the decision was made to proceed with a 




test in this population as well as explore pre-determined parameters CPET can provide as to their 
discrete prognostic value for a disease inherently difficult to predict individual outcomes.  
Secondary to the exercise testing was the addition of health status questionnaires. Numerous 
questionnaires have been used across the globe within IPF studies although to date, these have not 
been designed specifically for ILD or IPF patients. Permission was obtained from the authors of both 
K-BILD (Kings College Hospital NHS Trust) and IPF-PROM (Imperial College Healthcare NHS Trust) to 
better understand the relationship between exercise outcomes and an individual’s perception of their 
quality of life and health status. The validity of K-BILD has been documented and indeed, the 
questionnaire is now widely used across numerous late phase ILD studies, however the same cannot 
be said of IPF-PROM. This study has been listed by the author (A.M Russell) as part of its validation 
and the hope is, with its increasing use in different IPF cohorts that longitudinal MCIDs can be attained 
for total and domain scores to better understand its meaning.  
Research question: In order to test this hypothesis, the study set out to investigate the feasibility and 
safety of CPET in a population of mild to moderate IPF patients, a test previously not routinely 
considered for such patients and one for which a relatively small amount of data exists for its safety 
and outcomes. Secondly, with longitudinal follow up, the outcomes will provide a greater 
understanding and answer questions on the relationship of CPET parameters to more sensitive 
changes in patient’s own perceived health status and allow comparisons to 6 Minute Walk Test 
(6MWT), Forced Vital Capacity (FVC) or Transfer factor for carbon monoxide (TLCO), the routine clinical 
tests used globally today.  
3.2 Methods  
This prospective observational follow-up study was conducted at the North Bristol ILD Service located 
at Southmead Hospital, Bristol. Written informed consent was obtained from each of the study 
participants prior to enrolment and study participation. Subjects were recruited between June 2019 
and May 2020 from the outpatient clinic environment and all have a multidisciplinary team meeting 
consensus diagnosis of IPF based upon the ATS/ERS/JRC/ALAT 2011 guidelines (Raghu et al. 2011). The 
reasons for this enrolment timeline were two-fold. Firstly, the deadlines given by the sponsor for study 
and MSc data collection completion, but also, from a retrospective search of IPF patient numbers 
attending clinics at Southmead Hospital and the author’s personal time allowance for this study, it was 
felt 11 months would be necessary for successful enrolment of the planned numbers.    
Due to the previously discussed data including IPF patients undertaking CPET, seen in Chapter 2, a 
cautious approach to patient enrolment to this study was undertaken to maximise patient safety. A 




at baseline. This was with the knowledge that non-exercise, interventional studies of IPF patients 
entering large phase III global trials have a mean TLCO % between 40-50% (Richeldi et al. 2014, King et 
al. 2014, Noble et al. 2011). Results derived from this patient cohort may provide evidence of safety 
to allow more inclusive criteria when considering lung function parameters, especially TLCO and could 
allow for the study of a more moderate to severe IPF population potentially providing results across a 
wider heterogeneity of patient types.  
Two major amendments were submitted to the REC and subsequently approved for changes to the 
study protocol during the recruitment and subsequent follow up stages. Evidence became available 
(Thomas et al. 2019) that the aging lung can differ in speed in its functional decline. Given the average 
age of this cohort being greater than 70, this influenced the study recruitment. Considering this, the 
strict use of the FEV1/FVC ratio cut off being above 0.7 (as a determining measurement of obstructive 
vs restrictive disease) was changed. The decision was made to alter the exclusion criteria to read ‘<70% 
unless within normal range for age (pre bronchodilator)’. Although two individuals had been screen 
failed prior to this change, it did allow inclusion beyond this accepted change (Table 3.1).  
The second, and increasingly important adjustment to the protocol, was the study follow up time 
period. This major study amendment permitted follow up time for lung function and vital status to be 
observed for a period of up to 5 years. This decision was made given the heterogeneity of our study 
subjects disease course as previously discussed. Although always progressive, the disease path over 
12 months, in this milder cohort may not provide the evidence of progression needed to make any 
firm conclusions on the many CPET variables available. The aim of an extended observation period will 
allow assessment of continued lung function testing (as part of standard clinical care) against the 
parameters of CPET tested at baseline and 12-month follow-up (where applicable). Given these results 
over an extended period, the aim is for this feasibility study to aid power calculations and application 
for a larger future study.   
3.2.1 Study Population  
Dependant up on an individual’s FVC% predicted being above or below 80%, patients were sub divided 
in to a ‘mild’ or ‘moderate’ category. Although evidence for such staging based solely on % predicted 
FVC is limited, it is likely for accuracy, additional variables should be utilised (Kolb and Collard 2014), 
this provided an additional safety measure for follow up.  Those patients with a milder disease would 
undertake both a baseline and repeat CPET at the 12 months follow up. Due to the uncertainty of the 
ability of those with reduced lung function to perform a maximal exercise test, the decision was made 
to take only baseline measurements from CPET at the start of the study. Key exclusion criteria were 
also primarily in place for reasons of safety and in line with ATS/ACCP guidelines (Society and 
Physicians 2003): Patients requiring oxygen treatment (due to the deficiency of safety evidence of 
undertaking CPET in this patient cohort), history of infarction within 6 months or unstable angina 




resulting in a non-maximal test. The indications for exercise termination included acute myocardial 
infarction (MI) or suspicion of MI, onset of moderate-severe angina, serious dysrhythmias & at the 
request of the subject.   
Key Inclusion Criteria  Key Exclusion criteria  
Male or female aged ≥ 40yrs  Cognitive behaviour/Inability to perform CPET  
Multidisciplinary team meeting consensus diagnosis of IPF based 
upon the ATS/ERS/JRC/ALAT 2011 guidelines  
Mobility issues  
Chest high resolution computed tomography (HRCT) and, if 
available, surgical lung biopsy pattern consistent with diagnosis 
of IPF  
• History of myocardial infarction (MI) within 6 months or 
unstable angina within 1 month.  
• Severe or untreated arterial hypertension (>200mmHg 
systolic at rest, >120mmHg diastolic  
FVC ≥ 50% and <80% predicted (Moderate) or ≥80% predicted  
 
FEV1/FVC < 0.7 unless within normal range for age 
(prebronchodilator)  
 Patients using O2 treatment  
     
Table 3.1. Key study inclusion/exclusion criteria.  
Patients were followed up at 12 months ± 3 weeks from the initial exercise test, with a further 4 years 
of scheduled follow up to planned. This 12 month initial period of follow-up was chosen given the 
acceptance by global licensing authorities including the US Food and Drug Administration (FDA) and 
the European Medicines Agency (EMA) among others that the key lung function comparator (FVC) is 
a suitable marker of decline in IPF patients (Collard et al. 2003, Behr et al. 2015) and can be prognostic 
of mortality in this population over such a period of time (Zappala et al. 2010). Figure 3.1 below 




Figure 3.1. Patient flow for study involvement from initial approach in clinic visit to extended follow up to 5 years.  
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3.3. Ethics  
The study was sponsored by the University of Bristol and was reviewed by the Bristol Interstitial Lung 
Disease clinical team at Southmead hospital, the research and Innovation department at North Bristol 
NHS Trust, The Health Research Authority (IRAS 223450), an independent research ethics committee 
and the Academic Respiratory Unit, University of Bristol. Following a major amendment to the study 
protocol to allow ≤ 5-year follow-up of data from routine clinical lung function appointments, all 
patients were asked for further written consent.  
Potential participants were initially approached by members of their clinical care team, to brief them 
on the purpose of this research. At this time, all patients were reassured that there was no 
requirement to participate and decline for participation would not change their individual care plan. 
Following this and after an initial interest in study participation, a PIS was provided to each individual 
and a carer should it be requested, explaining the purposes of the research and the details of their 
study involvement. Each participant was provided the opportunity to discuss the study with a member 
of the clinical or research team should they wish. Should any of the patients at this point feel 
sufficiently informed and motivated to sign the consent form, they could do so. Otherwise, all were 
given opportunity to consider the study further. Those indicating interest in participating were given 
the opportunity to go away and consider their options further and contact the research team at a later 
stage should they be willing to participate (given maximum of 2 weeks). A member of the research 
team undertook a follow up phone call at one week after the initial approach. Consent was taken at 
the clinical trials unit or outpatients department on the Southmead Hospital site, by a member of the 
research team, for those that did not consent at the initial screening visit.  
No patients were enrolled into the study that were (or had been in the previous 4 months) involved in 
an interventional study, including Clinical Trials of Investigational Medicinal Products (CTIMPs) of any 
description. Patients could partake if they were involved in questionnaire-based studies.  
All data will be stored securely for a period of 5 years. Participants consented for their information to 
be stored in its anonymised form for this length of time. The cross-referencing list and data will be 
stored electronically on a Bristol University protected computer for a period of 5 years also. Beyond 





3.4. Lung Function Tests  
3.4.1. Pulmonary Function Tests   
Pulmonary function tests were undertaken by all patients ± 3 weeks from the date of CPET. All tests 
were performed in accordance with ATS/ERS guidelines (Graham et al. 2019) and repeat 
measurements taken after 12-months.   
Included in the measurements recorded during pulmonary function testing were forced expiratory 
volume during first second of expiration (FEV1), forced vital capacity (FVC), total lung capacity (TLC) 
and single breath transfer factor for carbon monoxide (TLCO) measured by an nSpire HDpft (nSpire 
Health GmbH, Germany). These chosen measurements make up the standard data set for routine 
clinical lung function tests within the hospital and can reliably be replicated over the full follow-up 
period.  
Measured parameters were presented as actual values (litres) as well as percent predicted values of 
the European Community for Coal and Steel reference values.  
All patients were asked to score their self-perceived breathlessness during their activities of daily living 
according to the Medical Research Council (MRC) dyspnoea scale (see Figure 3.2).  
  
Fig 3.2. The MRC breathlessness scale (adapted from (Fletcher 1952).  
3.4.2. 6-Minute Walk Test  
Study participants undertook a baseline and follow-up 6 MWT with a member of the Trust physiology 
team conducted in accordance with the American Thoracic Society guidelines (Laboratories 2002) in a 
15m corridor at the hospital’s respiratory outpatient unit.  Measurements utilised for the purposes of 
this study were total distance achieved (m), % of theoretical distance walked alongside oxygen 
saturation at initiation of test and minimum saturation level during.  




All patients underwent a symptom limiting CPET that was performed and assessed by the respiratory 
physiology team at North Bristol Trust in line with the guidelines of the ATS/ACCP (Society and 
Physicians 2003), (ergoselect 100, ergoline GmbH, Germany).   
Workload was determined primarily by reviewing the patient’s normal intensities of exercise and 
previous levels of activity (with increases between 5W & 15W) but also additional factors including 
gender and body size in order to ensure a maximal effort was achieved within 8-12 minutes. Despite 
a recent ERS CPET standardisation statement suggesting a respiratory exchange ratio (RER) >1.05 
(Radtke et al. 2019) is indicative of a maximal effort test, this has been contradicted by Thomas et al 
(Thomas et al. 2019, Thomas and Sylvester 2020). To be certain of a successful test, the team’s decision 
was an RER ≥1.1 was required, although this also needed to be accompanied by at least one of the 
following markers (as determined by the physiologist) to confirm a maximum effort; maximum heart 
rate (HR max) > 80% of maximum predicted HR which was calculated by the sum of 220 – patient age, 
maximum minute ventilation during exercise >85% predicted based on maximum voluntary 
ventilation (MVV) at rest, and finally a plateau in VO2 with an increased workload.   
A decision for this study was made by the clinical and physiology team to use a cycle ergometer. This 
choice was based upon the perceived higher safety in this vulnerable patient group over a treadmill, 
although as suggested by Alessandro Mezzani (Mezzani 2017) in a recent published seminar, a number 
of other benefits may also be present (Figure 3.3).  
  
Figure 3.3. Advantages/ disadvantages of treadmill versus cycle ergometer for CPET.  
  
Data collection and analysis were made by nSpire Zan 600 USB system (nSpire Health GmbH, 
Germany). The test could be discontinued at the discretion of the attending physiologist although no 
minimum Sp02 was pre-defined.   
The protocol included a seated rest period for 3 minutes to allow the patient familiarisation with the 
equipment and apparatus (facemask and ECG probes), followed by unweighted peddling for the same 
time, allowing baseline VO2 measurements to be attained. Subjects were asked to maintain a rate of 
60 revolutions per minute throughout the exercise period. Anaerobic Threshold (AT) was calculated 




Following cessation of the test, the subject remained seated with unweighted peddling and reduced 
cadence for a recovery period for a further 2 minutes (see Figure 3.4.)  
  
 
Fig 3.4. CPET ramp protocol with a target of 10 minutes to patient exhaustion.  
Continuous measurements for the following pre-defined variables were made during the exercise 
period:  
· Peak oxygen consumption (VO2 peak, ml/kg/min),  
· Peak oxygen consumption at anaerobic threshold (AT)  
· Carbon dioxide production (VCO2)  
· Peak minute ventilation (VE peak) - (marker of ventilatory function during exercise),  
· VE/VCO2 slope as derived from the above values - (reflects changes in ventilatory drive)  
· Peripheral capillary oxygen saturation SpO2 - (marker of hypoxaemia indicating possible ventilatory 
limitation to exercise)  
· Peak power output (W) - (marker of musculoskeletal function)  
· Heart rate (HR) - (marker of cardiac function during exercise), · 
Breathing reserve (BR) - (potential indicator of ventilatory defect)   
3.4.4. Questionnaires:  
All patients completed two Visual Analogue Scores (VAS) namely a standardised day/night cough score 
and the Bristol VAS (measuring breathlessness and fatigue) (Yates et al. 2018a) as well as two ILD 
specific Quality of Life questionnaires (QoL), Kings Brief ILD (K-BILD) (Patel et al. 2012) & IPF-Patient 
Reported Outcome Measures (IPF-PROM) (Russell 2017). These were all repeated at the 12 months 
follow up, with the patients blinded to their baseline answers. Due to the lockdown of hospitals due 
 
Time (minutes) 
CPET ramp protocol 
Rest   and unweighted  
peddling   
10 +/ -  minutes 2   Recovery  




to COVID-19, those patients unable to attend study appointments for follow up, were asked to 
complete the questionnaires at home and return by post.   
  
3.5. Primary & Secondary outcomes  
Given the limited data of use of CPET in such an IPF cohort, this feasibility study was aimed to gain 
insights on the practicality of undertaking CPET in this mild to moderate group of patients, understand 
the likely attrition rates of study participants as well as the safety of such a strenuous exercise test in 
this study population. Secondary endpoints, gained from insights of previous analysis on the use of 
CPET prognostication in IPF, included the change from baseline at 12 months for CPET variables, 
correlation between CPET parameters and lung function changes as well as changes to health status 
(using questionnaires) over a 1-year period.  
3.6. Statistical Analysis  
Categorical variables are reported as absolute numbers and percentages. Normality of continuous 
data was initially verified using D’Agostino and Pearson normality test. Mean and standard deviation 
(SD) were used to describe parametric data; median and interquartile range (IQR, in brackets) for 
nonparametric data. Differences between two groups were verified by t-test with Welch’s correction 
(continuous data), χ2-tests (categorical data) and paired t-tests for comparison in variables from 
baseline to 12 months. Pearson’s correlation was used to determine correlations between parametric 
variables. Data were analysed using GraphPad Prism version 8.0. A P value of <0.05 was considered 
statistically significant.  
  
3.7. Discussion  
Ethics approval: ‘Always allow longer than you expect’ would be a take home message having been 
through the process. Although the IRAS application itself has been relatively straight forward, ensuring 
timely approval from both the sponsor and NHS centre was at times difficult and ultimately led to an 
approximate 6-month delay in study initiation. The author’s presentation to the REC, including 
numerous questions from both lay members and healthcare professionals on the committee, 
surrounding employment within a pharmaceutical company was of particular interest, highlighting the 
high degree of cynicism of the industry as a whole.   
One final delay in study initiation came as a result of the required Research Passport needed by both 




Southmead Hospital. The process for this remains unclear and is ill-defined. Thanks must go to 
individuals across many university sites who pointed me in a direction to someone who ‘may know’.   
Personal key learnings from the methodology have however been the initial hypothesis generation, 
functionality of the integrated research application system (IRAS) and local Regional Ethics Committee 
(REC) presentation. All of which were unknown at the start of this research.  
3.7.1. Challenges of study design:   
Study Funding: Although student study time was funded for the period of data collection, this was 
limited, and the hope was to gain approval for a National Institute for Health Research (NIHR) Clinical 
Research Network (CRN) funding to provide some additional nursing support from the academic 
research team. Whilst the precedent for such an exercise study in a similar patient cohort although 
lacking a longitudinal component had previously been set, our application was declined. A subsequent 
review was requested and despite approval for an amount of funds being awarded by the national 
respiratory CRN lead, this was later overturned. Although not essential to the setup of the study, it did 
place further pressure on timelines for the trawl of outpatient clinic appointments, patient interaction 
and introduction of the study and gaining of consent, resulting ultimately in an additional delay in 
patient recruitment.  
Study Administration: Taking a large proportion of workload throughout the study period, the 
administration needed has provided great learning simply in the time allowance. Ranging from initial 
study documents (Patient Information Sheet (PIS), consent forms), ethics approval, Clinical Research 
Folder (CRF) through to the search of clinic appointments & naturally exercise appointments with the 
physiology team. The teamwork needed for larger studies has been very evident and whilst single 
handed management has been sustainable for such a feasibility study, it would not be recommended 
for anything much larger.  
COVID-19 pandemic: Like every study ongoing around the globe, this research has been hugely 
disrupted by the virus. Due to study timelines and follow up, the last patient out was due in May 2020, 
with almost a third of repeat CPET test due between February and May 2020. Whilst the investigator 
was able to remotely contact all outstanding patients at the initiation of lockdown, enabling 
completion of questionnaires by post, there remains an amount of missing data. As can be seen from 
figure 3.1 and as will be discussed further in the next chapter, five patients in total (4 mild and 1 
moderate) were lost to the study due to COVID-19. As a result of the temporary closure of all lung 
physiology testing and the subsequent capacity reduction upon reinstatement (due to the need to 
ventilate rooms post patient and requirement for PPE), routine lung function data was able to be 




undertake further CPET testing after the initial lockdown in early 2020. Study continuation was sought 
by the sponsor to enable the 5-year follow up amendment to take place (beyond its planned closure 
in May 2020). This delay in approval, due to the sponsors workload with COVID-19 and allowance of 
reconsent via email or post, led sadly to the loss of three patients to this extended follow up, who 
deceased in this interim period. One further deceased patient had given previous reconsent at 1 year 




Chapter 4: Results  
  
A total of 74 consecutive IPF patients were prospectively assessed for eligibility and subsequently 
approached for entry to the study. Screen failure and decline to partake excluded 32 patients, leading 
to enrolment and consent gained for 42 patients. Prior to study commencement and baseline testing, 
a further 4 patients withdrew consent, 5 patients developed exclusions (2 newly planned surgery, 2 
undiagnosed cardiac arrhythmia and 1 frailty leading to inability to perform CPET). A further patient 
died prior to study initiation, see figure 4.1.   
  
Figure 4.1. Study enrolment.   
A total of 31 patients (23 moderate and 9 mild) underwent baseline testing, however due to the impact 
of COVID-19 previously discussed, a further 5 patients (4 mild and 1 moderate) were lost to follow-up, 




similar to those observed across other IPF study populations, with a male predominance (n=22, 82%) 
and a mean age of 75 years (SD ± 1.5 years). Although symptomatic at baseline, with a median Medical 
Research Council (MRC) breathlessness score of 2 (IQR 2-3), indicating that individuals feel ‘short of 
breath when hurrying on a level or when walking up a slight hill’, lung function was relatively well 
preserved with an FVC % predicted of 91% and gas transfer (TLCO) of 61%. Approximately one third 
(33%, n=9) of the final study population (5 mild and 4 moderate) received antifibrotics during the 
12month observational period. The most common comorbidities included gastro-oesophageal reflux 
disease (GORD), hypertension and coronary artery disease, with over half the patients (52%) having 
>1 comorbidity. At completion of 1 year follow up, all patients remained alive. See table 4.1.  
  
Characteristic   Overall n=27  Mild n=19  Moderate n=8  P value  
Age (yrs) mean (SD)  75 (+/- 1.5)  75 (+/- 1.5)  74 (+/- 1.5)  0.440  
Gender (male n, %)  22, 82%  14, 74%  8, 100%  0.280  





0, 0%  
10, 37%  
17, 63%  
  
0, 0%  
9, 47%  
10, 53%  
  
0, 0%  
1, 12.5%  
7, 87.5%  
  
0.552  
BMI (kg/m)  28.5 (+/- 0.86)  28.9 (+/-1.2)  27.7 (+/- 1.0)  0.585  
MRC (median, IQR)  2 (2-3)  2 (2-3)  2 (2-3)  0.964  
Antifibrotics (n,%)  9, 33%  5, 26%  4, 50%  0.375  
Co-morbidities        n/s  
Gastro-oesophageal reflux  
Hypertension  















Lung function parameters           
FVC (L)  
FVC (% predicted)  
2.96 (+/- 0.14)  3.11 (+/- 0.18)  2.61 (+/- 0.16)  0.050  
91 (+/- 3.1)  99 (+/- 2.3)  70 (+/- 1.8)  <0.0001  
FEV1/FVC ratio  78 (+/-1.5)  76 (+/- 1.8)  82 (+/- 2.6)  0.080  
TLCO % predicted  61 (+/- 1.7)  63 (+/- 2.2)  57 (+/- 2.2)  0.055  
6MWT   n=25  n=18  n=7    
Distance achieved (m)  
% theoretical distance (m)  
350 (+/- 12.7)  
78 (+/- 3.3)  
349 (+/- 15.7)  
78 (+/- 3.9)  
354 (+/- 22.1)  
76 (+/- 6.4)  
0.827  
0.821  
CPET   n=27  n=19  n=8    
VO2 peak/kg (ml/kg/min)  20.9 (+/- 0.75)  20.6 (+/- 0.97)  21.7 (+/- 1.11)  0.489  
VO2/kg  at AT (ml/kg/min)  13.6 (+/- 0.67)  13.8 (+/- 0.83)  13.0 (1.13)  0.585  
VE peak (L/min)  69.9 (+/- 4.07)  69.0 (+/- 5.00)  72.1 (+/- 7.38)  0.731  
VE peak (% predicted)  74.5 (+/- 2.8)  71.0 (+/- 3.2)  82.9 (+/- 4.4)  0.045  
VE/VCO2 at AT   28.2 (+/- 0.59)  28.7 (+/- 0.76)  27.2 (+/- 0.83)  0.201  
Minimum O2 saturation during CPET (%)  91 (+/- 0.9)  91 (+/- 1.2)  92 (+/- 1.0)  0.723  
Peak work rate (W)  104.8 (+/- 5.08)  103.6 (+/- 6.74)  107.6 (+/- 6.62)  0.673  
Peak work (% predicted)  44 (+/- 1.7)  44 (+/- 2.2)  43 +/- 2.2)  0.565  
HR (bpm)  141 (+/- 4.2)  141 (+/- 4.9)  139 (+/- 8.7)  0.793  
HR (% predicted)  97 (+/- 2.9)  98 (+/- 3.4)  95 (+/- 5.7)  0.711  
BR max (L/min); median (IQR)  26.5 (18.4-32.5)  28.8 (18.8-33.3)   0.083  






Total   
Psychological domain  
Breathlessness and activity domain   
Chest symptoms domain  
65 (+/- 2)   
69 (+/- 3)  
56 (+/- 2)  
78 (+/- 3)  
64 (+/- 2)  
69 (+/- 4)  
52 (+/- 3)  
76 (+/- 4)  
61 (+/- 3)  
52 (+/- 3)  





IPF-PROM questionnaire   n=27  n=19  n=8    
Total   
Physical breathlessness  
Psychological breathlessness  
Well-being   
Energy  
20 (+/- 5)  
5 (+/- 0.3)  
5 (+/- 0.3)  
5 (+/- 0.4)  
5 (+/- 0.3)  
20 (+/- 1.05)  
5 (+/- 0.3)  
5 (+/- 0.3)  
5 (+/- 0.5)  
5 (+/- 0.4)  
21 (+/- 1)  
5 (+/- 0.5)  
6 (+/- 0.5)  
5 (+/- 0.4)  






VAS Cough (cm) (median, (IQR))  1.7 (0.8-2.8)  1.5 (0.2-2.6)  2.3 (1.4-3.0)  0.135  
Bristol VAS breathlessness (cm)   1.9 (0.8-3.3)  1.8 (0.8-3.4)  2.4 (1.1-4.7)  0.630  
Bristol VAS fatigue (cm)  3.7 (1.1-5.1)  3.7 (1.1-5.1)  3.8 (1.4-6.3)  0.457  
  
  
Table 4.1. Baseline characteristics of IPF participants All data shown as mean with standard deviation (SD) unless otherwise stated. All 




Reasons for exercise cessation across the mild and moderate cohort fell into two categories, namely 
breathlessness and muscle (leg) fatigue (n=10, 37% and n=17, 63% respectively). Within the mild 
patient group who were undertaking repeat CPET at 12 months, this was more evenly split, with 
breathlessness being the cause of discontinuation in 9 patients (47%) and leg fatigue in 10 (53%).  
Across the whole cohort, the percentage of patients stating they undertake regular exercise was 56% 
(n=15) although no reasons were given as to why the remaining patients chose not to exercise 
routinely and no difference between the mild and moderate groups for those undertaking exercise 
routinely was observed (58% vs 50% respectively) (p>0.05).  
One patient described dizziness related to his breathlessness during CPET, but no other adverse events 
were recorded. There were no serious adverse events  
  
4.1. Baseline measurement comparisons between mild and moderate groups:  
From table 1, it can be seen baseline demographics between the mild and moderate IPF groups were 
statistically comparable. As per the study inclusion and subgroup definitions, participants in the 
moderate IPF group had a statistically lower baseline FVC% predicted when compared to those in the 
milder group (moderate 70% ± 1.8 vs mild 99% ± 2.3, p<0.0001). Furthermore, although not reaching 
statistical significance, there was a trend towards a reduced TLCO in those patients within the more 
advanced disease moderate subgroup (moderate 57% ± 2.2 vs mild 63% ± 2.2, p= 0.055). No difference 




Baseline QoL questionnaires showed lower scores (indicating a reduced patient perceived QoL) for the 
patients with moderate disease for total K-BILD score (moderate 60 ±2 vs mild 64 ±2, p= 0.058) as well 
as a similar trend in the individual domains of chest symptoms and psychological when compared to 
those with mild disease, although these values were not statistically significant. When comparing the 
results within the IPF-PROM total and domain scores, where a higher score is indicative of a reduced 
quality of life, no significant differences were seen. Study patients showed an increase in psychological 
experience of breathlessness (moderate 6± 0.5 vs mild 5± 0.3, p= 0.121) although again, this was not 
statistically meaningful.  
No differences were observed in the Visual Analogue Scores (VAS) for cough, breathlessness or fatigue 
between the two groups.  
Participants across both groups achieved the anaerobic threshold (AT) during baseline testing and a 
respiratory exchange ratio (RER) of >1.10 allowing an expectation of a maximal effort test. No tests 
were stopped prematurely. Baseline CPET values were all within expected published ranges for age 
(Society and Physicians 2003) being relatively well preserved, not unexpected given the milder disease 
nature of this patient population. Of note, was a significant difference between groups in % predicated 
peak minute ventilation (moderate 82.9% ± 4.4 vs mild 71.0% ± 3.2, p= 0.045) likely indicating the 
increased necessity for oxygen uptake in this patient group although no evidence is published to 
suggest any prognostic use for this difference.  
Our initial baseline data analysis correlating CPET variables with QoL scores resulted in acceptance of 
two posters at national and international congress (Winter British Thoracic Society 2019 and American 
Thoracic Society 2020), see appendix F and G. From this initial data of CPET variables measured, some 
significant correlations to both questionnaires were observed. At anaerobic threshold (AT), VO2 
peak/kg positively correlated with K-BILD total scores (r=0.42, p=0.03), breathlessness/activity (r=0.47, 
P=0.014) and chest domains (r=0.44, p=0.002) (Pearson’s correlation). Similarly, IPF-PROM total score 
and wellbeing domains significantly correlated with VO2 peak (r=-0.43, p=0.02 and r=-0.44, p=0.02) 
with a trend towards statistical significance for total IPF-PROM and VO2 peak at AT (p=0.06). The 
ventilatory equivalents for oxygen (VE/VO2) at AT also strongly correlated with total K-BILD score 
(r=0.39, p=0.001) although there were no significant correlations with the individual domains of either 
questionnaire.   
  
Baseline Variable  Correlation 
coefficient  
P value  
(Spearman’s  
Peak VO2/kg/min at AT      




    vs Breathlessness and Activity domain  0.47  0.014  
    vs Chest domain  0.44  0.002  
    vs Total   0.42  0.03  
IPF-PROM      
    vs Total score  -0.36  0.06  
Peak VO2      
K-BILD      
    vs Chest domain  0.42  0.03  
IPF-PROM      
    vs Total score  -0.43  0.02  
    vs wellbeing domain  -0.44  0.02  
FVC % predicted      
    vs Total K-BILD    0.14  
    vs Total IPF-PROM    0.50  
TLCO % predicted      
    vs Total K-BILD    0.16  
    vs Total IPF-PROM    0.32  
  
Table 4.2. Baseline CPET parameter correlation to QOL scores and pulmonary function testing.  
With regards the more widely performed exercise test of 6MWT and total questionnaire scores, total 
scores for both K-BILD and IPF-PROM significantly correlated with 6MWT distance (K-BILD r=0.44, 
p=0.03 and IPF-PROM r=-0.43, p=0.03). The expected difference between groups in distance walked 
was not observed, possibly due to the inherent difficulties of this test, with regards individual 
motivation, baseline fitness and mobility issues affecting movement. Baseline and minimum SpO2 
results from 6MWT did not show significant correlations (Total K-BILD p=0.25 and p=0.32 respectively, 
Total IPF-PROM p=0.53 and p=0.55 respectively). Considering the results from the lung functions 
parameters, again no significant correlations were observed (FVC % predicted: Total K-BILD, p=0.14; 
Total IPF-PROM p=0.50 and TLCO % predicted: Total K-BILD, p=0.16; Total IPF-PROM, p=0.32).   
No significant correlation between baseline CPET parameters and VAS scores were seen (p>0.05).  
  
4.2. Measurements at 1 year follow up  
Total study cohort  
Previous work undertaken by Collard et al. (Collard et al. 2003) have described the utility of % FVC 
decline as a surrogate marker of survival in IPF patients. Their work has shown, over a similar 12 month 
follow up period, a drop of 10% FVC % predicted will significantly reduce expected mortality versus a 




follow up, the mean reduction in FVC % predicted for the whole study group (n=27) was -3.56% (± 
1.37, p=0.04). Whilst statistics dictate this to be significant, it is likely to be below those deemed 
clinically meaningful. Similarly, with TLCO % predicted, data from recent Czech registry data (Doubková 
et al. 2018), confirmed a 12 month drop of 15% TLCO predicted conferred a worse overall survival. Our 
study group had a mean decline of 3.23% (± 1.47, p=0.04), again statistically significant but well below 
the data evidence for clinical significance.   
For the 6MWT parameters, there was no statistically significant reduction in either distance achieved 
(-4.8m ± 6.9, p=0.50) or in the % theoretical distance 0.15% (±1.6, p=0.92).  
Within the K-BILD questionnaire, there was a statistically significant reduction in the breathlessness 
and activity domain from baseline to follow up of 4.81 points (±1.96, p=0.02). This drop in score is 
suggestive of a worsening health status, although it is difficult to predict the clinical significance. 
Published data (Sinha et al. 2019) has suggested a minimum clinically important difference (MCID) of 
a 7-point reduction for this domain, although this was assessed from an ILD cohort of only 57 patients, 
of which 17 were IPF. As a reduction in activity and inability to perform the usual daily activities is 
often an early effect mentioned by IPF patients, such a 5-point drop could potentially hold some merit 
in disease development and QoL.     
Parameter  Change at one year follow up (n=27)  P 
value  
  
Lung function /walk test  Mean % change (+/- SD)    
FVC % predicted  -3.6 (+/- 1.4)  0.015  
TLCO % predicted  -3.2 (+/- 1.5)  0.037  
6MWT distance % theoretical distance   -0.16 (+/- 1.6)  0.920  
K-BILD questionnaire  Mean unit change (+/- SD)     
Total   
Psychological domain  
Breathlessness and activity domain   
Chest symptoms domain  
-2.30 (+/- 1.73)  
-1.71 (+/- 3.13)  
-4.81 (+/-1.96)  





IPF-PROM      
Total   
Physical breathlessness  
Psychological breathlessness  
Well-being   
Energy  
0.52 (+/- 0.75) 0.11 
(+/- 0.25)  
0.33 (+/- 0.27)  
-0.33 (+/- 0.23)  






VAS Cough (cm) median  -0.21  0.601  
Bristol VAS breathlessness (cm) median  0.0  0.876  





Table 4.3. Total cohort change in Lung function, K-BILD, IPF-PROM and Visual analogue scores of patients at 1 year follow up. Paired t-test or 
Wilcoxon paired signed rank test.   
  
There were no statistically significant differences in the VAS scores for cough, breathlessness and 
fatigue or in the IPF-PROM from baseline to 12 months (p>0.05).  
4.2.1. Mild group repeat CPET follow up  
Aside from the 4 mild patients lost to follow up, a further 6 were unable to attend their planned test 
date due to the impact of the coronavirus COVID-19 pandemic and prohibited the return of these 
patients to the hospital for non-emergency care. This left a total of thirteen patients who returned for 
repeat CPET at 1 year.   
As can be seen in table 4.4, several CPET parameters saw a statistically significant decline over the 
12month period. Perhaps the most studied variable within CPET testing, that of VO2 peak declined by 
an average of 2.5 ml/kg/min across this small subset of patients (21.58 ml/kg/min ± 0.8 vs 19.08 ± 0.8, 
p=0.017). According to a German registry of over 10,000 health volunteers undertaking CPET, this peak 
figure would place our study patients in the bottom 10% with age matched healthy individuals (Rapp 
et al. 2018). Although as alluded to in earlier chapters, this follow up measurement is well above the 
suggested threshold by Fell et al. of a peak VO2 <8.3ml/kg/min (HR 3.24, CI 1.10-9.56, p=0.03) being 
prognostic for early mortality (Fell et al. 2009). In the absence of minimally clinically important 
differences (MCID) being established for CPET variables in any IPF population, interpretation of such 
a decline in this mild group is difficult to quantify. Mezzani (Mezzani 2017) stated an average 
individual, after the age of 30 years will decrease their VO2 peak by approximately 10% per decade 
due to numerous factors including stroke volume and the muscular ability to utilise oxygen with 
increasing age. This being the case, our cohort exhibit an accelerated decline in this output. One 
patient did not reach AT at follow up and this data was removed from the CPET follow up comparisons 
seen in table 4.4.  
Several other physiological parameters resulting from CPET provided statistically significant 
differences from baseline to follow up (see table 4.4), including;  
• VO2 peak at AT (14.12 ml/kg/min ± 0.92 vs 11.82 ± 0.5, p=0.044  
• Minute ventilation (VE) peak (75.31 L/min ± 5.8 vs 66.08 ± 6.0, p=0.007)  
• Peak work (106W ± 7.3 VS 90.77 ± 7.2, p=0.022)  
• Heart rate (HR) (142.3 bpm ± 6.7 vs 133.0 ± 6.2, p=0.040)  
• Breathing reserve (BR max) at AT (21.8 (12.4-34.2) vs 33.8 (20.2-55.7), p=0.0002)  
  




VO2 peak (ml/kg/min)  21.58 ± 0.8  19.08 ± 0.8  0.017  
VO2 peak at AT (ml/kg/min)  14.19 ± 0.9  11.83 ± 0.5, n=12  0.044  
VE peak (L/min)  75.31 ± 5.8  66.08 ± 6.0  0.007  
VE peak % pred  75.54 ± 3.7  65.88 ± 3.4  0.007  
VE/VCO2 at AT  29.68 ± 0.9  31 ± 1.3, n=12  0.353  
Minimum O2 saturation during CPET 
(%)  
91.46 ± 1.5  
  
87.92 ± 1.9, n=12  
  
0.182  
Peak Work (W)  106.9 ± 7.3  90.77 ± 7.2  0.022  
Peak Work (% predicted)  44.31 ± 1.1  37.69 ± 2.4  0.002  
HR (bpm)  142.3 ± 6.7  133 ± 6.2  0.040  
HR (% predicted)  98.69 ± 4.7  91.77 ± 4.7  0.022  
BR max (median, (IQR))  21.8 (12.4-34.2)  33.8 (20.2-55.7)  0.0002  
6MWT        
Distance achieved (m)  346.9 ± 20.5  340.8 ± 20.1  0.563  
% theoretical distance (m)  76.38 ± 5.1  76 ± 4.7  0.872  
Lung function         
FVC % predicted  98.77 ± 2.4  93.38 ± 2.9  0.010  
TLCO % predicted  62.31 ± 2.7  59.31 ± 3.3  0.161  
  
Table 4.4. Baseline and 1 year follow up data for patients within mild group (those with matched tests).  
  
As within the overall study population, there was a significant reduction in FVC% predicted at 12 
months although again, the mean percent predicted decline was <10% (baseline FVC 98.77% ± 2.44 vs 
follow up FVC 93.88% ± 2.9, P=0.01). Whilst Zappala et.al (Zappala et al. 2010), described an 
association of a more marginal FVC % decline (5–10%) and overall mortality, this was considered 
significant over a 6 month follow up, so interpretation of such a decline over a year is more difficult.  
In this same mild cohort of patients, statistically significant reductions were observed in both the 
domains of breathlessness & activity (-7.21 ± -2.98, p=0.033) and chest (-9.59 ± -4.15, p=0.040) with  
a trend towards significance in the total score (-5.57 ± -2.88, p=0.077) at follow up. Notably, these 
mean unit changes of total K-BILD score (-5.57) and breathlessness and activity domain (-7.21) exceed 
the MCID reported by the questionnaire authors (5 and 7 unit change respectively) (Sinha et al. 2019).  
When relating this significance to actual patient numbers, a total of 5/13 reached the MCID for total 
score and 8/13 for the breathlessness domain. Furthermore, the reduction of >-9 units is approaching 
the estimated MCID of -11 unit decline for chest symptoms.      




The second questionnaire, IPF-PROM, showed a statistically significant worsening in the psychological 
experience of breathlessness (0.76 ± 0.34, p=0.044). To date, no unit MCID for changes in domain 
score have been published and therefore the clinical significance of such a change is unknown.   
  
K-BILD questionnaire  Unit change  
(mean, SD) n=13  
P value  
Total   
Psychological domain  
Breathlessness and activity domain   
Chest symptoms domain  
-5.57 (+/-2.88)  
-5.17 (+/- 5.2)  
-7.21 (+/- 2.98)  





IPF-PROM      
Total   
Physical breathlessness  
Psychological breathlessness  
Well-being   
Energy  
1.54 (+/- 0.89) 
0.54 (+/- 0.39)  
0.77 (+/- 0.34)  
-0.15 (+/- 0.34)  






VAS Cough (cm) median  -1.6   0.391  
Bristol VAS breathlessness (cm) median  0.0   0.716  
Bristol VAS fatigue (cm) median  -0.1   0.956  
  
Table 4.5. Change in K-BILD, IPF-PROM and Visual analogue scores of mild IPF patients with repeat CPET at 1 year follow up. Results shown 
as mean change in questionnaire score with standard deviation (SD), unless otherwise stated. Paired t-test used for parametric data and 
Wilcoxon matched pairs signed rank test for non-parametric data.   
  
No statistical significance was seen for the VAS scores for cough, breathlessness or fatigue from 
baseline to one year (p>0.05).  
Finally, we explored the correlation between the changes of K-BILD at 12 months and the CPET 
variables at baseline to better understand how exercise testing may reflect the patients experience of 
their disease. Of interest, a lower VO2 peak/ml/min at anaerobic threshold correlated with greater 
declines in total K-BILD score (r=-0.62, p=0.024) and the psychological domain at follow up (r=-0.63, 
p=0.022). No other CPET parameters significantly correlated to changes in K-BILD score.  
As seen previously, the results of the baseline FVC% predicted and TLCO% predicted showed no 
significant correlation to the changes in K-BILD over the 12 months follow up (p=0.70 and p=0.62 
respectively).  
When considering the reasons for CPET discontinuation in the follow up tests, seven patients cited 




single patient suggested a dry mouth was their reason for ending the test. No serious adverse events 
were reported.  
  
4.3 Discussion  
Whilst CPET remains the gold standard for pulmonary exercise testing (Ferrazza et al. 2009), given its 
unique assessment of any ventilatory, cardiac and metabolic limitations to exercise and the safety of 
such a test is well documented across multiple morbidities (Patel et al. 2019, Kleber and Köln 2018, 
Ney et al. 2016), its utility in the IPF clinical setting is minimal, perhaps due to the lack of evidence to 
support its use either as a marker of current disease state or indeed as a prognostic tool. This data 
deficiency was highlighted in our systematic review, seen in chapter 2. The heterogeneity of IPF 
disease course allied to the retrospective nature of the majority of published studies has greatly 
limited conclusions that could be drawn. Furthermore, whilst estimates of MCID have been given for 
the QoL questionnaire, K-BILD, suggestive that a patient’s perception of their own illness may be 
indicative of the disease state, this is not the case for CPET parameters in our patient cohort, where 
MCID’s are yet to be established.  
This small feasibility study has provided strong evidence that CPET can be undertaken in a mild to 
moderate IPF population successfully. Whilst side effects of the test were minimal and transient (slight 
dizziness and dry mouth both n=1), study attrition was high with just under two thirds (64%) of those 
enrolled completing the protocol. This can somewhat be explained in the latter end of the study by 
the effects of COVID-19 and patient isolation, however a significant number were unable to initiate 
the study after giving consent (10 patients, 24%). This is largely due to the patient demographics and 
comorbidities (frailty & undiagnosed cardiac disease) and will go some way to aiding power calculation 
for larger similar studies.  
Interpretation of the CPET data suggests peak VO2 is associated with a clinically meaningful 
patientperceived reduction in health status despite only a limited change and relative stability of lung 
function parameters (<10% decline in FVC and <15% decline in TLCO). Whilst a similar correlation 
between VO2 peak and QoL scores has been seen before, notably El Naggar (El Naggar 2017), who 
concluded a negative correlation (r=-0.35) between VO2 peak performance and a non-IPF specific 
health questionnaire (Saint Georges Respiratory Questionnaire, SGRQ), no longitudinal measurements 
were explored. Interestingly, the same study noted a correlation between VO2 and TLCO (r=-0.53), a 
result not replicated in our study. In our cohort, VO2 peak correlated with patient reported outcome 
measures at baseline. This correlation remained over the 12 months of follow up with significant 
declines in both measurements. The extent to which VO2 peak is a useful predictive marker in IPF 




from <8.3 to <14.2 ml/kg/min (Fell et al. 2009, Triantafillidou et al. 2013, Vainshelboim et al. 2016), 
have reported to predict mortality, whilst others have failed to identify a significant association 
(Wallaert et al. 2011, Miki et al. 2003). Extended follow up of our prospective cohort may shed further 
evidence as to the true impact of this measurement on the long-term outcomes in IPF patients.   
When considering the milder population and specifically their follow up results, the decline in exercise 
performance from baseline to one year is marked. Whilst a limited reduction in FVC% predicted is 
observed and expected, this is accompanied with a reduced minute ventilation (VE) and an increased 
breathing reserve (BR). A BR >20% is suggestive that this cohort is not adversely affected by ventilatory 
limitation. Assessment of baseline and follow up activity levels of participants does not suggest a 
significant change of habits, with 42% and 46% taking regular exercise at baseline and follow up 
respectively. Patients did not report cardiac or pulmonary vascular dysfunction and test instructions 
were identical on each occasion. One possible explanation for such a decline may lie in the patient’s 
perception of disease, specifically breathlessness. We have seen the MCID for the K-BILD 
breathlessness and activity domain was surpassed (>7-unit reduction) over the follow up period. The 
hypothesis for the reduced exercise performance is the self-imposed deconditioning of participants 
who fear exercise will lead to a breathless episode.  As with any population, healthy or not, reduced 
activity levels will lead to a reduction in exercise tolerance. Vainshelboim (Vainshelboim 2016) has 
previously described a similar phenomenon, studying the benefits of exercise training in IPF patients 
(figure 5.1) and whether such deconditioning can be reversed. No specific exercise routine was 






Figure 5.1. Suspected mechanism for patient deconditioning and reversal with exercise training.  
   
Examining other outputs of our mild group CPET follow up results, a large number of variables showed 
a statistically significant decline over 1 year although interpretation of their clinical meaning is difficult 
given the lack of data for MCID in such a patient population. Layton et al (Layton et al. 2017) explored 
the prognostic use of CPET outputs for a more severe ILD cohort awaiting transplantation. Of note, 
was the workload % predicted cut off of 35% (HR = 4.71, 95% CI = 2.64–8.38) being an independent 
predictor of mortality or the need to consider transplantation. Whilst Leyton’s study did not look at 
longitudinal changes, the decline in our mild group mean did approach this value (37.69% ± 2.4) and 
further follow up over time may again provide greater knowledge to the importance of this 
measurement.  
Consideration of the 6MWT results for this same population suggests this to be a less specific test for 
measurement of exercise decline. Du Bois et al (du Bois et al. 2011) have previously described an MCID 
of >50m over a 24-week period being predictive of a fourfold increase in risk of death at 1 year. This 
parameter, alongside the % distance predicted remained stable in our cohort with no significant 
difference between baseline and follow up, contradictory to the exercise reduction observed on CPET. 
One possible explanation for this could be the reduced baseline achievements of our group (mean= 
350m vs 392m) potentially meaning maximum distanced was not attained, or simply that the outputs 
of CPET provide greater insight across cardiovascular, pulmonary and skeletal muscle systems and may 
be more explicit in determining functional changes.   
The use, for the first time in an exercise study, of two IPF specific patient reported health 
questionnaires has provide an interesting insight into an individual’s perception of their own disease 
and exercise capabilities. As touched upon already, it appears that a number of baseline parameters 
across both K-BILD and IPF-PROM correlate with the outputs of CPET, including those more closely 
related to an exercise challenge test, namely the chest and breathlessness domains of K-BILD and the 
energy domain of IPF-PROM as well as the total scores across both. The period of extended follow up 
of our patient group may again shed more light on the importance of these scores from a prognostic 
perspective. From our 12-month data in the mild cohort, it is of interest to see where the statistically 
significant declines are seen, similar to above, the chest and breathlessness domains of K-BILD and the 
psychological experience of breathlessness in IPF-PROM. Whilst K-BILD has been more widely used 
and is validated across multiple study populations, the increase in this IPF-PROM domain (0.77 (+/- 
0.34), p=0.044) remains unclear given the lack of MCID values. However, this finding could support 
the psychological aspect and an individual’s fear of hypoxia leading to patient deconditioning, given 




Finally, despite previous studies undertaken within the Bristol ILD service (Yates et al. 2018a)  
confirming the validity of visual analogue scales (VAS) across dyspnoea and fatigue and its correlation 
to changes in total K-BILD score, this was not seen in this study group, with little or no change in scores 
from baseline to 12 months. Results for the cough VAS were however in line with this same study, 
finding no significant changes over the year.  
Questions remain over the utility of FVC% and TLCO% predicated as either a marker of current disease 
or indeed future progression. We found no correlations either at baseline or follow up between any 
of the CPET outputs or questionnaires. Whilst some reports outlined in chapter 2 suggest a correlation 
of VO2 and DLCO, it is possible the milder disease state of this cohort did not allow sufficient 
deterioration over this initial 12 months follow up. This can potentially be confirmed over subsequent 
years and repeat lung function testing. Furthermore, despite our total cohort FVC% decline over the 
12 months follow up being statistically significant with a loss of -3.6% (± 1.4), this was only marginally 
greater than that seen in a general population study of over 60 year olds, giving an annual expected 
FVC% decline of −2.46% (−3.07–−1.85) (Luoto et al. 2019). It is probable these standard PFT 
measurements will provide greater prognostic utility when used in conjunction with other dynamic 




4.3.1. Limitations  
Several limitations of this study exist making interpretation difficult to assess across a wider IPF 
population. Firstly, and perhaps most importantly, the study participants were a relatively small and 
homogenous sample of patients. Whilst there is no standardised definition for the severity of IPF 
disease, according to the pulmonary function parameters currently used in clinical trials, patients with 
a FVC >50–55% of predicted and a TLCO >35–40% of predicted are typically diagnosed as having mildto-
moderate disease, while patients with severe or advanced disease present with FVC and TLCO values 
lower than the abovementioned thresholds (Caminati et al. 2017). With our inclusion criteria meaning 
all patients needed both FVC% predicted and TLCO % predicted >50%, suggestive of a milder cohort, 
patients in our moderate cohort did seem to be more impaired in terms of exercise limitations and 
desaturation. Such inclusion may limit the overall utility of results, particularly in terms of feasibility 
of CPET across IPF phenotypes; for example, those with exercise induced pulmonary hypertension 
versus those with relatively normal pulmonary vascular response to exercise, and the risk of Type II 
error may be relatively high. Whilst our preference would be to have had a broader range of 




recruiting patients with a higher MRC score could have led to early completion of testing, before the 
limit of the pulmonary and cardiovascular systems had been reached, adversely influencing the 
results. It may be possible to utilise other outcomes of CPET not requiring a maximal effort, for 
example an Oxygen Uptake Efficiency Slope (OUES), although this measurement was not available at 
the time of initiation of this study on the analysis dataset provided. Our knowledge gained of the 
performance and safety of the test of those patients classified as moderate in this study (FVC % 
predicted <80%) would give more confidence to allow a follow up CPET test at the 12-month review 
period and potentially expand the inclusion criteria below the 50% thresholds.  
Almost a quarter of patients who gave consent for entry in the study developed exclusions or were 
lost to follow up. Part of this can be explained by the unforeseen COVID-19 pandemic, during which 
this group of patients were classified as ‘extremely vulnerable’ and asked to isolate making a follow 
up CPET test impossible. Whilst this may play an important role to inform power calculations for future 
studies involving CPET as an outcome measure by utilising the expected mean changes across CPET 
variables and lung function parameters from this study population, it again limits the generalisability 
of our outcomes due to resulting smaller sample size.   
This study adds confidence and supports the feasibility of IPF patients undertaking repeated CPET in a 
mild to moderate population. Some ad-hoc patient feedback has suggested a positive outlook towards 
their individual exercise tolerance as most have self-imposed ‘restrictions’ on exercise due to the fear 
of breathlessness and none of the study population had undertaken a maximal exercise effort since a 
diagnosis of IPF.   
  
4.3.2. Conclusion   
The study outcomes provide some evidence that CPET could be a useful tool to assess the change in 
an individual’s health status over time and may add to the armoury of clinicians when faced with the 
difficult patient discussions around disease progression and prognosis.  
Future work should look to confirm the results of this study in a larger, more heterogenous IPF 
population. This study has provided strong evidence of the safety of CPET in a mild to moderate cohort 
and furthermore, patients are willing to partake in such a test in a longitudinal study. Inclusion of a 
more severe patient group likely measured by FVC and/or DLCO % predicted can be combined with the 
patient’s own assessment of their functional ability (e.g. K-BILD). Establishing MCID for longitudinal 
measurements derived from CPET will provide a significant move forward in our knowledge and in 




assessment tools, potentially quantitative fibrosis CT- derived measures, individual comorbidities, 
drug treatments and QoL scores provide a more accurate estimation of a patient’s expected disease 
course.  
Sadly, since the study closure, four patients have deceased. Next steps will be to continue observations 
of the twenty-three patients through routine clinical physiology appointments and a hope to add to 
our knowledge of the usefulness of CPET longitudinal data and prognostic accuracy and its potential 
for wider use in the clinical setting, akin to the 6MWT. With data from this increased timeframe, the 
team anticipate presenting the most comprehensive prospective follow up of IPF patients undertaking 
CPET to date. With ongoing surveillance of participant lung function, and improved knowledge of 
morbidity and mortality in this group of patients, the aim is to accurately predict study numbers for a 
larger, multi-site study for the use of CPET in IPF patients. To utilise our knowledge gained to inform 
inclusion and exclusion criteria and importantly, secure funding to fully answer the questions only 





Chapter 5: Personal review and learnings  
  
Study reflections  
Despite the numerous challenges posted over the last 3 ½ years, since the inception of the idea of 
undertaking a research MSc, it is with a significantly greater understanding of clinical research that I 
am writing now. Whilst much of the research process can be controlled, from hypothesis to endpoints, 
recruitment to follow up, the ‘known unknowns’, for me, ethics approval provided a steep learning 
curve. Resulting in a very early extension to the study timelines (and University fees), undertaking the 
completion of the IRAS form, presentation to the Regional Ethics Committee (REC) and subsequent 
major amendments were an eye opener. Accompanied by this and touched on earlier is the sheer 
volume of administration needed prior and during the study, both in electronic and paper form and a 
necessity for the sponsor and NHS research alike. If there was an ability to turn back time, or pass 
learnings to future students, a few changes could save many months of process:  
Research Passport – a requirement to undertake research on the NHS premises, this 
littleknown approval process remains confused. There is a necessity to streamline this process, agree 




Short courses – Offered across the Medical School, attendance of several courses over the 
study period has been essential. From statistics through to paper and thesis writing, these days have 
added greatly to undertaking research and such opportunities should be maximised.   
Funding – Whilst not always possible or even available, I would be keen to secure funding to 
aid additional nurse support for such studies. The part time nature of this MSc has at times led to 
difficulties in my person clinic attendance, primarily during recruitment but also follow up. It is 
important to recognise the additional work the clinical research team undertook on numerous 
occasions, to gain consent, undertake questionnaire and ensure the clinical research folder was up to 
date. Furthermore, the amazing work of the physiology team over the study period to ensure patient 
testing was on time according to study protocol and minimise travel of patients to the hospital for 
multiple appointments.  
With the benefit of hindsight and a better understanding of the safety of CPET in IPF patients, this 
study would undoubtably benefit from a wider inclusion criteria. Our knowledge gained from this and 
other ongoing research in this field would likely allow us to revise downwards the lower limits of lung 
function parameters and permit a repeat of exercise testing of all participants. Given the acceptance 
of this study group to repeat CPET after 12 months, it could also add value to continue annual exercise 
testing alongside their routine clinical lung function to better understand the changes within individual 
CPET parameters and the longitudinal importance of each in predictions of prognosis.  
The near future presents opportunities for publication of this data and presentation across physiology 
and respiratory conferences. Longer term data will aid our understanding of the importance of 
individual outcomes across all the tested parameters (CPET, PFTs, questionnaires) and armed with this 
information, allied to our improved understanding of safety, the hope would be to initiate a large scale 
study to validate such findings and the prognostic use of CPET itself.  
One of the greatest rewards from the last couple of years has been the direct interaction with patients. 
Having worked in the therapy area for more than 10 years from early phase drug discovery through to 
large global phase III studies from within a pharmaceutical setting, whilst patients remain front of 
mind, they are often of sight. It has been clear throughout how enthusiastic this group of patients are 
to support and add to our understanding of the disease they are living with on a daily basis. In the 
knowledge results of such studies may not benefit them directly, it was important to all, anything they 
could do to benefit others was a ‘must’. It was a privilege to meet each of them, often with carers, 
who share a common goal in one day finding a cure for IPF.  
The arrival of an unprecedented global pandemic undoubtably adversely affected our desired 




all study participants to shield for many months due to their vulnerability to the virus. Teamwork and 
support of the sponsor meant we were able to maximise our data return via postal questionnaires and 
e mail reconsent. Whilst only emergency visits were allowed into hospital and clinic appointments 
moving online, routine lung function testing was halted for a period towards the close of the study. 
Any patients with an outstanding test (for study purposes) were contacted by the physiology team to 
arrange the earliest possible appointment on the re-opening of the department.   
On a personal note, the undertaking of this study has given me insight into set up, delivery and 
interpretation of clinical research. From hypothesis generation, study design, presenting to a REC and 
patient enrolment through to the outputs of data presentation and publication. A revised paper of 
this study has been submitted to BMC Pulmonary Medicine which can be seen in Appendix H. A first 
for me was to present my own generated data at a national respiratory congress alongside experts in 
the field of ILD. The work undertaken in this study and within the literature review has been cited at 
subsequent pulmonary congresses and stands Bristol ILD service in good shape for future 
collaborations within the field of exercise and ILD.  
Most of all, it has provided me an unparalleled opportunity to engage with such an enthusiastic and 
willing group of patients.   
My hope is, this data will add something to the multitude of ongoing work globally in IPF prognosis, to 
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Appendices :  
  
Appendix A: K-BILD Questionnaire   




This questionnaire is designed to assess the impact of your lung disease on 
various aspects of your everyday life. Read each question carefully and 
answer by SELECTING the response that best applies to you. Please answer  




PATIENT INFORMATION:  
  
  



























Appendix B: IPF-PROM Questionnaire  
  
Patient Identifier :  
Date:  
  
This questionnaire is designed to help us learn more about how Idiopathic Pulmonary 
Fibrosis affects your life   
The information and the answers you give will be treated with the utmost confidentiality   
There are no right or wrong answers   
Please read each item and place an ‘X’ in the box that best matches your experience over 
the last two weeks  
If you do not experience an item put an ‘X’ in the 'none' box.   
Please respond to all items.  
We would like to thank you very much for taking the time to answer these questions and 
help us with our research   
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During the last two weeks how would you rate your overall quality of life?  
Excellent                            Good                                 Fair                             Poor                      Very Poor  
       
  
During the last two weeks, because of IPF, how much of the time have you ……………..  
1. Felt that your breathing difficulties have affected your quality of life?  
 None of the time  A little of the time   Most of the time  All of the time   
                        
  
During the last two weeks, because of IPF, how much of the time have you ……………..  
2. Felt that your fear of getting out of breath has limited your daily life?  
 None of the time  A little of the time   Most of the time  All of the time   
                         
  
During the last two weeks, because of IPF, how much of the time have you ……………..  
3. Stopped you doing any of the things you like to do?  
 None of the time  A little of the time   Most of the time  All of the time   
                        
  
Please make sure you have put an ‘X’ in one box for each question before moving on to the next 
page………………….  




During the last two weeks 
All of the time   
86  
  
, because of IPF, how much of the time have you……………..  
4. Felt breathless with gentle physical exercise?  
   None of the time  A little of the time   Most of the time  
                        
  
During the last two weeks, because of IPF, how much of the time have you ……………..  
5. Stopped for breath when walking at your own pace on the flat level (e.g. along the pavement; 
at home)  
 None of the time   A little of the time   Most of the time  All of the time   
                        
  
During the last two weeks, because of IPF, how much of the time have you ……………..  
6. Felt breathless with any of your everyday activities?  
 None of the time  A little of the time   Most of the time  All of the time   
                        
  













During the last two weeks 






, how much of the time have you ……………..  
7. Felt that IPF has brought worry to your life?   
 None of the time  A little of the time   Most of the time  
                        
  
During the last two weeks, because of IPF, how much of the time have you ……………..  
8. Felt frightened about the future?    
 None of the time  A little of the time   Most of the time  All of the time   
                       
  
During the last two weeks, how much of the time ……………..  
9. Has it been difficult to manage the uncertainty of living with IPF?  
  
 None of the time  A little of the time   Most of the time  
 
All of the time   
                        
  











During the last two weeks 








, because of IPF, how much of the time have you ……………..  
10. Felt lethargic?   
 None of the time  A little of the time   Most of the time  
                        
  
During the last two weeks, because of IPF, how much of the time have you ……………..  
11. Felt too tired to do your usual everyday activities?   
 None of the time  A little of the time   Most of the time  All of the time   
                        
  
During the last two weeks, because of IPF, how much of the time have you ……………..  
12. Felt frustrated by being too tired to do the things you like to do?  
 None of the time  A little of the time   Most of the time  All of the time   
                        
  
Please make sure you have put an ‘X’ in one box for each question   
Thank you for completing 







During the last two weeks 









































































King et al. 2001 





in IPF. Median 
follow up 20 months 
(maximum 
14.8 years).  
238 IPF pts 
with 
histological 
UIP.   
  
80 pts excluded  
from the final 
model 
derivation. 
Cycle ergometer, blood gas 
analysis.   
P (A-a)O2 corrected for 
FiO2, VD/VT, VO2, maximal 
work load 
CTD, left ventricular 
failure, occupational 
and environmental 
exposure, or history of 
drug exposure known to 
cause pulmonary 
fibrosis. Incomplete 
case records.   
Survival 
(defined as 
death or time 
of censoring: 
Censored if 













IPF n=12).   
Kaplan-Meier survival curves developed for 
group as whole and stratified by sex, age and 
smoking status. Univariate Cox proportional 
hazards regression analysis (adjusted for age and 
smoking) for each variable. Variables with 
p<0.25 included in multivariate analysis. 
Pearson's correlation to avoid multicollinearity. 
Forward elimination process used to develop 
preliminary model. mulitvariable influential 
points removed. Composite scoring system 
developed, weighting categories according to p 
values and HR, and using Akaike's Information 
criteria .    
155 D (125 IPF, 19 other causes, 11 unknown and attributed 
to IPF).    
105 patients censored (n=79 alive at time of analysis, n=13 
LTx, n=12 non-IPF deaths, n=1 lost to follow up).  
Composite scoring model developed to predict survival in 
IPF which included age, smoking history, clubbing,  
extent of profusion of interstitial opacities, 
presence/absence of PH on CXR, % predicted TLC and 
PaO2 at the end of maximal exercise.  Exercise PaO2 only 
exercise variable included in the model, accounting  for 
10.5% of score (PaO2 maximal exercise HR 0.74, CI 
0.67-0.82, p<0.0001). 
CPET performed in study as part of wider analysis of predictive factors in IPF.   
  
Histological UIP increased potential  selection bias of a  less severe IPF population. 
The radiological component of the scoring system used CXR rather than HRCT  
(HRCT not obtained during early years of the study).   
Only 158/238 (66%) of the original cohort were used to derive the complete model 
and thus possibility for selection bias.  




of the predictive 
value of CPET for 
IPF respiratory 
deaths.  Mean 
follow up 2.7 years 
(7.2 months - 9.0 
years).  
41 IPF pts.  Exercise treadmill (Sheffield 
protocol). PaO2, PaCO2, 
HR, respiratory frequency (f), 
Vt, VE, peak VO2, VE/VO2, 
VE/VCO2, VO2/HR, AaDO2 
& PaO2-slope.  
CTD, Sarcoid, OP, EP, 
HP, Cardiac disease, 
anaemia, primary 
cardiac disease, 




weakness. Steroid or 
immunosuppressive 
treatment prior to 
study entry. Death 
from a non-respiratory 





Exercise parameters (between groups split by 
PaO2-slope) compared using Mann-Whitney. 
Univariate Cox proportional hazards model to 
compare initial parameters then entered into 
multiple regression analysis using stepwise 
evaluation. Relationship between Pao2 slope 
and other variables were analysed by linear 
regression with stepwise technique. Survival 
times compared using Kaplan Meier curves 
and statistical significance determined by log 
rank test.  
23 respiratory deaths. Median survival 2.9 years. In 
univariate analysis,  VO2 max (HR 0.997, 0.995-0.999 CI, 
p=0.012), VO2/HRR max) (HR 0.69, 0.51-0.93 CI, p= 
0.014), PaO2 slope (HR 0.68, 0.51-0.89 CI,  p=0.006),  
VE/VCO2 (HR 1.04, 1.006-1.07 CI,  p=0.020) & age (HR  
1.1, 1.02-1.18 CI, p=0.014) associated with survival in 
IPF.  On multiple regression,  PaO2 slope (HR 0.84, 
0.730.97 CI, p=0.015) and age (HR 1.096, 1.01-1.19 CI, 
p=0.025) independently related to survival. PaO2 at rest and 
during maximum exercise did not influence survival. When 
PaO2 slope was divided into steep (≤- 
60mmHg/l/min) and gentle (>-60mmHg/l/min), median 
survival time after CPET significantly shorter in steep group 
(1.6 vs 4.5 yrs).   
Retrospective, single centre cohort.  
  
Large number of exclusion criteria .  
  
Outcomes limited to respiratory deaths.   
  
PaO2 slope (as an indicator of exercise induced hypoxaemia) had the greatest 
correlation with survival. 
Kawut et al. 2005, 
USA  Retrospective study of CPET and 
6MWTD variables 
associated with 
survival in pts 
referred for lung 
transplant. Median 
follow up 271 days 
(23-983). 
51 pts with IIP 






referred for lung 
transplant.   
Cycle ergometer. Pulse 
oximetry. SaO2 (unloaded, 
peak, recovery), Peak VO2/kg, 
VO2/HR peak, VCO2 
unloaded, VE unloaded. 
Pts evaluated at another 
lung transplantation 
centre. Other forms of 




osis X, EP .and 
granulomatous DPLD 
e.g. sarcoidosis.  
All-cause 
mortality. 





Cox proportional hazards regression to identify 
predictors of time-to-death. Individual models 
were constructed using LTx as a timedependant 
covariate to 'control' for receiving a LTx. ROC 
curve analysis was used to define cut-off for 
variables associated with dying on the 
transplantation list.   
7 lung transplantations and 17 deaths (1 
posttransplantation). 28/51 (55%) UIP/IPF, CTD-UIP 
(n=4), NSIP (n=6), HP (n=2), DIP (n=1), COP (n=1), LIP 
(n=1) and unclassifiable ILD (n=7).  A 6MWTD <350m 
(HR 4.6, 1.5-14.2 CI, p=0.009), peak VO2/kg (HR 0.88, 
0.790.99 CI, p=0.039) (no threshold determined) and 
VE/VCO2 >46 (p=0.05) (non-proportional and increased 
over time so could not be estimated with a single HR) 
were each associated with increased risk of death. Sp02 
<95% during unloaded exercise had 75% chance of dying 
on transplantation list (sensitivity 86%, specificity 89%).  
67% chance of death if 6MWTD <350m.  
Retrospective single centre cohort.   
  
Only half pts reached AT which limited analysis (low number of endpoints).   
Additional oxygen use during CPET was variable. Generalisability questionable  
As highly selected cohort of severe ILD. Source population, patterns of referral to 





Swigris et al. 2009, 
USA  Retrospective study exploring 
prognostic role of 
SpO2 and SaO2 at 
rest and during 
maximal exercise 
in SSc-ILD 
exercise.  Median 
follow up 7.1 
years.  
83 patients with 
SSc-ILD  Cycle ergometer. Blood gas analysis and pulse oximetry. 
SpO2 and SaO2 at rest and 
during maximal exercise (SpO2 





Mortality  Cox proportional hazard models were used to 
examine the prognostic capabilities of SpO2, 
dichotomised by <89% or ≥ 89% and also as 
continuous variables. Kaplan Meier survival 
curves were generated.  
39 deaths (number of transplantations not recorded). In 
Cox proportional hazards models, SpO2 predicted 
mortality; SpO2max < 89% (HR 2.4, 95% CI 1.2 to 4.9, p 
=0.02), SpO2max fall >4%  from baseline (HR 2.4, 95% 
CI 1.1 to 5.0, p = 0.02), alongside ∆Sp02 (HR 1.08, 95% 
CI 1.03 to 1.14, p = 0.002). Controlling for FVC%, the 
∆Sp02 remained a significant predictor of mortality (HR 
1.07, 95% CI 1.01 to 1.14, p = 0.02). No other CPET 
variables reported.  
No other CPET variables described in analysis and thus potential for reporting 
bias.    
 
Fell et al. 2009, 
USA  study evaluating prognostic value of 
CPET in IPF. 
Mean follow up 
not reported. 
117 IPF pts. 10 






and 6 months.    
Cycle ergometer. Blood gas 
analysis. Peak VO2/kg 




pattern other than UIP 
Survival Multivariate Cox proportional hazard models 
studied the predictive value of peak VO2 
adjusting for age, gender, smoking status, 
baseline FVC % and baseline DLCO%. 
Resulting HR were plotted against peak VO2 to 
determine thresholds. Survival thresholds 
examined with Kaplan Meier survival curves, 
log-rank tests and Multivariate Cox 
proportional hazard models.  
Peak VO2/kg examined as a continuous variable did not 
predict survival HR 0.969 (p=0.55). However, a  baseline 
threshold peak VO2 <8.3ml/kg/min was associated with 
an increased risk of death (n=8; HR 3.24 1.10-9.56 CI, 
p=0.03).   
  
No other CPET variables reported.  
Retrospective, single centre study.  
Number of deaths in each group not reported. Analysis was not by a priori plan. 
Small number pts below VO2 max threshold in analysis. Caution in interpreting  
generalisability to IPF population as  64% (75/117) required a surgical lung biopsy 
for diagnosis. No other CPET outcomes reported.  
Wallaert et al. 2011, 
France  Retrospective multicentre study 
evaluating 
prognostic role of 
CPET in determining 
3-year survival in 
IPF.  
63 IPF patients  Cycle ergometer.  Blood gas 
analysis. Peak VO2/kg, 
VE/VO2 at ventilatory 
threshold, VE/CO2, 
(VO2/HRR), P(A-a)O2, 
ventilatory reserve and lactate.  
Non-IPF associated 
ILD. Pts in which 
blood gas analysis had 
not been performed.  
3-year survival 
(absence of 
D or LTx).   
Demographic data, resting pulmonary function 
and CPET parameters in the survivors were 
compared to the those who died/received lung 
transplantation by univariate survival analysis. 
Multivariate logistic regression analysis 
explored prognosis at 3 years. Kaplan Meier 
curve and log-rank test was performed, with 
model validation by ROC curve analysis.    
19 patients: D (n=14) or LTx (n=5) at 3 years. 
Multivariate logistic regression analysis highlighted four 
parameters to be independently correlated with mortality: 
TLC (% pred), VE/VO2 at ventilatory threshold, FVC (% 
pred) and P(A-a)O2. The most appropriate logistic 
regression model incorporated two variables, with the 
lowest 3 year survival when TLC (<65%) and VE/VO2 at 
ventilatory threshold (>45) (AUC 0.811, sensitivity was 
98%, specificity 50%, positive predictive value 80% and the 
negative predictive value 64%).   
Retrospective study.  
  
Presence of PH not studied.   
  
Inadequate description of exclusion criteria.  








and clinical course 
in sarcoidosis. 2 





Analysis of 102 
patients (47 
incomplete notes)  
Cycle ergometer, capillary 
blood gas analysis.   
  
P (A-a)O2  
Patients who could not 
complete CPET > 6 




with clinical signs of 
acute infection. For the 
longitudinal subgroup 
analysis: Patients with 














Associations between sarcoidosis clinical parameters 
(including the need for prolonged 
immunosuppressive therapy > 1 year) and P(A- 
a)O2 during exercise were assessed by analysis 
of variance statistical methodology.   
Univariate then multivariate backward binary 
logistic regression analysis used to assess 
clinical variables independently associated 
with need for prolonged immunosuppression.  
Multivariate regression analysis suggested that FVC (OR 
0.954, 0.917-0.992 CI, p =0.009) and P(A-a)O2 (OR 1.098, 
1.039-1.160 CI, p<0.0001) during exercise were 
independently associated with a need for prolonged 
immunosuppressive treatment.   
  
Unable to determine exact clinical characteristics of this 
longitudinal cohort from the data presented. No other 
CPET variables reported.  
No other CPET variables described in analysis and thus potential for reporting bias.    
Lopes et al. 
2012, Brazil 
Retrospective 
study to identify 
CPET measures 
that predict FVC 
and DLco 
progression over 5 
years in patients 
with thoracic 
sarcoidosis.  
42 pts with 
histologically 
confirmed 
sarcoidosis.   
Cycle ergometer, blood gas 
analysis. Peak VO2 (% pred), 
% peak VO2 at lactate 
threshold,VCO2/VO2, 
VO2/HRR,  maximum 
respiratory rate, breathing 
reserve, HRR, P(A-a)O2, 
∆Sp02, ∆lactate. 
History of smoking. 
Mycobacterial 
infection, exposure to 
aero-contaminants or 
medications known to 
cause granulomatous 
disorders.  Those with 
known medical history 
or laboratory diagnosis 
of concomitant 






FVC/DLCO variation over study period 
evaluated by Wilcoxon signed rank test. 
Correlations between CPET measures and 
FVC/DLCO variation over 5years used 
Spearman's rank correlation (except breathing 
reserve and relative variations of FVC). ROC 
curve analysis used to determine cut offs for 
CPET measurements are predictors for lung 
function decline. Multiple logistic regression 
used to identify factors independently related to 
decreased lung function.   
Statistically significant reductions in FVC (relative 
variation -5.1% (-23.1% - 0%) and DLCO (relative 
variation -2.5% (-44.4% - 0.93%) at 5 years follow up. 
Peak VO2 (% pred), breathing reserve, maximum RR, 
P(A-a)O2 and ∆Sp02 correlated with FVC and DLCO 
values that had declined >10% from the initial values 
measured (p<0.0001 for all parameters). P(A-a)O2 
>22mmHg (RR 70.0 p=0.001) and breathing reserve <40% 
(RR 20.8, p=0.014) independently predicted lung function 
decline (FVC % pred and DLCO% pred). 
Retrospective, single centre study.  
  
Potential for selection bias (tertiary centre for sarcoid – 
more likely to have severe patients). Small number of patients resulting in high  RR 
values. 









prognostic role of 
6MWT and CPET 
in IPF. Follow up 9-64 
months.  
25 pts with IPF Cycle ergometer, pulse 
oximetry. VE/VCO2 slope, 




ECHO), pts taking 
beta blockers. 
Pulmonary fibrosis 
due to environmental 
and occupational 
exposure, drug toxicity 
or  
autoimmune 
rheumatological disease  
Survival Parameters of study were evaluated by Wald 
test, likelihood ratio test and the score (log rank) 
tests with Bonferroni correction. Parameters 
achieving statistical significance were then 
evaluated in a multiple regression Cox 
proportional hazard model with a stepwise 
model selection.   
8 D by end of the observation period. 21 patients reached 
the AT. VE/VCO2 slope, VO2 peak/kg & VE/VCO2 at 
AT were significant survival predictors. Optimal model 
for mortality risk estimation combined VO2 peak/kg with  
DLCO (P<0.0001). Per 1 unit increase in VO2 peak/kg 
(1mL/kg min) and DLCO% (1%), mortality rate is reduced 
by 32% and 13% respectively. VO2 peak threshold of 
14.2mL/min/kg was associated with an increased mortality 
risk.  
Prospective study with  low mortality rate in small numbers of pts.  Data 
generated from sub-analysis of RCT. 
  
 
Gläser et al. 
2013, Germany 
study evaluating 
predictive value of 
CPET measures 
for the presence of 
PH in IPF. 
Investigate 
diagnostic and 
prognostic use of 
gas exchange during 
CPET in pts 
with/out PH. 
Follow up 2 years. 
135 pts (73 with 
PH) IPF.   
  
No follow up 
data for 2 pts, 
reducing cohort 
to 133. 
Cycle ergometer, pulse 
oximetry. Peak VO2, VO2 at 
AT (ml/min), VE/MVV, VE 
vs VCO2 slope, VE  max, Vt 
max, Vt max/ IC, VE/MVV. 
Pts with left heart 




and/or PH resulting in a 
life expectancy <24 
months, inability to 














Mann-Whitney or X-test used for comparison of 
IPF pts with/without PH.  
  
Cox proportional hazards analysis used for 
pulmonary variables and end point. Kaplan 
Meier survival plots constructed with 
differences in survival analysed by log-rank test. 
Cut off values for best discrimination 
determined using ROC curve analysis.  
37 D and 6 LTx during follow up. The presence of PH is 
best predicted by gas exchange efficiency during exercise 
and peak oxygen uptake (VE vsVO2 slope pred (≥ 152.4, 
AUC 0.938, 0.892-0.984 CI) and VO2 peak pred (≤ 56.3, 
AUC 0.832, 0.753-0.911 CI)).  By univariate analysis, the 
presence of PH as determined by RHC was the most 
powerful prognosticator in IPF (whole group) (mPAP HR 
1.07, 1.04-1.11 CI), with CPET outcomes of peak VO2 
pred (HR 0.96 p=0.001) and VO2 at AT pred (HR 0.97 
P=0.017) also being statistically significant.  In multivariate 
analysis, invasively measured PH and peak 
VO2 pred were independent predictors for survival.  
Retrospective multicentre study.  
  
Potential recruitment bias due to selected cohort (specialist centres,  excluded 
left heart disease). 





predictive value of 
CPET and ECHO 





38 pts with IPF. 




was censored at 
date of 
transplantation.  
Cycle ergometer. Peak workload 
(% predicted), VO2 peak (% 
pred), VE peak (% pred), 
breathing reserve (%),  
HRR peak (% pred), VE/ 
VCO2 ratio at AT, 
VO2/HRR (% pred), ETCO2 
at max (kPa) 
Non -IPF ILD. Pts 
where CPET and 
ECHO were 
performed more than 2 
weeks apart.  
Survival 
Pearson's correlation coefficients were calculated 
for sPAP & CPET parameters. Patients were 
grouped into those with/without sPAP≥ 
40mmHg and differences in exercise parameters 
analysed with unpaired t-test or chisquare test.  
ROC curve analysis was used to determine 
variables that predict sPAP≥ 40mmHg. Kaplan-
Meier survival curves then evaluated the 
prognostic value of these parameters on survival. 
HRs were calculated using multivariate Cox 
proportional hazard models (with FVC and CPI 
included in the model to correct for functional 
severity of IPF) to determine predictive value of 
parameters on survival.  
24 D and 3 LTx during follow up. 29/38 (765) had a 
reduced VO2 peak (ie. <84% predicted). Mean peak VO2 
5.5ml/min/kg; 66.6% predicted). VE/VCO2 at AT was 
significantly higher in patients with sPAP ≥ 40mmHg 
(n=11) compared to those with sPAP≤ 40mmHg (n=27), 
(54.0±21.9 vs 37.9±7.5, p=0.021). VE/VCO2 at AT was 
shown to be a good predictor of sPAP ≥ 40mmHg by 
ROC curve analysis but only VE/VCO2 at AT and not 
sPAP ≥ 40mmHg was shown to predict survival. Pts with 
VE/VCO2 at AT ≤ 45 (n=24) had a significantly better 
prognosis that those with VE/VCO2 ≥ 45 (n=14),   
81.3±14.1  vs 21.0±4.9 months respectively; HR 4.58, 
p=0.001. Parameters reflecting functional severity of IPF 
did not add to the predictive value of VE/VCO2 at AT for 
survival.      
Retrospective analysis of prospective database. Single centre.  
Vainshelboim 




evaluating role of 
12 week exercise 
training program 
on survival at 40 
months follow up.  
Evaluation of the 
role of CPET 
variables in the 
prognostication of 
IPF.  
34 pts with IPF Cycle ergometer, pulse 
oximetry. Peak VO2/kg, peak 
work rate, VE/VO2 nadir , 
VE/VCO2 ratio at AT, tidal 
volume reserve. 
Non-IPF ILD. 
Clinically unstable in 
preceding 3-6 months, 
severe co-morbid 
illness, unstable 








ROC curve analysis was used to determine cut 
off points of CPET variables for mortality. Cox 
regression analysis for survival analysis and 
comparison between significant cut-off points 
(log rank test). HR for death or LTx (Wald 
test).  
9 deaths and 2 LTx  (considered fatalities in statistical 
analysis).Poorer survival and significant increased risk of 
mortality associated with cut off points for: peak work 
rate<62 watts (AUC 0.854, 0.73-0.98 CI, p=0.005), peak 
VO2 <13.8mL/kg/min (AUC 0.731, 0.56-0.9, p=0.031), 
tidal volume reserve <0.48 L/breath (AUC 0.810, 
0.660.96, p=0.01), VE/VCO2 at AT >34 (AUC 0.783, 
0.60.96, p=0.02) & VE/VO2 nadir >34 (AUC 0.736, 
0.560.9, p=0.002). Bivariate analysis of these cut offs 
(above and below the threshold) revealed HRs as follows: 
Peak work rate 9.2 (1.9-42.6), Peak VO2 4.4 (0.94-20.3), 
Tidal volume reserve 7.6 (1.6-35.2), VE/VO2 nadir 8.3 
(2.231.6), VE/VO2 at AT 4.6(1.2-17.3). Non survivors 
were characterised by higher dyspnoea levels, the presence 
of PH (assessed by ECHO sPAP>35mmHg), and CPET 
markers of reduced ventilatory efficiency (VE/VO2 nadir 
p=0.039, VE/VCO2 at AT p=0.008) and reduced exercise 
capacity (Peak work rate p=0.01, Peak VO2 p=0.02).  
Exercise training intervention had no survival benefit over 
standard care. Higher prevalence of PH in non survivors.  
Prospective observational study analysis as part of a  wider single centre RCT.   
  




Layton et al. 2017, 
USA  study evaluating  predictive value of 
CPET for one-year 
transplant free 
survival in a 





192 pts had CPET 
was performed on 
oxygen. Four 
tests terminated 
due to oxygen 
desaturation 
(nadir SpO2 <  
80% despite  








reducing cohort to 
185 pts.  
Cycle ergometer, pulse 
oximetry. Peak VO2 
(ml/kg/min, % predicted) , 
workload (watts, % 
predicted), VE/VCO2 slope 
(% predicted), ETCO2 mmHg 
& O2 pulse. 
Pts not being 
evaluated for lung 
transplant, those that 
did not require oxygen 
with exercise, no 
follow up data 
available at 1 year 





ion (at one 
year).  
79 deaths/transplantations during follow up 
period. Comparison of variables between those 
who died /transplanted (D/LTx) and those who 
survived transplant free were compared using 2-
sample independent t test. Survival was calculated 
by Kaplan-Meier method, with univariable Cox 
regression analysis  to identify predictors of 1yr 
transplant free survival. Multivariable cox model 
with forward stepwise elimination method to 
identify prediction of transplant free survival (and 
to predict survival excluding those transplanted. 
ROC used to test thresholds of these predictors. 
Mixed cohort of ILD patients analysed: IPF n=135 (70%) 
, sarcoidosis n=15 (8%), HP n=6 (3%), NSIP n=12 (6%),  
ILD with mixed connective tissue disorder n=24 (13%). 
113/192 (59%) survived transplant free. More patients 
with sarcoidosis in the survival transplant free group then 
the D/LTx group and more patients with NSIP in the 
D/LTx group  (p=0.028).  Multivariable cox regression 
identified CPET variables of  peak workload <35% 
predicted  (HR 4.71, 2.64-8.38 CI and AUC =0.740) and 
nadir CPET SpO2 <86% despite 30% FiO2 (HR 2.27, 
1.41-3.68 CI, AUC=0.645) as discriminatory parameters 
predicting one-year mortality or need for transplant, 
alongside FVC% predicted <45% (HR 1.82, 1.15-2.87 CI 
AUC 0.624). Notably the presence of PH (present in 50% 
pts determined by combination of RHC or ECHO) was 
not an independent predictor of prognosis in this study.  
Retrospective, single centre cohort. Potential for selection bias, unidentified  
confounding and missing co-variate data. Generalisability to general ILD patients 
questionable as highly selected cohort of advanced ILD patients.  
Source population , patterns of referral transplant, waiting times and cohort  
characteristics may differ from other transplant programs. 
  
Table 1: Study characteristics of papers selected for full data extraction.  
Abbreviations: Pts, patients; IPF, idiopathic pulmonary fibrosis; ILD, interstitial lung disease; NSIP, non-specific interstitial pneumonia; HP, hypersensitivity pneumonitis; CTD, connective tissue disease; SSc, systemic sclerosis; COP, cryptogenic organising pneumonia; UIP, usual interstitial pneumonia; DPLD, diffuse parenchymal lung disease; 
LAM, lymphangioleiomyomatosis; EP, eosinophilic pneumonia; 6MWTD, 6-minute walk test distance;  CPET, cardiopulmonary exercise testing; AaDO2, alveolar-arterial oxygen pressure difference; FiO2, fraction of inspired oxygen; VD/VT, physiological dead space/tidal volume ratio; VO2, oxygen uptake, VCO2, carbon dioxide production; 
PaO2, partial pressure of oxygen; PaCO2, partial pressure of carbon dioxide; VT, ventilatory threshold (highest VO2 sustained without lactic acidosis); AT, anaerobic threshold; Vt, tidal volume; tidal volume reserve, Vt max-Vt resting; IC, inspiratory capacity; VE, minute ventilation; breathing reserve, VE/MVV during exercise; VE/VO2, peak 
oxygen uptake; VE/VCO2, ventilatory efficiency; kg, kilograms; OR, odds ratio; HR, hazards ratio; HRR, heart rate; SaO2, oxygen saturation of arterial blood; SpO2, oxygen saturations measured by pulse oximetry; max, maximal; MVV, maximum voluntary ventilation (can be measured or estimated as FEV1 X 41) ; ∆, change in; VO2 slope, 
PaO2 plotted against VO2; VO2/HRR max or oxygen pulse, oxygen delivery per heartbeat; ETCO2, end tidal carbon dioxide; D, died/deaths; LTx, lung transplantation, sPAP, systolic pulmonary artery pressure, ROC, receiver operating characteristic curve; FVC, forced vital capacity; CPI, composite physiologic index; TLC, total lung capacity; 
DLCO, diffusion capacity of lungs for carbon dioxide; RHC; right heart catheter; ECHO, echocardiogram; PH, pulmonary hypertension; PWP, pulmonary capillary wedge pressure; AUC, area under the curve; RCT, randomised controlled trial; CI, confidence interval; pred, predicted; %, percentage; P(A-a)O2, alveolar-arterial oxygen pressure 
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Interstitial lung disease (ILD) heterogeneity poses challenges in terms of prognostication; including 
end of life discussions and optimal timing for transplantation. Efforts are required to develop definitive 
prediction models for use in clinical practice. Cardio-Pulmonary Exercise Testing (CPET) provides a 
comprehensive assessment of the physiological changes in the respiratory, cardiovascular, and 
musculoskeletal systems in a controlled laboratory environment, that has shown promise in terms of 










We conducted a systematic review to identify CPET variables that predicted longitudinal outcomes in 
ILD. Two databases were searched to identify all studies reporting prognostic value of CPET in 
predicting disease-specific outcomes in longitudinal studies of ILD. Two authors independently 







The initial search identified 658 unique citations. Thirteen studies were identified that examined the 
prognostic value of CPET in ILD, all of which reported a prognostic role for CPET parameters in 
predicting clinical outcomes in ILD, with survival being the principle clinical outcome measured. Issues 
with study quality (relating primarily to the inherent problems of retrospective studies, patient 
selection and presentation of numerous CPET parameters), limits the strength of conclusions that can 
be drawn from the studies reviewed.  
Conclusions  
There is insufficient evidence to support its use in facilitating ‘real-world’ clinical decisions. Additional 
prospective studies are required to validate these preliminary findings.   
  
Introduction   
  
The Interstitial Lung Diseases (ILD) are a group of heterogeneous diseases characterised by alveolar 
and interstitial damage, varying degrees of inflammation and/or fibrosis, architectural distortion and 
impaired gas exchange. ILD may be attributed to a known cause (e.g. drugs, connective tissue disease 
or inhalation of dusts or organic antigens) or unknown cause, such as Idiopathic pulmonary fibrosis 
(IPF) (2000). The prognosis is often poor, particularly for IPF which is typically progressive with a 
median survival of 2-5 years from diagnosis (Ley et al. 2011). ILD is also the leading cause of disease 
related mortality in connective tissue diseases (CTD) such as systemic sclerosis (SSc) (Steen and 
Medsger 2007) and myositis (Johnson et al. 2016). There is however vast heterogeneity in terms of 
presenting features, severity, disease course, treatment response and individual survival (Bellaye and 
Kolb 2015). This leads to challenges for patients and clinicians in terms of end of life discussions 
(Schroedl et al. 2014), treatment choices, optimal timing for transplantation (Mura et al. 2012) and 
conduct of clinical trials (Albera 2011, Gordon and Domsic 2016).   
  
Previous studies of ILD have identified declining functional capacity and muscle weakness as strongly 
predictive of disease progression and increased mortality(Panagiotou et al. 2016), whilst measures of 
gas exchange may be more valuable predictors of outcome than measures of lung mechanics (Lederer 
et al. 2006, Flaherty et al. 2006, Ley et al. 2011). Hypoxia after 6-minute walk test (6MWT) and a history 
of arthritis appear to predict progression in SSc-ILD (Wu et al. 2018). Nevertheless, further efforts to 
develop definitive prediction models are required for clinical practice (Kolb and Collard 2014, Ley et 





Cardio-Pulmonary Exercise Testing (CPET) provides a comprehensive assessment of the physiological 
changes in the respiratory, cardiovascular, and musculoskeletal systems in a controlled laboratory 
environment (Layton et al. 2017), that has shown promise in terms of prognostic value in a number of 
chronic respiratory conditions (Ferrazza et al. 2009, Arena and Sietsema 2011).    
  
The primary objective of this systematic literature review was to evaluate the prognostic value of CPET 
in predicting disease-specific outcomes in longitudinal studies of ILD. If a prognostic role for CPET were 
confirmed, it could be used to guide earlier intervention for at-risk patients, support cohort 
enrichment for ILD clinical trials and allay anxiety and unnecessary monitoring amongst patients with 
stable ILD.   
  
  
Materials and methods  
  
  
Reporting of protocol and review registration  
The study protocol was prepared in accordance with Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines (Shamseer et al. 2015) and registered in the International 
Prospective Register of Systematic Reviews (PROSPERO 110198/2018).   
  
Eligibility criteria   
Studies that reported the relationship between CPET assessment and disease progression, prognosis or 
the presence/emergence of specific clinical outcomes of ILD were included.   
  
Using the PICO framework, we evaluated publications that fulfilled the following criteria:   
Population   
Adults (18 years or older) with a diagnosis of ILD (including but not limited to idiopathic pulmonary 
fibrosis, CTD-related ILD and sarcoid-related ILD).  
Intervention  
  
Studies reporting the outcome of CPET assessment as a prognostic factor. All available methods of 1) 
performing formal CPET and 2) reporting CPET results were included.   
Comparison  
Patients with/who developed relevant outcomes (see below) were compared with those who did not, 




Outcome measures  
The primary objective was to evaluate the prognostic value of CPET in predicting disease course and 
outcomes in longitudinal (retrospective or prospective) studies of ILD. The relationship between CPET 
results and a number of clinically relevant outcomes including, but not limited to, relevant clinical 
phenotype and disease demographics (e.g. disease duration, gender, age, lung physiology), disease 
outcomes (e.g. death, hospitalisation), surrogates of disease severity (including, but not limited to lung 
physiology, circulating biomarkers etc.), health-related quality of life (HRQOL) and functional status, 
were examined.    
  
Study design  
Eligible studies included cohort (retrospective or prospective) and observational longitudinal studies, 
that reported outcomes at a time point distinct from the baseline CPET (i.e. were of an appropriate 
design to evaluate prognostic value). The following types of studies were excluded: 1) animal studies 
2) studies including patients with lung disease where an ILD cohort was not described and reported 
separately 3) studies designed to develop or validate health measurement scales 4) randomized 
controlled trials 5) case reports 6) qualitative research 7) non-original research publications (i.e., 
editorials, reviews) 8) abbreviated reports (e.g. letters to editors) and conference proceedings. An 
amendment to our originally registered protocol (English language articles only) was made to enable 
the inclusion of a relevant non-English (French) publication.  
  
Search strategy   
The search criteria were developed in accordance with search recommendations for systematic 
reviews of evaluations of prognostic variables (Altman et al. 2000). Electronic searches were 
performed in Medline and EMBASE, with no publication date or language restrictions.  Full details of 
the specific search criteria applied are detailed in the supplementary material (Supplementary 
material 1). All titles and abstracts generated by the search criteria were screened independently by 
two review authors (R.D. and C.S.) identifying those studies relevant and eligible for full text review. 
Agreement between reviewers in the study selection process was assessed using Cohen’s Kappa 
statistics (Cohen 1968).  Any discrepancies/disagreements were resolved by discussion between 
reviewers and included a third party (SLB) if necessary. Discussions between reviewers resolved any 
discrepancies at each stage of the study selection process. Review articles or editorials focussing on 
the “prognostic aspects of cardiopulmonary exercise testing in Interstitial Lung Disease” were also 






Data extraction   
A standardised form was used (initially by RS and CS, with subsequent verification by SB) to 
independently extract relevant study details from each of the selected studies that included: date of 
publication, journal or publication source, study design, initial population of the study, study inclusion 
criteria, study exclusion criteria, CPET method, CPET analysis endpoints, disease outcomes assessed 
and a summary of key findings. Study corresponding authors were contacted when clarification was 
required.   
  
Data synthesis  
Formal meta-analysis was planned if appropriate and feasible. In anticipation of wide heterogeneity 
in design, CPET methods and CPET analysis, a narrative, qualitative synthesis of results was planned if 
quantitative analysis was not possible.  
  
Risk of bias assessment  
The QUIPS (Quality in Prognosis Study) risk of bias tool was used to assess the risk of bias within every 
included study (Huguet et al. 2013). Kappa statistics were applied to assess preliminary agreement 
between reviewers for bias assessment. Discussions between reviewers were undertaken to achieve 
consensus where discordance existed in the preliminary bias assessment for any domain 
(Supplementary material 2).  
  
Results  Study selection  
Initial simultaneous searches in EMBASE (n=573) and Medline (n=373), performed on 13th April 2019, 
identified a total of 946 articles. After removal of duplicates (n=288), 658 articles generated by the 
search were screened for eligibility and exclusion criteria based on titles and abstract review. There 
was moderate initial agreement between the two reviewers (Cohen’s kappa 0.462 – see 
Supplementary material 3), with discordance in 20 abstracts, that was easily resolved through 
discussion. Eighteen articles proceeded to full text review and this led exclusion of a further 5 studies. 
A total of 13 studies were deemed eligible for inclusion. The full study selection process is detailed in 
Figure 1. Table 1 summarises the study design and reported findings of the thirteen papers that 







Geographical participation and date of publication  
Three studies were undertaken in Europe (5/13, 38%)(Triantafillidou et al. 2013, van der Plas et al. 
2014, Gläser et al. 2013, Wallaert et al. 2011, Kollert et al. 2011), four in USA (5/13, 38%)(Fell et al. 
2009, Kawut et al. 2005, Layton et al. 2017, Swigris et al. 2009, King et al. 2001) and the remainder in 
Israel (Vainshelboim et al. 2016), Japan (Miki et al. 2003) and Brazil (Lopes et al. 2012). The majority 
of studies were published in the last 10 years (10/13, 70%)(Layton et al. 2017, Triantafillidou et al. 
2013, van der Plas et al. 2014, Gläser et al. 2013, Vainshelboim et al. 2016, Lopes et al. 2012, Wallaert 
et al. 2011, Swigris et al. 2009, King et al. 2001, Kollert et al. 2011) and only three studies published in 
the years preceding 2009 (Miki et al. 2003, Fell et al. 2009, Kawut et al. 2005).  
  
Study characteristics  
Most studies were retrospective cohort analyses (11/13, 85%), with variable follow-up periods (range 
23 days(Kawut et al. 2005) - 20 years(Swigris et al. 2009)). The majority of retrospective studies 
evaluated independent risk factors for survival or mortality outcomes in ILD (9/11, 82%) and had an 
average follow up time of between 1-4 years (Gläser et al. 2013, Kawut et al. 2005, Layton et al. 2017, 
van der Plas et al. 2014, Miki et al. 2003, Vainshelboim et al. 2016, Triantafillidou et al. 2013, Wallaert 
et al. 2011, King et al. 2001). The longest planned follow up was in a study examining a cohort of 
systemic sclerosis ILD patients (truncated at 20 years) (Swigris et al. 2009).   
  
There were two prospective studies (Triantafillidou et al. 2013, Vainshelboim et al. 2016). One 
investigating the relationship between CPET and survival characteristics in IPF had a variable duration 
of follow up between 9-64 months (Triantafillidou et al. 2013). The other prospective study used CPET 
as part of a wider investigation into the role of exercise testing in the prognostication of ILD and 
followed patients up for a fixed period of 40 months (Vainshelboim et al. 2016).   
  
Study populations  
Of the studies identified, 8/13 (62%) exclusively recruited patients with IPF, two recruited only 
sarcoidosis patients (Lopes et al. 2012, Kollert et al. 2011), and one study systemic-sclerosis associated 
ILD (Swigris et al. 2009). The remaining studies (2/13, 15%) evaluated more heterogeneous cohorts of 
ILD patients referred for lung transplantation assessment (Kawut et al. 2005, Layton et al. 2017).   
  
The prognostic value of CPET has been retrospectively reported in a total of 703 patients with IPF, and 
prospectively in a further 59 patients in 2 small, single centre studies (n=25 (Triantafillidou et al. 2013) 
and n=34 (Vainshelboim et al. 2016) respectively).  Patients were recruited to studies according to 




Thoracic Society (ATS) international consensus statement for the diagnosis of IPF(2000, Miki et al. 2003, 
Triantafillidou et al. 2013, van der Plas et al. 2014, Fell et al. 2009, King et al. 2001) and the later 2002 
ATS/ERS (European Respiratory Society) international consensus classification of the idiopathic 
interstitial pneumonias (including IPF) (Wallaert et al. 2011, Kawut et al. 2005, Society and Society 2002). 
The updated 2011 ATS/ERS/JRS/ALAT evidence based guidelines for the diagnosis of IPF (Raghu et al. 
2011) were applied in all (Triantafillidou et al. 2013, Gläser et al. 2013, Layton et al. 2017, Vainshelboim 
et al. 2016) but one of the studies (van der Plas et al. 2014) published after 2011 (the latter was a 
retrospective study that may have recruited patients prior to the publication of the 2011 guidelines).   
  
The prognostic role of CPET in outcomes of secondary causes of ILD (such as connective tissue disease 
(CTD), drug-induced ILD, occupational causes of ILD and hypersensitivity pneumonitis (HP)) in 
granulomatous disease or in other forms of idiopathic interstitial pneumonias (IIP) has not been 
extensively reported. No prospective studies were identified. Only one retrospective study was 
identified that examined the prognostic role of measures obtained during CPET in a cohort of SSc 
associated ILD patients (n=83) (Swigris et al. 2009). Patients with SSc met diagnostic criteria adopted 
by the 1980 American Rheumatology Association and those with SSc sine scleroderma met criteria 
proposed by Poormoghim and colleagues (Poormoghim et al. 2000). A diagnosis of ILD was based on 
chest radiography in n=60 patients (Swigris et al. 2009).   
  
Two additional retrospective studies have explored the role of CPET in predicting longitudinal 
outcomes in a total of 144 histologically confirmed sarcoidosis patients (Lopes et al. 2012, Kollert et 
al. 2011), representing Scadding disease stages 1-4 (SCADDING 1961).   
  
We identified two retrospective studies that examined the role of CPET in predicting outcomes in 
mixed populations of ILD patients (Layton et al. 2017, Kawut et al. 2005). Cumulative patient numbers 
were small (a heterogeneous group of connective tissue disorders n=28, HP n=8, unclassifiable ILD n=7, 
sarcoid n=15, IIP n=21 (NSIP n=18, COP, DIP, COP). Whilst the cohorts could be considered to be 
representative of mixed ILD cohorts, patient numbers for each subtype were too small to consider each 
subgroup separately.   
  
With regards to the study participant populations, the QUIPS risk of bias was considered to be low for 
only 3/13 (23%) studies (Triantafillidou et al. 2013, Wallaert et al. 2011, Vainshelboim et al. 2016), 
with the majority regarded as having a moderate (6/13, 46%) or high (4/13, 31%) (Miki et al. 2003, 
Layton et al. 2017, Kawut et al. 2005, Kollert et al. 2011) risk of bias. The generalisability of one study 




(Fell et al. 2009), a condition that can often be confidently diagnosed without biopsy in the presence 
of typical radiological findings and by consensus agreement in the multidisciplinary team setting 
(Walsh et al. 2016) and thus raising concerns as to whether this cohort was representative of IPF 
populations in the ‘real world’. The generalisability of a further study that assessed the extent to which 
gas exchange measurements could predict the need for prolonged immunosuppressive therapy in 
sarcoidosis, was limited by the lack of clearly defined clinical characteristics e.g Scadding disease stage, 
in the subset of patients followed longitudinally (102/149)(Kollert et al. 2011). Two studies examined 
disease outcomes that necessitated a particular baseline clinical phenotype e.g. recruitment from 
source populations referred for lung transplant evaluation and thus by definition only analysed 
selected cohorts of advanced ILD patients (Layton et al. 2017, Kawut et al. 2005). Others incorporated 
a priori patient grouping, for example the presence of pulmonary hypertension (Gläser et al. 2013), to 
enrich populations with patients at high risk of developing outcomes of interest, or required the active 
exclusion of patients with a relevant phenotype e.g. those that died from a cause other than 
respiratory failure (Miki et al. 2003).   
  
Study attrition was generally reported to be low, which may reflect the retrospective nature of the 
majority of the studies identified. The QUIPS risk of bias for study attrition was reported to be high in 
two studies, increasing the potential for selection bias;  >25% patients identified were excluded from 
the analysis by Lopes et al.(Lopes et al. 2012) (15 pts excluded: smoking history (n=10), concomitant 
respiratory disease (n=2), cardiac disease (n=2), neuromuscular disease (n=1), reducing final cohort to 
42 pts), whilst in the study by King et al. (King et al. 2001), 34% (80/238) of the originally identified 




Prognostic factor measurement  
CPET was the sole prognostic factor for the majority of studies 8/13 (62%), with a minority using CPET 
as part of a broader repertoire of exploratory physiological tests including 6MWT (Kawut et al. 2005, 
Triantafillidou et al. 2013, Layton et al. 2017) or lung function parameters (Gläser et al. 2013). One 
study used CPET in conjunction with clinical, radiological and resting physiological tests to devise a 
scoring system to predict survival in newly diagnosed cases of IPF (the CRP score: Clinical Radiological 
Physiological score) (King et al. 2001).  
  
In two studies, CPET was used as the principle method to achieve a standardised form of maximal 




oxygenation measurements were taken to determine the effect of exercise on gas exchange. In both 
of these studies, typical CPET measures, such as maximal oxygen consumption (VO2max) were not 
recorded.   
  
Across all studies, the bias rating for prognostic factor measurement using the QUIPS tool was 
considered low-to-moderate (Table 2), with the majority of studies reporting a standardised approach 
to CPET and analysis that would be easily reproducible and less amenable to bias. Most studies 
provided a sufficient description of the CPET protocol used, adhering to the 2003 American Thoracic 
Society statement on cardiopulmonary exercise testing (Society and Physicians 2003) (6/10, 
60%)(Kawut et al. 2005, Wallaert et al. 2011, van der Plas et al. 2014, Layton et al. 2017, Triantafillidou 
et al. 2013, Gläser et al. 2013). Others used the European Respiratory Society 1997 (Miki et al. 2003) 
and updated 2007 (Vainshelboim et al. 2016, Palange et al. 2007) recommendations. In others 
important details were missing e.g. if oxygenation was measured during CPET (van der Plas et al. 2014). 
Variation in the methodological approach to CPET was also observed. For example, in one study, 
oxygen usage during CPET was an inclusion criteria (Layton et al. 2017), whilst in another, supplemental 
oxygen during exercise was supplied variably to participants depending on a pre-study requirement 
for home oxygen or saturation on room air <90% (Kawut et al. 2005). In 7/13 (54%)  studies, blood gas 
analysis was used to assess the adequacy of gas exchange during exercise (Fell et al. 2009, Miki et al. 
2003, Lopes et al. 2012, Wallaert et al. 2011, Kollert et al. 2011, Swigris et al. 2009, King et al. 2001), 
whilst the remainder used pulse oximetry, considered by some experts to be a suboptimal substitute 
(Society and Physicians 2003). A broad range of quantitative CPET parameters were 
presented/analysed (summarised in Table 1), raising the possibility of reporting bias (see later).  
  
All but one study used cycle ergometry. Treadmill exercise testing was used as the method of CPET in 
the remaining study; in which exercise increments were chosen for participants based on patient’s 
daily activities and parameters of resting pulmonary function, raising concerns whether a standardised 
approach had been adopted (Miki et al. 2003). Additionally, non-uniform speed increases, often 
inherent to treadmill testing, results in nonlinear metabolic rate increases and fundamental difficulties 
in calculating an accurate external work rate and an estimation of peak VO2. Thus direct comparisons 
of peak VO2 obtained during treadmill testing studies cannot be compared with those obtained from 
cycle ergometry studies.   
  
Outcome measurement  
The most commonly reported outcome was mortality/survival 11/13 (85%). The majority of these 




mortality, considering death or lung transplantation as composite end-point. One study used an 
outcome measurement that was restricted to respiratory deaths only (Miki et al. 2003) and another 
study assessed the discriminatory ability of CPET to identify patients who would die on the lung 
transplant list before receiving transplantation (Kawut et al. 2005). Other outcomes included 
interceding pulmonary hypertension (PH) (Gläser et al. 2013) and decline in pulmonary function (FVC 
and DLCO) or duration of immunosuppressive therapy in sarcoidosis (Lopes et al. 2012, Kollert et al.  
2011).  
  
Using the QUIPS tool, the risk of bias in the approach to outcome measure assessment was considered 
low-to-moderate, in all studies.   
  
Reported prognostic associations of CPET in ILD   
  
All studies reported at least 1 positive association between CPET and clinical outcomes, raising the 
possibility of positive reporting bias (Table 1). Significant heterogeneity in study design, study 
populations (and classification criteria adopted), CPET protocols, CPET endpoints and defined 
endpoints precluded any useful attempt at meta-analysis.  
  
Idiopathic pulmonary fibrosis  
The prognostic role of peak VO2 has been examined across several studies of IPF. Fell et al. (Fell et al. 
2009) retrospectively suggested a baseline threshold of peak VO2 8.3ml/kg/min predicted survival in 
117 patients with IPF (peak VO2 <8.3ml/kg/min HR 3.24, CI 1.10-9.56, p=0.03). Patient numbers in the 
subgroup with peak VO2 < 8.3ml/kg/min were small however (n=8, 7%), compared to the 46% patients 
that actually died, suggesting that the threshold sensitivity was not high. In another study, 
Triantafillidou et al. (Triantafillidou et al. 2013) prospectively identified a threshold of 14.2ml/kg/min 
for survival in 25 patients with moderate IPF (mean FVC 77.5 ± 21.8), whilst Vainshelboim et al. 
(Vainshelboim et al. 2016) suggested VO2 <13.8 ml/kg/min as one of 5 CPET parameter thresholds 
(peak work rate, tidal volume reserve, VE/VO2 nadir and VE/VCO2 at AT) predicting survival in a 
prospective cohort study of 34 patients with IPF. Finally, Gläser et al. identified that the presence of 
PH (invasively assessed by right heart catheter) and peak VO2 % predicted were the only variables 
independently predictive of survival in a retrospective cohort of 133 patients, and application of % 
predicted values showed statically significant superiority to absolute data values. These results 
contrast with the findings of other studies where no independent association between survival in IPF 




of disease severity, follow-up periods and accompanying disease co-morbidity may have impacted on 
results of these studies and larger prospective studies are required to ascertain the prognostic role of 
peak VO2 in predicting IPF survival.   
  
Gläser et al. found that the development of interceding PH in IPF was best predicted by reductions in 
ventilatory efficiency, the VE/VCO2 slopepred (cut off of ≥152.4, AUC 0.938; CI 0.892-0.984), with a 
sensitivity of 87.2% and specificity of 88.4%, but analysis of PH subgroup alone did not identify any 
CPET parameters that provided independent prognostic information.  VE/VCO2 at AT has also been 
shown to be discriminating factor to determine the presence of PH across a cohort of IPF patients 
(adjusted OR 1.182; CI 1.029-1.384, p=0.021, n=81), but once again the prognostic value of this 
parameter has not been determined (Boutou et al. 2011).   
  
The prognostic value of an alternative measures of ventilatory efficiency, the ventilatory equivalent 
for carbon dioxide at AT (VE/VCO2 at AT), in predicting survival in IPF has also been examined (van der 
Plas et al. 2014). In a retrospective study of 38 IPF patients, those with VE/VCO2 at AT >45 had a 
significantly worse survival compared to patients with VE/VCO2 at AT ≤ 45 (HR 4.58, p=0.001), and this 
parameter remained a strong predictor even after correcting for functional severity of ILD, highlighting 
its possible use in the early detection of vascular impairment. Furthermore, the ventilator equivalent 
for oxygen at AT (VE/VO2 at AT) >45 was reported to be an independent poor predictor of 3 yearsurvival 
in a cohort of 63 IPF patients (Wallaert et al. 2011), findings consistent with the univariate analysis of 
Miki et al. (Miki et al. 2003). Results suggest that the magnitude of hyperventilation at ventilatory 
threshold may be determining prognostic value, but further prospective studies are required to 
confirm the value of these parameters of ventilatory efficiency in the prognostication of  
IPF.   
  
Exercise induce hypoxaemia was also considered as a potential prognostic factor in IPF. Miki et al (Miki 
et al. 2003) found that only two factors, age and PaO2 slope (defined as change in arterial oxygen 
pressure in mmHg / change in VO2 uptake during exercise (∆PaO2/∆VO2)), provided independent 
prognostic information in a cohort of 41 IPF patients (HR 1.096, CI 1.012-1.187, p=0.025 and HR 0.841, 
CI 0.731-0.967, p=0.015 respectively) and stratification of patients according to this slope 
(≤60mmHg/l/min or >-60mmHg/l/min) identified significant differences in median survival (1.6 years 
vs 4.5 years respectively). Measurement of this parameter does however, require invasive arterial 
blood gas analysis during exercise testing, that is unavailable in the many clinical exercise laboratories. 




derived parameter included in their comprehensive clinical-radiologic-physiologic scoring model to 
predict survival in IPF, and when weighted, accounted for as much as 10.5% of the maximum score in 
the complete model. Nevertheless, there were methodological limitations in this latter study; only 
158/238 patients performed exercise testing and patients received supplemental oxygen when 
significant hypoxaemia ensued.   
  
As a consequence of the utilisation of numerous different CPET parameters, CPET cut-off values, and 
timing of mortality evaluation, it was not possible to determine definitive thresholds for mortality or 
the development of pulmonary hypertension based on the analysed data.   
  
Non-IPF Interstitial Lung Disease   
In mixed populations of ILD patients with advanced disease and referred for lung transplantation 
(Layton et al. 2017, Kawut et al. 2005), oxygen saturations during CPET exercise were amongst the 
variables that were predictive of lung transplantation or death.  Layton et al. (Layton et al. 2017) 
demonstrated a workload threshold during CPET <35%, nadir CPET SpO2 <86% and FVC <45% were 
predictive of lung transplantation or death within 1 year of their CPET, with HR of 4.71 (CI 2.64-8.38, 
p<0.001) and HR 2.27 (1.41-3.68, p=0.001) and HR 1.82 (1.15-2.87, p=0.01), respectively. Kawut et al. 
(Kawut et al. 2005) identified more than 15 different variables, including at least 6 CPET variables (SaO2 
unloaded, peak and recovery, VO2/kg peak, VO2/Heart rate, carbon dioxide production, minute 
ventilation, and VE/VCO2) that predicted all-cause mortality in this patient population, with worse 
survival for patients with SaO2 <95% during unloaded exercise (Kaplan Meier log rank test p=0.0025) 
or low six minute walk test distance (6MWTD) <350m (p=0.001). The authors went on to study factors 
that might predict death on the transplantation list and identified that desaturation during exercise or 
6MWTD <350m, were again associated with poor outcomes; for a patient with SaO2 <95% during 
unloaded exercise, there was a 75% chance of dying on the list.    
  
Across the two studies that examined longitudinal outcomes in sarcoidosis, the alveolar-arterial 
oxygen pressure gradient during exercise P(A-a)O2, a measure of arterial desaturation during exercise, 
was independently associated with both the need for prolonged immunosuppressive therapy (>1 year) 
(odds ratio (OR) 1.098 (CI 1.039-1.160, p<0.001)(Kollert et al. 2011) and decline in pulmonary function 
at 5 years (>10% decline in FVC or DLCO from baseline)(with P(A-a)O2 >22mmHg Relative Risk (RR) 70.0 





Only one study specifically examined the role of CPET in predicting survival in SSc-ILD (Swigris et al. 
2009). Whilst typical CPET measurements e.g. VO2max were recorded, attempts to correlate these with 
survival were not described. In similarity to the studies in sarcoidosis and IPF, diffusion limitation, 
measured in this study as the change in peripheral pulse oximetry during CPET exercise (SpO2), 
correlated with survival. The risk of death was 2.4 times greater in SSc-ILD individuals whose SpO2max 
fell <89% (Hazards Ratio (HR) 2.4, CI 1.2-4.9, p=0.02), and 2.4 times greater for subjects whose SpO2 
max fell >4% from baseline (HR 2.4, CI 1.1-5.0, p=0.02).  
  
Further interpretation of the prognostic value of CPET parameters in ILD is limited by moderate-tohigh 
risk of bias across domains the QUIPS tool, with a ‘high’ risk of bias rating present in at least one QUIP 
domain in 9/10 (90%) studies. The main issues with study quality were related to confounding and 
statistical domains (see Table 2) and are discussed in more detail in following sections.   
  
Study confounders, statistical analysis and reporting  
The majority of studies were considered to be at ‘high’ risk of bias due to inadequate account of potential 
confounding factors or methods of statistical analysis/reporting (Table 2).    
  
The data used in the majority of studies was obtained from existing databases and/or case note review 
(85%, n=11). As the data was not collected as part of a designed study, several potential confounders 
variables were not recorded, for example the presence of co-morbid disease (Wallaert et al. 2011, Fell 
et al. 2009, Miki et al. 2003, Gläser et al. 2013, Lopes et al. 2012, Swigris et al. 2009), body mass index 
(Triantafillidou et al. 2013, Fell et al. 2009, Miki et al. 2003, Kawut et al. 2005, van der Plas et al. 2014, 
Lopes et al. 2012) and smoking status (Wallaert et al. 2011, Kawut et al. 2005, Gläser et al. 2013, Lopes 
et al. 2012).   
  
The most important potential confounder was baseline ‘disease severity’ which was only specifically 
addressed as a confounder in one study; through the inclusion of lung function parameters and a 
composite physiological index (as markers of disease severity) into the Cox regression model used for 
analysis (van der Plas et al. 2014). This same study also stratified patients in an attempt to control for 
other potential confounders. Patients were sub-grouped into those with a systolic pulmonary artery 
pressure greater than or less than 40mmHg, in an attempt to control for interceding pulmonary 
hypertension, but this reduced subgroup sample sizes and thus may have reduced the statistical power 





 Eligibility criteria were used to increase uniformity of study participants and reduce potential 
confounders. For example two studies used participants referred for transplantation and thus by 
definition analysed distinct cohorts of more advanced patients but this selection bias reduced the 
generalisability of results (van der Plas et al. 2014, Layton et al. 2017). Other studies focused on 
healthier populations of ILD patients who did not need supplemental oxygen during CPET testing, but 
this, unsurprisingly,  resulted in low mortality rates (n<10) leading to reporting bias (Vainshelboim et 
al. 2016, Fell et al. 2009, Triantafillidou et al. 2013).   
  
Multiple regression analysis was the dominant statistical methodology used to determine the 
relationship between CPET parameters and clinical outcomes in ILD. Whilst this approach is generally 
considered to be one of the better statistical approaches to minimise unknown confounders, many of 
the studies reported on sample sizes much smaller than the minimum requirement for multiple logistic 
regression analysis as determined by Bujang et al. (Bujang et al. 2017). Furthermore, of all of the 
studies examined, only one detailed an a priori power calculation (Vainshelboim et al. 2016).  Many 
studies were likely to be underpowered to detect the outcomes proposed.   
Stepwise multiple regression was used by some studies to determine the optimal model parameters 
to predict increased mortality (Triantafillidou et al. 2013, King et al. 2001). One criticism of this 
statistical approach is that model selection is conducted through parameter inference, which may lead 
to over-fitting of some parameters or exclusion of confounders that are not statistically significant 
(Whittingham et al. 2006). Furthermore, the order of parameter entry (or deletion) and the number 
of parameters, can also affect the selected model (Derksen and Keselman 1992), whilst the multiple 
hypotheses tests, performed as part of this analysis, increases the probability of Type I error 
(Whittingham et al. 2006). The authors of one study did however attempt to overcome some of these 
limitations by checking for consistency between forward selection and backward elimination 
algorithms (Triantafillidou et al. 2013).   
Only one study specifically attempted to reduce multicollinearity between parameters considered for 
inclusion into the multiple regression analysis (King et al. 2001). Multicollinearity is more common in 
observational studies and if ignored may lead to unreliable estimates of regression coefficients, 
inclusion of redundant variables  and increased type II error (S, A and B 2000). King et al. (King et al. 
2001) used Pearson’s correlation coefficient to detect variables that were highly correlated; for 
example PaO2 at maximal exercise and resting PaO2, entering only the most statistically significant 






Maximum oxygen consumption (VO2max) is a measurement of the capacity for aerobic exercise and is 
determined by variables that define oxygen delivery by the Fick equation (Society and Physicians 2003); 
thus gas exchange across the lung, oxygen content of blood, oxygen delivery to tissues and oxygen 
uptake in the tissues can all affect the VO2max. In healthy individuals, constraints of the cardiovascular 
system are most responsible for limiting VO2max (Wagner 1996, Stickland et al. 2012). In patients with 
ILD, limitation to exercise may generally occur as a consequence of one of more of: 1) ventilatory 
mechanical limitation (unable to increase tidal volume (VT) sufficiently and may reach their maximal 
predicted minute ventilation (% pred VEmax)), 2) abnormal gas exchange (or reduction in ventilatory 
efficiency, indicated by variables such as the increment in minute ventilation (VE) relative to carbon 
dioxide production (CO2; VE/VCO2) 3) and/or diffusion limitation (indicated by variables such as 
reduction in oxygenation ≥ 4% or hypoxia at anaerobic threshold (AT)/peak exercise).    
  
To our knowledge, this is the first study to systematically review and critically appraise studies that 
have reported the prognostic value of CPET in ILD. This field has gained recent attention with the 
majority of studies published within the last 8 years. Thirteen studies were identified that examined 
the prognostic value of CPET in ILD, all of which reported a prognostic role for CPET parameters in 
predicting clinical outcomes in ILD, with survival being the principle clinical outcome measured. Issues 
with study quality (relating primarily to the inherent problems of retrospective studies, patient 
selection and presentation of numerous CPET parameters), limits the strength of conclusions that can 
be drawn from the studies reviewed and thus whilst the associations presented shed important light 
to the potential role of CPET in disease prognostication in ILD, there is insufficient evidence at the 
moment to support its use in facilitating ‘real-world’ clinical decisions.   
  
The exclusion of unpublished studies (e.g. conference abstracts) and abbreviated reports from this 
review may also increase the potential for publication bias, although this priori decision was taken to 
ensure sufficient information was available to enable detailed data extraction from each study.    
  
We identified one study that described the prognostic value of CPET in IPF that was not originally 
eligible for inclusion in our study analysis due to the full text being published in French (Wallaert et al. 
2011). The decision was taken to amend our published protocol to include this study as the subject of 
the study was deemed to be important by independent reviewers.    
  
This work has identified a number of considerations for future prognostic studies of CPET in ILD. 




interplay of patient, genetic, environmental and treatment factors. As such, a multivariable approach 
to the design and analysis of future prognostic studies of ILD is essential if we are to confirm a specific 
role for CPET in routine monitoring. In contrast to randomised controlled trials, there are no robust 
standards defining the need to register or publish protocols for prognostic research and as such it is 
not always transparent whether statistical analysis were part of a priori plan (Hemingway et al. 2009). 
Almost all studies in this review examined multiple prognostic CPET variables and as such there is 
potential for selective reporting bias that could be largely overcome by more stringent protocol 
registration with pre-specified outcomes of interest.   
  
Conclusion  
The quality of existing studies on the role of CPET in the prognostication of ILD limits the conclusions 
that can be drawn from such work. Larger prospective studies are needed to establish the role of CPET 
















Appendix E: Details of inter-reviewer agreement during initial title and abstract review for 
eligible articles  
  
Details of agreement between reviewers for the title and abstract review  
  
    Reviewer 2      
Reviewer 1     Include  Exclude  Totals  
Include  9  20  29  
Exclude  0  629  629  
Totals    9  649  658  
  
Number of observed agreements: 638 (97.0% of the observations)   




Kappa = 0.462 (95% confidence interval 0.267-0.658)   
SE of kappa= 0.100  
The strength of agreement is considered to be ‘moderate’.   
  
Of the 20 citations for which there was disagreement, 9 papers were included in full text analysis. 




















Appendix F: Poster accepted for Winter British Thoracic Society 2019  
  
The use of cardiopulmonary exercise testing in Idiopathic Pulmonary Fibrosis: Feasibility and correlation with 
quality of life measures.   
  
Davis R1, Viner J2, Dixon C2, Morley A1, Adamali H3, Maskell N1, Barratt SL1,3  
  
1. Academic Respiratory Unit, University of Bristol, Bristol, UK  
2. Respiratory Physiology, North Bristol NHS Trust, Bristol, UK  






The heterogeneity of idiopathic pulmonary fibrosis (IPF) in terms of disease course and treatment response leads 
to challenges for patients and clinicians in terms of optimal timing for transplantation(Mura et al. 2012) and/or 
end of life discussions (Schroedl et al. 2014). The use of cardiopulmonary exercise testing (CPET) in IPF 
prognostication remains largely unexplored.   
  
Objectives:    
1) To explore the feasibility of undertaking CPET in this population  
2) To explore the correlation between baseline CPET variables, physiological variables and quality 
of life (QOL) scores.   
  
Methods:   
Consecutive IPF patients (n=74) were approached, with prospective recruitment of 42 participants to the study.  
Patients with FVC <50% and/or DLCO <50% were excluded. King’s Brief ILD (K-BILD) questionnaire assessed QOL.  
Patients undertook incremental exercise testing to maximal exertion using a cycle ergometer, with 
contemporaneous physiological testing (FVC, DLCO).  
  
Results  
32 patients were excluded from the study (22 screening failures, 10 declined), with study attrition of an 
additional 10 patients (n=4 withdrew consent, n=1 death prior to testing, n=5 developed exclusions). Thirty-two 
patients (23 mild IPF with FVC>80%, 9 moderate IPF with FVC 50-80%), 26M:6F and median age (IQR) 75 years 
(71-79), underwent CPET. One patient failed to reach anaerobic threshold (AT) and was excluded from the 
analysis. Median (IQR) pulmonary and exercise results were: FVC 92% (75-102), DLCO 62% (54-69), minimum 
SpO2 93%  
(88-95), VO2 peak/kg 21 (17.4-23.8) mL.kg-1.min-1 and VE/VCO2 27.2 (25.4-30.5). Median (IQR) QOL scores for 
each domain were: total K-BILD 64.4 (58.1-68.7), psychological 68.3 (56.9-80.9), breathlessness/activity (B/A) 
50.2 (48- 
62.7) and chest symptoms 85.2 (85.2-100).   
  
VO2 peak/kg correlated with chest (r=0.36, p=0.049) and B/A (r=0.43, p=0.016) domains of the K-BILD 
questionnaire. VO2 peak/kg at AT also correlated with total K-BILD scores r=0.37, p=0.039 and chest domains 
(r=0.535, p=0.002). Total KBILD scores did not correlate with %FVC (r=0.26, p=0.15), %DLCO predicted (r=0.11, 
p=0.544) or SpO2 (r=0.01, p=0.959) (Spearman’s).  
  
Conclusions   
Initial results suggest CPET is a feasible method of testing in mild-moderate IPF. Whilst QOL did not correlate 




exploration. Longitudinal data will hopefully provide further information on the usefulness of CPET as a 


































Appendix G: Poster accepted for American Thoracic Society 2020  
  
  
The use of cardiopulmonary exercise testing in Idiopathic Pulmonary Fibrosis: correlation with baseline quality 
of life measures.   
  
Davis R1, Viner J2, Dixon C2, Morley A1, Adamali H3, Maskell N1, Barratt SL1,3  
  




2. Respiratory Physiology, North Bristol NHS Trust, Bristol, UK  
3. Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK  
  
Rationale:  
The heterogeneity of idiopathic pulmonary fibrosis (IPF) in terms of disease course and treatment response leads 
to challenges for patients and clinicians in terms of optimal timing for transplantation and/or end of life 
discussions. The use of cardiopulmonary exercise testing (CPET) in IPF prognostication remains largely 
unexplored. We report on the preliminary baseline data obtained from a study evaluating the role of CPET as a 
prognostic tool in patients with IPF.   
  
Objectives:    
To explore the correlation between baseline CPET variables, physiological variables and quality of life (QOL) 
scores.   
  
Methods:   
Consecutive IPF patients (n=74) were approached, with prospective recruitment of 42 participants to the study.  
Patients with FVC <50% and/or DLCO <50% were excluded. King’s Brief ILD (K-BILD) and IPF-Patient Reported 
Outcome Measure (IPF-PROM) questionnaires assessed QOL. Patients undertook incremental exercise testing to 
maximal exhaustion using a cycle ergometer, with contemporaneous physiological testing (FVC, DLCO).   
  
Results  
32 patients were excluded from the study (22 screening failures, 10 declined), with study attrition of an 
additional 10 patients (n=4 withdrew consent, n=1 death prior to testing, n=5 developed exclusions). Thirty-two 
patients (23 mild IPF with FVC>80%, 9 moderate IPF with FVC 50-80%), 26M:6F and median age (IQR) 75 years 
(71-79), underwent CPET. One patient failed to reach anaerobic threshold (AT) and was excluded from the 
analysis. Median (IQR) pulmonary and exercise results were: FVC 92% (75-102), DLCO 62% (54-69), minimum 
SpO2 93% (88-95), VO2 peak/kg 21 (17.4-23.8) mL.kg-1.min-1 and VE/VCO2 27.2 (25.4-30.5).   
  
  
VO2 peak/kg correlated with chest (r=0.36, p=0.049) and B/A (r=0.43, p=0.016) domains of the K-BILD 
questionnaire, in addition to total (r = -0.46, p=0.009) and energy (r= -0.45, p=0.012) domains of the IPF-PROM. 
VO2 peak/kg at AT also correlated with total K-BILD scores r=0.37, p=0.039 and chest domains (r=0.535, p=0.002), 
but only the energy domain (r= -0.38, p=0.036) of IPF-PROM. Total K-BILD and IPF-PROM scores did not correlate 
with baseline FVC % predicted, DLCO % predicted or minimum SpO2 (Spearman’s rank).  
  




In this cohort of mild-moderate IPF patients, baseline physiological testing did not correlate with patient QOL 
measures.  The relationship between oxygen consumption during CPET and QOL measures, requires further 
exploration. Longitudinal data will hopefully provide further information on the usefulness of CPET as a 























Appendix H: Revised paper submitted to BMC Pulmonary Medicine  
  
Title: A role for cardiopulmonary exercise testing in detecting physiological changes underlying health 
status in Idiopathic pulmonary fibrosis: a feasibility study  






1Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol, UK  
2Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK   
  
Abstract   
Introduction  
There is limited data available on the use of CPET as a predictive tool for disease outcomes in the 
setting of IPF. We investigated the feasibility of undertaking CPET and the relationship between CPET 




A prospective, single-centre observational study.  
Results  
Thirty-two IPF patients (mild n=23, moderate n=9) participated in the study, n=13 mild patients 
attended for repeat CPET testing at 12 months.  At baseline, total K-BILD scores and total IPF-PROM 
scores significantly correlated with 6MWT distance, but not with baseline FVC % predicted, TLCO % 
predicted, baseline or minimum SpO2.  VO2 peak/kg at AT positively correlated with total scores, 
breathlessness/activity and chest domains of the K-BILD questionnaire (p<0.05). VO2 peak significantly 
correlated with total IPF PROM scores and wellbeing domains (p<0.05), with a trend towards statistical 
significance for total IPF-PROM and VO2 peak/kg at anaerobic threshold (p=0.06).  
There was a statistically significant reduction in FVC% predicted at 12 months follow up, although the 
mean absolute decline was <10% (p<0.05). During this period VO2 peak significantly reduced (21.6 
ml/kg/min±2.9 vs 19.1±2.8; p=0.017), with corresponding reductions in total K-BILD and 
breathlessness/activity domains that exceeded the MCID for responsiveness. Lower baseline VO2 
peak/kg at anaerobic threshold correlated with greater declines in total K-BILD scores (r = -0.62, 0.024) 
at 12 months. Whilst baseline FVC% predicted or TLCO % predicted did not predict change in health 
status,    
Conclusion   




CPET measures of VO2 peak correlated with both baseline and change in K-BILD measurements at 1 
year, despite relatively stable standard lung function (declines of <10% in FVC), suggesting its potential 
sensitivity to detect physiological changes underlying health status.   
  
  
Introduction   
Idiopathic Pulmonary Fibrosis (IPF) is a progressive fibrosing lung disease of increasing 
prevalence(Navaratnam et al. 2011), associated with median survival of only 3-5 years from diagnosis 
(Raghu et al. 2006b, Ley et al. 2011).  Disease heterogeneity continues to present challenges for 
clinicians with regards to prognostication and optimal timings for lung transplantation and/or 
advanced care planning (Mura et al. 2012, Schroedl et al. 2014). In the setting of large-scale clinical 
trials, a decline in forced vital capacity (FVC) has been used as a primary outcome measure(Richeldi et 
al. 2014, King et al. 2014) and as a surrogate for mortality, although this has not been universally 
endorsed(Wells et al. 2012, King et al. 2005).   
  
Cardiopulmonary exercise testing (CPET) is the considered the gold standard for evaluating 
maximal/symptom-limited exercise tolerance, encompassing respiratory, cardiovascular and 
musculoskeletal assessments, in a controlled laboratory environment(Layton et al. 2017, Sue and 
Wasserman 1991, Palange et al. 2007).    
  
However, there is limited data available on the use of CPET as a predictive tool for disease outcomes 
in the setting of IPF. A recent systematic review identified only two small-scale prospective studies 
that investigated the role of CPET in the prognostication in IPF (Triantafillidou et al. 2013, 
Vainshelboim et al. 2016) and concluded that there was insufficient evidence to support its use in 
facilitating ‘real world’ clinical decisions at the current time.   
  
We have investigated the feasibility of undertaking CPET in a population of mild and moderate IPF 
patients in terms of the attrition of participants, information on safety data, and willingness to engage 
with the study protocol. Secondary end-points included: the change in CPET parameters over a 1 year 
period and the correlation between baseline CPET parameters and change in lung function, 6MWT 





We hypothesised that CPET would be feasible in population of mild to moderate IPF patients and more 
sensitive to change in patient’s health status than 6MWT, FVC or TLCO.   
  
Methods  
Study design  
This was a prospective, single-centre observational study undertaken at a large secondary care 
institution in the UK, providing secondary and tertiary care to patients with Interstitial Lung disease 
(ILD) within the South-West of England. The study was approved by the Health Research Authority 
and Research Ethics Committees (IRAS 223450).   
  
Study Subjects  
Patients with a multidisciplinary team (MDT) diagnosis of IPF, based upon the American Thoracic 
Society/European Respiratory Society 2018 guidelines(Raghu et al. 2018), were prospectively 
recruited to the study between June 2018 and May 2019. Written informed consent was obtained 
from each patient.   
  
Patients were divided into a ‘mild’ or ‘moderate’ category dependent on their baseline Forced Vital 
Capacity (FVC ≥ 50% - <80%: moderate; FVC  ≥ 80% mild).  Those patients in the ‘mild’ disease group 
would undertake both a baseline and repeat CPET at 12 months. It was decided by the study 
committee, due to the uncertainty of the ability of those with reduced lung function to perform a 
maximal exercise test, that those in the ‘moderate’ disease group would undertake only a baseline 
CPET test.   
  
Inclusion and exclusion criteria   
Inclusion criteria were an MDT consensus diagnosis of IPF, male or female aged ≥ 40yrs, TLCO ≥ 50% 





Key exclusion criteria were: FEV1/FVC ratio < the lower limit of normal, mobility issues preventing the 
participant to undertake cycle ergometry, history of myocardial infarction (MI) within 6 months or 
unstable angina within 1 month, uncontrolled arrhythmias causing symptoms or haemodynamic 
compromise, history of recent syncope (within last 6 months), acute thrombosis within previous 6 
months, cognitive impairment/ inability to perform CPET, severe or untreated arterial hypertension 
(>200mmHg systolic at rest, >120mmHg diastolic) and patients using oxygen treatment.  
  
Participant testing   
Pulmonary function testing  
Pulmonary function tests were performed in accordance with ATS/ERS guidelines(Graham et al. 2019), 
using the European Community of Coal and Steel (ECCS) reference equations(Quanjer et al. 1993). 
Forced expiratory volume during first second of expiration (FEV1), forced vital capacity (FVC), and 
transfer factor for carbon monoxide (TLCO) were undertaken at baseline (within 4 weeks of CPET) and 
at 12 months (± 4 weeks) (nSpire HDpft, nSpire Health GmbH, Germany). The MRC score, age (years), 
height (meters), and body weight of the patients (kilograms) were also recorded.   
  
6-minute walking test (6MWT)  
A 6MWT was performed at baseline (and within 3 months of CPET) according to ATS 
guidelines(Laboratories 2002), using the Enright reference equation(Enright and Sherrill 1998). The 
following data were collected and analysed: distance achieved (metres), oxygen saturation at the 
initiation of the test, the minimum saturation level, percentage of theoretical distance achieved and at 
the end of the test.   
  
Cardiopulmonary Exercise Testing (CPET)   
CPET was performed using a standardized protocol in accordance with the American Thoracic 
Society/American College of Chest Physicians (ATS/ACCP) statement(Society and Physicians 2003), 
using Wasserman(Wasserman et al. 1994) and Jones(Jones et al. 1985) reference equations. All 
patients underwent a symptom-limited CPET to exhaustion or intolerability with an 
electromagnetically braked cycle ergometer (Ergoselect 100, ergoline GmbH, Germany) using a ramp 
protocol over 8-12 minutes. The protocol included 3 min of rest, 2 min of unloaded cycling (at 60 




recovery period (patient dependent). The work rate increment for each ramped exercise test was 
selected depending on the patient’s level of daily activity (either 5 or 10 watt/min ramp).  
  
Subjects were asked to maintain a rate of 60 revolutions per minute throughout the exercise period. 
Several markers were used to determine if a maximal effort test was performed; a respiratory 
exchange ratio (RER; VCO2/VO2) ≥1.1, maximum heart rate (HR max) > 80% of maximum predicted HR 
(220-age), maximum minute ventilation during exercise >85% predicted based on MVV at rest 
(maximum voluntary ventilation) and a plateau in VO2 with an increased workload. CPET could be 
discontinued at the discretion of the supervising attendant if clinically indicated.   
  
Cardiopulmonary data were collected and analysed with nSpire Zan 600 USB system (nSpire Health 
GmbH, Germany).   
  
The following parameters were recorded:   
• Peak oxygen consumption (VO2 peak, ml/kg/min),   
• Oxygen consumption at anaerobic threshold  
• Carbon dioxide production (VCO2)  
• Peak minute ventilation (VE peak)(marker of ventilatory function during exercise),  
• VE/VCO2  slope as derived from the above values (reflects changes in ventilatory drive)  
• Peripheral capillary oxygen saturation SpO2 (marker of hypoxaemia indicating possible 
ventilatory limitation to exercise)   
• Peak power output (W)(marker of musculoskeletal function)   
• Heart rate (HR) (marker of cardiac function during exercise),   Breathing reserve (BR)   
  
Anaerobic threshold was determined noninvasively through the plot of VCO2 versus VO2 (V-slope 
method). Predicted minute ventilation was automatically calculated by the software as a function of 
maximal voluntary ventilation (MVV), where MVV = FEV1 L x 40. The BR was automatically calculated 
from the software as the difference between the maximum voluntary ventilation at rest and the peak 
ventilation. The % predicted VO2 peak and % theoretical VO2 peak at AT were not determined in this 




not representative of the male predominant and elderly population, characteristic of IPF 
patients/populations.   
  
Health status questionnaires and patient-reported outcomes  
Patients were asked to complete the King’s Brief ILD questionnaire (K-BILD)(Patel et al. 2013) and 
IPF-Patient reported outcome measure (IPF-PROM) (Russell A et al. 2018), in addition to the 
Leicester Cough visual analogue scale (VAS) for cough (Key et al. 2010) and Bristol VAS for 
breathlessness and fatigue (Yates et al. 2018b), at baseline and at 12 months.  
  
The K-BILD is a self-completed health status questionnaire that comprises 15 items in three domains 
of psychological, breathlessness and activities and chest symptoms. The K-BILD scoring system 
implements logit transformation of raw item response scores to provide total score ranges of 0–100, 
where 100 represents best health status. The minimally important clinical difference (MCID) for the 
logit version of the K-BILD questionnaire is 5 for total K-BILD, 6 for Psychological, 7 for Breathlessness 
and activities and 11 for Chest symptoms (Sinha et al. 2019).   
  
The IPF-PROM(Russell A et al. 2018) is a self-completed 12 item health status questionnaire that 
measures the physical and psychological experience of breathlessness; emotional well-being and fatigue. 
The questionnaire has been validated in terms of face and content validity. The scores range from 12-48, 
where 48 indicates worst health status.   
  
Outcomes  
We wished to study the feasibility of undertaking CPET in a population of mild and moderate IPF 
patients: the attrition of participants, information on safety data, and willingness to engage with the 
study protocol. Secondary end-points included: the change in CPET parameters over a 1 year period 
and the correlation between baseline CPET parameters and change in lung function, 6MWT and health 





Statistical analysis  
Categorical variables are reported as absolute numbers and percentages. Normality of continuous 
data was initially verified using D’Agostino and Pearson normality test. Mean and standard deviations 
(SD) were used to describe parametric data; median and interquartile range (IQR, in brackets) for 
nonparametric data. Differences among two groups were verified by t-test with Welch’s correction 
(continuous data), χ2-tests (categorical data) and paired t-tests for comparison in variables from 
baseline to 12 months. Pearson’s correlation was used to determine correlations between parametric 
variables. Data were analysed using GraphPad Prism version 8.0. A p value of <0.05 was considered 




Study population   
Forty-two consecutive IPF patients were prospectively enrolled to the study. Four patients 
subsequently withdrew consent, 1 patient died and 5 patients developed exclusion criteria prior to 
commencement of the study. A further 5 patients did not complete the study and were lost to follow 
up (4 mild, 1 moderate). The final population studied thus consisted of 27 patients (mild n=19 and 
moderate n=8) (Figure 1). Patients were predominantly male (n=22, 82%) with a mean age of 75 years 
(±6.0 years) and were symptomatic at baseline with a median MRC breathlessness score of 2 (IQR 23). 
Approximately one third (33%, n=9) of patients (mild n=5, moderate n=4) received antifibrotics during 
the observational period. At completion of 1 year follow up, all patients remained alive.   
  
Feasibility  
There was excellent willingness to engage with the study protocol.  
  
All patients achieved a RER > 1.1 and the vast majority of patients also achieved >80% of their maximal 
predicted heart rate (25/27, 93%) and /or had limited breathing reserve, providing corroboration that 





At baseline, all participants achieved the anaerobic threshold during testing and at 1 year follow up only 
one patient failed to achieve the anaerobic threshold.   
  
Breathlessness and fatigue were the most commonly cited reasons for terminating CPET. Of patients 
completing the study (n=27; 19 mild and 9 moderate IPF), baseline CPET was terminated due to 
breathlessness in 37% (10/27), the majority of which had mild IPF (90%, 9/10). Leg/muscle fatigue was 
cited as a reason for terminating CPET in 63% patients (17/27), of which 59% (10/17) had mild disease. 
There were no significant differences in the reasons for terminating CPET between those that 
completed and did not complete follow-up.   
  
At 1 year repeat CPET, 54% (7/13) described breathlessness as the reason for stopping and 38% (5/13) 
muscle fatigue. A dry mouth was cited as the main contributing reason for stopping in one patient.    
  
One patient described dizziness related to his breathlessness during CPET but no other adverse events 




Baseline measurements between mild and moderate IPF groups  
Baseline demographics between mild and moderate IPF groups were statistically comparable (Table 
1). As per a priori subgroup definitions, participants in the moderate IPF group had a statistically lower 
baseline FVC % predicted compared to those in the mild IPF group (mild 99% predicted ±10.0, range 
85-125% predicted) vs moderate 70% predicted ±5.1, range 62-75% predicted, p<0.0001). In keeping 
with these findings there was a trend towards a lower TLco in those within the moderate IPF group 
(mild 63% predicted ±9.5), range 50-83 % predicted vs moderate 57% predicted ±6.2, range 50-65% 
predicted, p=0.055). No significant difference in the 6MWT distance measured between mild and 
moderate groups was observed.   
  
Patients with moderate disease had numerically lower total K-BILD, chest symptom and psychological 




(total K-BILD mild disease 67 (±10.3) vs moderate disease 60 (±6.6), p=0.058).  There were no 
significant differences in VAS scores of cough, breathlessness or fatigue between mild and moderate 
IPF groups or IPF-PROM measurements.    
  
Whilst baseline CPET values were all within ‘normal’ published ranges (Society and Physicians 2003), 
peak minute ventilation (% predicted) was significantly higher for those with moderate IPF compared 
to those with mild disease (mild 71.0% (±13.9) vs moderate 82.9% (±12.4, p=0.045) (Table 1).  
  
Of the baseline CPET parameters measured, VO2 peak/kg at anaerobic threshold positively correlated 
with total scores (r=0.42, p=0.03), breathlessness/activity (r=0.47, p=0.014) and chest domains (r=0.44, 
p=0.02) of the K-BILD questionnaire (Pearson’s correlation). Similarly, total IPF PROM scores and 
wellbeing domains significantly correlated with VO2 peak (r=-0.43, p=0.02 and r=-0.44, p=0.02), with a 
trend towards statistical significance for total IPF-PROM and VO2 peak/kg at anaerobic threshold 
(p=0.06). VE/VCO2 at anaerobic threshold also correlated with total K-BILD score (r=0.39; p=0.001) at 
baseline, although there were no significant correlations with the individual domains of the 
questionnaire or IPF-PROM.   
  
Total K-BILD scores (r=0.44, p=0.03) and total IPF-PROM scores (r=-0.43, p=0.03) both significantly 
correlated with 6MWT distance, but not with baseline FVC % predicted (Total K-BILD, p=0.14; Total IPF-
PROM p=0.50), TLCO % predicted (Total K-BILD p=0.16; Total IPF-PROM p=0.32), baseline or minimum 
SpO2 (Total K-BILD p=0.25 and p=0.32, respectively, Total IPF PROM p=0.53 and p=0.55, respectively). 
There were no significant correlations between baseline CPET parameters and VAS scores (p>0.05).   
  
Measurements at 1 year follow up  
Total IPF cohort  
At one year of follow up, the mean reduction in FVC and TLCO % predicted for the whole IPF  cohort 
(n=27) was -3.6% (±7.1, p=0.02) and -3.2% (±7.5, p=0.04) respectively (Supplementary Table 1). Whilst 
statistically significant, values were below those deemed clinically significant (Collard et al. 2003, 
Flaherty et al. 2006). There was no significant reduction in 6MWT distance achieved (mean reduction  
4.8m±34.7, p=0.50; mean reduction in 6MWT distance as % theoretical distance 0.2% (±7.9, p=0.92). 




K-BILD questionnaire from baseline to 1 year, suggesting worse health status (-4.8±10.2, p=0.02), 
although this did not reach the published MCID for responsiveness for this domain (Sinha et al. 2019). 
There were no statistically significant differences in the VAS scores for cough, breathlessness and 
fatigue or in the IPF-PROM from baseline to one year (p>0.05).   
Follow up of mild IPF group with repeat CPET  
Thirteen patients from the mild IPF group returned for repeat CPET at 1 year; the coronavirus COVID19 
pandemic prohibited the return of the remaining six patients at the one year follow-up time point as 
planned. All but one patient achieved anaerobic threshold.   
  
Upon repeat CPET testing there were statistically significant declines in the VO2 peak  (21.6 
ml/kg/min±2.9 vs 19.1±2.8; p=0.017), VO2 peak at AT (14.2 ml/kg/min±3.2 vs 11.8±1.6, p=0.044) VE 
peak (75.3 L/min ±20.9 vs 66.1±21.6; p=0.007), peak work (106.9 W±26.3 vs 90.8±25.9; p=0.022) heart 
rate response (142.3 bpm±24.0 vs 133±22.3; p=0.040) and increased breathing reserve at anaerobic 
threshold (BRmax) (21.8 L/min (12.4-34.2) vs 33.8 (20.2-55.7); p=0.0002), compared to baseline values 
(Table 2).   
  
There was a statistically significant reduction in FVC% predicted at 12 months, although the mean 
absolute decline was <10% (baseline FVC 98.8% predicted±8.5 vs follow up FVC 93.4% predicted±10.3, 
p=0.01). In these same patients, statistically significant reductions in breathlessness/activity (-7.2±10.8; 
p=0.033) and chest (-9.6±-15.0; p=0.040) domain scores of the K-BILD questionnaire were observed, with 
a trend towards statistical significance for reduction in the total B-ILD score (-5.6±-10.4; p=0.077) at 
follow up. Notably, the mean unit change of total K-BILD and breathlessness/activity domain scores 
exceeded the minimally clinically important difference previously reported (5 and 7 unit change 
respectively)(Sinha et al. 2019), with 5/13 patients achieving the MCID for total K-BILD score and 8/13 
for the breathlessness/activity domains (Table 3).    
  
There were no statistically significant differences in the VAS scores for cough, breathlessness or fatigue 
VAS score from baseline to one year (p>0.05). There was statistically significant worsening in the 
psychological experience of breathlessness as reported by the IPF-PROM (0.8±1.2, p=0.044), although 





Reductions in K-BILD scores observed at 12 months were correlated with baseline CPET measurements. 
Lower baseline VO2 peak/kg at anaerobic threshold correlated with greater declines in total K-BILD 
scores (r = -0.62, 0.024) and psychological domains of the K-BILD at follow up (r= -0.63, p=0.022). No 
other baseline CPET parameters significantly correlated with change in K-BILD score in this small 
cohort, including peak work rate. Furthermore, there was no significant correlation with the baseline 
FVC% predicted (p=0.70) or TLCO% predicted (p=0.62) and change in K-BILD score (Pearson’s 
correlation).   
  
Discussion  
CPET is considered the gold standard for evaluating exertional dyspnoea and exercise intolerance in 
patients with cardiorespiratory conditions (Molgat-Seon et al. 2020), yet currently lacks a defined role  
in the management of ILD (Raghu et al. 2011, Molgat-Seon et al. 2020). A recent systematic review by 
our group highlighted the insufficient available evidence to support the use of CPET in disease 
prognostication in ILD, emphasising that heterogeneity in terms of the ILD populations studied and 
the retrospective nature of the majority of published studies limited the conclusions that could be 
drawn (Barratt et al. 2020). Furthermore, the minimally clinically important differences for CPET 
parameters in ILD have not been established.  
  
Our study has shown that CPET can be undertaken in both mild and moderate populations of IPF 
patients, without any significant adverse events, although study attrition was high and complicated 
by COVID-19 restrictions, such that only 64% patients completing the protocol.    
  
Our prospective data suggests that baseline CPET VO2 peak is associated with clinically meaningful 
patient-perceived reduction in health status at 1 year, in spite of comparatively stable lung function 
parameters (<10% decline in FVC and <15% decline in TLco). VO2 peak is an integrated measure of 
respiratory, cardiovascular and neuromuscular function (Society and Physicians 2003). In a progressive 
disease such as IPF, the finding of reduced exercise performance at one year was not a surprising one. 
However, results suggest that this reduction was not as a consequence of ventilatory limitation. There 
was no change in the CPET ventilatory mode and the development of cardiac +/- pulmonary vascular 
dysfunction was not apparent. One possible explanation might be that patients became more 
deconditioned with reduced activity levels in response to their perceived worsening of breathlessness. 
El Naggar et al (El Naggar. 2017) have previously shown that VO2 peak correlated with health status of 




CPET parameters and associated health status were not explored. In our cohort, VO2 peak during 
exercise correlated with patient reported outcome measures at baseline, it significantly declined at 
12 months and also correlated with the change in patient reported health status at 12 months.   
  
Existing literature conflicts as to whether VO2 peak might predict disease outcomes in IPF; peak VO2 
thresholds ranging from <8.3 to <14.2ml/kg/min (Triantafillidou et al. 2013, Fell et al. 2009, 
Vainshelboim et al. 2016) have been reported to predict mortality in IPF, whilst others studies have 
failed to identify any significant association (Wallaert et al. 2011, Miki et al. 2003, van der Plas et al. 
2014). Ongoing follow up of our prospective cohort will be used to further study the use of baseline 
CPET parameters to predict longer-term outcomes in these patients.   
  
It is recognised that this study has limitations. Firstly, and perhaps most importantly, the study was 
conducted on a relatively small and homogenous sample of patients. This limits the overall 
generalisability of results, particularly in terms of feasibility of CPET across IPF phenotypes; for 
example those with exercise induced pulmonary hypertension versus those with relatively normal 
pulmonary vascular response to exercise, and the risk of Type II error may be relatively high.   
The vast majority of patients had mild IPF (72%) with a median MRC score of 2; again limiting the 
generalisability of results. Whilst it would have been preferable to have a broader range of 
symptomatic patients, exercise in patients with high MRC scores would be very restricted leading to 
early completion of tests before the limit of pulmonary and cardiovascular systems had been reached 
(O'Donnell et al. 2009) and thus negatively influencing the results. A further limitation of the study 
was that almost a quarter of patients enrolled in the study developed exclusions to CPET or were lost 
to follow up; a factor that will be helpful to inform power calculations for future studies involving CPET 
as an outcome measure. It was decided by the study committee in the planning of the protocol that 
due to the uncertainty of the ability and the safety of those with reduced lung function to perform a 
maximal exercise test, those in the ‘moderate’ disease group would undertake only a baseline CPET 
test. In retrospect, it would have been more valuable to undertake repeat CPET on all enrolled 
participants. With the experience gained from this study, this is something that could explored in the 
future. Finally, the COVID-19 pandemic adversely affected the ability to perform follow-up CPET 
testing, particularly in this highly vulnerable group of individuals; consequently the resulting sample 





Conclusion   
In conclusion, our study provides the initial data to support the feasibility of CPET in at least 
mildmoderate populations of IPF and the ability of repeated CPET to assess the change in health status 
over time. This may be clinically applied in the future to assess the response to pharmacological or 
non-pharmacological interventions from the patient’s perspective. Future work should concentrate 
on examining the relationship between CPET parameters, lung function and CT-derived measures of 
disease, establishing the MCID for longitudinal change in CPET in ILD.    
  
  
  
